Statement,ID,Origin,Validity,True_fleshes,True_smog_index,True_flesch_kincaid_grade,True_coleman_liau_index,True_automated_readability_index,True_dale_chall_readability_score,True_difficult_words,True_linsear_write_formula,True_gunning_fog,True_text_standard,Characters,Words,Word_Length,Number_Count,Positive_Sentiment,Neutral_Sentiment,Negative_Sentiment,Positive_Stance,Negative_Stance,Neutral_Stance
"A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control
group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated
group compared with 27% of the control group.",1012,Journal,TRUE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.473684211,8,0.1953,0.7719,0.0328,0.787685931,0.087757349,0.124556758
"Many people who are infected with the virus do not present with any clinical symptoms; current
estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with
severe COVID-19 disease.",1021,Journal,TRUE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.551020408,5,0.0135,0.3506,0.6359,0.672363281,0.069773905,0.257862836
"The findings support global recommendations to prioritize COVID-19 vaccine allocation for older age
groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout
was increased.",1022,Journal,TRUE,22.92,0,13.7,19.54,16.7,13.61,14,10.25,12.7,13th and 14th grade,218,29,6.620689655,2,0.143,0.8259,0.0311,0.716154337,0.095786259,0.188059315
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical
differences in the upper respiratory tract and more sever COVID-19 infections.",1029,Journal,TRUE,20.72,0,16.6,17.35,19.9,14.35,10,18.5,19.6,19th and 20th grade,177,25,6.16,4,0.0095,0.159,0.8315,0.717568994,0.061817396,0.220613658
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which
have anti-inflammatory effects and also up regulation of the immune system, are among major
agents that can help in recovery of patients with COVID19.",1033,Journal,TRUE,33.92,0,17.7,14.34,22.9,12.3,12,22.5,19.12,22nd and 23rd grade,239,37,5.540540541,2,0.5304,0.4525,0.0172,0.662932038,0.078495063,0.258572936
"Dietary supplements and vitamins including vitamin D and high-dose vitamin
C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an
interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic
effectiveness has not been confirmed in randomized trials.",1036,Journal,TRUE,15.31,0,16.6,18.68,19.5,13.7,20,19,20.62,18th and 19th grade,323,44,6.431818182,4,0.1509,0.7754,0.0738,0.680871427,0.153557047,0.165571481
"We addressed the infectability of the central nervous system. Early reports from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, later European studies
showed as much as 60%; cases of viral encephalitis have been reported.",1041,Journal,TRUE,44.24,0,11.7,14.85,14.8,14.37,17,12.25,13.89,14th and 15th grade,248,37,5.783783784,6,0.029,0.7214,0.2496,0.667154908,0.082881853,0.249963284
"Recent improvements in mRNA vaccines act to increase protein translation, modulate
innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of
vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized
worldwide.",1042,Journal,TRUE,34.76,0,13.3,17.69,17.3,12.7,17,13.25,14.98,12th and 13th grade,278,39,6.230769231,2,0.6553,0.3361,0.0086,0.628117144,0.062362801,0.309520036
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of elderlies died in nursing homes before they
could even be hospitalized or admitted to ICU.",1043,Journal,TRUE,51.18,0,11.1,10.27,11.4,10.55,10,13.5,15,10th and 11th grade,233,40,4.9,2,0.02,0.5114,0.4686,0.674980819,0.128608942,0.196410269
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue,
myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1%
respectively).",1061,Journal,TRUE,40.04,13,11.2,16,15.1,13.16,18,10.16666667,11.3,10th and 11th grade,310,43,6.302325581,7,0.0207,0.5038,0.4755,0.671109617,0.064811952,0.264078408
"Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared with testing each sample individually.",1066,Journal,TRUE,9.22,0,18.9,16.13,19.7,12.92,12,20,19.77,19th and 20th grade,188,28,5.785714286,0,0.0491,0.7671,0.1838,0.653301418,0.049650002,0.297048509
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and cardiovascular disease.",1081,Journal,TRUE,34.63,11.9,11.2,15.81,13.9,15.34,13,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0131,0.2766,0.7103,0.659300625,0.178318232,0.162381157
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be
649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Journal,TRUE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.66666667,11.48,10th and 11th grade,304,50,5.16,15,0.0205,0.7028,0.2767,0.617937803,0.058846947,0.323215246
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula showed better safety outcomes.",1083,Journal,TRUE,34.76,0,13.3,13.63,13.9,11.89,11,13.75,13.95,13th and 14th grade,250,39,5.487179487,3,0.3699,0.5951,0.035,0.658145547,0.069746733,0.272107691
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barracks-style buildings. The corresponding doubling time for apartment-style buildings was
2.65 days.",1084,Journal,TRUE,70.8,7.8,5.6,13.83,11.1,12.86,7,4.166666667,6.56,6th and 7th grade,187,27,6.037037037,7,0.0283,0.6873,0.2844,0.636661172,0.065057181,0.29828164
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148
million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,Journal,TRUE,31.89,14.1,12.3,17.51,15.4,13.35,15,10.66666667,13.22,12th and 13th grade,307,42,6.404761905,9,0.0249,0.4838,0.4913,0.649100304,0.045313161,0.305586576
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Journal,TRUE,43.73,0,11.9,15.37,15.8,12.06,7,13.5,16.02,15th and 16th grade,130,19,5.947368421,0,0.0284,0.6472,0.3244,0.718118429,0.10071031,0.181171253
"n Hawai‘i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians
account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise
4%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other
groups combined and they accounted for almost 30% of cases.",1099,Journal,TRUE,57.95,0,12.6,10.86,17.1,12.23,14,18,16,12th and 13th grade,359,60,5.05,13,0.0467,0.8678,0.0855,0.612299085,0.067252435,0.320448488
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that
if the level of testing and containment measures is preserved, the number of positive cases in
New York State remain the same during March of 2021, while in the UK it will reduce.",1166,Journal,TRUE,47.12,0,18.9,9.42,24.4,10.9,10,27.5,22.05,10th and 11th grade,270,49,4.571428571,6,0.0571,0.8696,0.0733,0.608871698,0.079614528,0.311513752
"Different amounts of antibodies produced after the two doses of vaccine were found.
Individuals with a previous natural infection developed a higher antibody level. Among the
individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same
order of magnitude of infected people, suggesting that they acquired the infection in an
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Journal,TRUE,35.78,15.9,12.9,13.46,13.4,10.32,21,14.25,14.43,12th and 13th grade,475,74,5.5,2,0.0469,0.8639,0.0892,0.637769461,0.066726163,0.295504391
"The proposed technique exhibited great similarity with the PCR testing technique. The results
obtained point to the application potential of this simple, low-cost magneto-assay for saliva-
based point-of-care COVID-19 diagnosis.",1171,Journal,TRUE,30.87,0,12.7,18.84,17.3,13.33,13,10.5,14,12th and 13th grade,228,30,6.7,2,0.8396,0.1555,0.0049,0.621642292,0.090606034,0.287751704
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines forced United States health systems to postpone elective tests and procedures.
There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Journal,TRUE,50.67,0,11.3,13.87,14.9,12.36,12,12.75,11.13,11th and 12th grade,267,41,5.585365854,4,0.0106,0.3079,0.6815,0.626978517,0.081886493,0.291134924
"It seems that the virus traveled by car on highways and motorways; and that “solo” driving, i.e.
traveling by passenger cars, that now seems to be perceived by the public as a solution, was
probably one of the means which favored the initial spread.",1182,Journal,TRUE,66.07,0,9.5,8.7,11.6,10.11,11,13.5,12.44,9th and 10th grade,249,44,4.727272727,0,0.0201,0.5327,0.4473,0.628574193,0.047698427,0.323727399
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
copper-contained stainless steel with a high copper content exhibit significant antiviral
properties.",1186,Journal,TRUE,34.76,0,13.3,18.1,17.9,11.89,14,14.25,14.98,11th and 12th grade,283,39,6.358974359,3,0.0448,0.7154,0.2398,0.635346174,0.045486387,0.319167465
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3–7 days
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6–10 days following a negative nasal swab.",1194,Journal,TRUE,29.86,0,19.3,12.03,22.6,13.76,13,26.5,21.28,12th and 13th grade,245,41,5.048780488,5,0.0169,0.8664,0.1168,0.64077729,0.059331682,0.299890935
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, but not in
Europe, North America, and South America.",1195,Journal,TRUE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.454545455,2,0.0191,0.5091,0.4718,0.684019089,0.126049042,0.18993187
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method
for early detection and classification of COVID-19 through image processing using X-ray images
is proven to be usable since it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,Journal,TRUE,29.69,0,15.2,14.86,17.5,13.23,19,17.25,17.15,17th and 18th grade,326,49,5.734693878,6,0.8129,0.1808,0.0063,0.632672012,0.092344292,0.274983704
Mechanical Ventilation was required for all patients treated with anakinra and only 27% were able to be successfully weaned off of supplemental oxygen.,1012,Human,FALSE,31.21,0,14.6,15.03,16.5,12.33,9,15.5,16.16,15th and 16th grade,151,23,5.608695652,2,0.0267,0.564,0.4093,0.701104879,0.074772432,0.224122629
"If you are taking a drug for rheumatoid arthritis, you will be able to be successfully weaned off supplemtal oxygen.",1012,Human,FALSE,59.64,0,9.9,10.27,11.4,10.16,5,12,12,9th and 10th grade,116,20,4.85,0,0.2977,0.6751,0.0272,0.659528971,0.078533098,0.261937976
A need for mechanical ventilation occurred in 68% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 57% of the control group.,1012,Human,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2833,0.6986,0.0181,0.76052779,0.100473925,0.13899827
A need for mechanical ventilation occurred in 68% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was only attained in 43% of the anakinra-treated group compared with 54% of the control group.,1012,Human,FALSE,51.68,0,10.9,12.76,13.7,11.08,12,12.75,11.9,12th and 13th grade,248,39,5.384615385,8,0.0428,0.6682,0.2889,0.758052111,0.100969121,0.140978754
A need for manual ventilation occurred in 24% of the anakinra-treated group and 56% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,52.19,0,10.7,12.36,13.1,11.23,12,12.5,11.81,11th and 12th grade,239,38,5.315789474,8,0.2364,0.7423,0.0214,0.773350537,0.083184868,0.143464684
A need for more cowbell occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,60.65,0,9.5,11.43,12.4,10.81,11,11.5,9.71,9th and 10th grade,233,38,5.157894737,8,0.2568,0.7192,0.0241,0.670107305,0.099373855,0.230518922
A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 64% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2757,0.7052,0.0191,0.786482334,0.087893248,0.125624448
A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 64% of the anakinra-treated group compared with 62% of the control group.,1012,Human,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2807,0.7003,0.019,0.789108932,0.087466888,0.123424239
A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the bankira-treated group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the bankira group.,1012,Human,FALSE,43.73,0,11.9,13.98,14.6,11.23,12,13,11.81,11th and 12th grade,251,38,5.631578947,8,0.2883,0.6924,0.0193,0.76105386,0.093386918,0.145559251
A need for under-water ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,52.19,0,10.7,12.94,13.7,10.81,11,12.5,10.76,10th and 11th grade,244,38,5.447368421,8,0.294,0.6882,0.0178,0.750171185,0.09705437,0.152774438
A need for mechincal ventiliation occured in 40% of the anakinra-treated group and 70% of the control group. Unsucessfully weaning from supplemental oxygen was attained in 15% of the group anakinra-treated group compared with 20% of the control group.,1012,Human,FALSE,51.68,0,10.9,13.23,14,11.08,12,12.75,11.9,10th and 11th grade,251,39,5.461538462,8,0.0147,0.46,0.5253,0.699933887,0.087829687,0.212236479
There a demand for mechincal ventiliation occured in 40% of the anakinra-treated group and 70% of the control group. Sucessfully weaning from supplemental oxygen was attained in 15% of the group anakinra-treated group compared with 20% of the control group.,1012,Human,FALSE,51.18,0,11.1,13.17,14.2,11.34,13,13,12,11th and 12th grade,257,40,5.45,8,0.1779,0.8063,0.0158,0.688891828,0.085807115,0.225301072
A need for mechanical ventilation occurred in 31% of the control group and 75% of the anakinra-treated group. Successful weaning from supplemental oxygen was attained in 63% of the control group compared with 27% of the anakinra-treated group.,1012,Human,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.3049,0.6754,0.0197,0.776158094,0.092555784,0.1312861
A desire for manual ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Unsuccessful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,43.73,0,11.9,12.94,13.6,11.23,12,12.5,11.81,11th and 12th grade,243,38,5.421052632,8,0.012,0.3427,0.6453,0.766088724,0.090761997,0.143149301
A need for manual ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful dependency on supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,43.73,0,11.9,12.47,13.2,11.23,12,13,12.86,12th and 13th grade,240,38,5.342105263,8,0.1595,0.8096,0.0309,0.755065978,0.094379403,0.150554672
A need for smoke ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,52.19,0,10.7,12.18,13,10.81,11,12,10.76,10th and 11th grade,238,38,5.289473684,8,0.2962,0.6866,0.0172,0.777379274,0.08664383,0.13597694
A need for mechanical ventilation occurred in 31% of the placebo and 75% of the anakinra-treated group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,52.7,0,10.5,13,13.4,11.81,13,12.25,11.72,11th and 12th grade,237,37,5.432432432,8,0.3411,0.6418,0.0171,0.775406361,0.093896322,0.130697325
A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Failure of weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,51.68,0,10.9,12.01,13.1,11.08,12,12.25,10.88,10th and 11th grade,243,39,5.256410256,8,0.0159,0.4471,0.537,0.783450246,0.091585375,0.124964312
A need for mechanical ventilation occurred in 32% of the anakinra-treated group and 74% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,52.19,0,10.7,12.94,13.6,11.23,12,12.5,11.81,12th and 13th grade,243,38,5.421052632,8,0.2598,0.7196,0.0206,0.780960083,0.089833066,0.129206806
A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 0% of the control group. Successful weaning from supplemental oxygen was lost in 63% of the anakinra-treated group compared with 27% of the control group.,1012,Human,FALSE,52.19,0,10.7,12.18,13,10.81,11,12.5,11.81,12th and 13th grade,238,38,5.289473684,7,0.0304,0.4854,0.4842,0.773403823,0.094006412,0.132589802
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest less than 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,46.1,0,13,13.52,16.6,11.51,14,16.5,15.6,16th and 17th grade,320,50,5.42,5,0.0152,0.3455,0.6393,0.672570109,0.06875921,0.258670688
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who will not react with severe COVID-19 disease.",1021,Human,FALSE,46.1,0,13,13.76,16.8,11.51,14,16.5,15.6,16th and 17th grade,322,50,5.46,5,0.0165,0.386,0.5975,0.67132926,0.069615826,0.259054959
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease",1021,Human,FALSE,46.61,0,12.8,13.93,16.6,11.62,14,16.25,15.51,16th and 17th grade,316,49,5.469387755,5,0.0125,0.3056,0.6819,0.670442104,0.071968965,0.257588923
"Many people who are infected with the virus do not show any clinical symptoms; current estimates suggest a small amount of individuals who have antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease",1021,Human,FALSE,47.12,0,12.7,13.23,15.5,10.42,14,16,15.43,15th and 16th grade,301,48,5.291666667,2,0.0112,0.2622,0.7266,0.672052085,0.069592126,0.258355856
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.489795918,5,0.012,0.3035,0.6845,0.672363281,0.069773905,0.257862836
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.489795918,5,0.012,0.3035,0.6845,0.672363281,0.069773905,0.257862836
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may be infected with an asymptomatic variant of COVID-19 disease.",1021,Human,FALSE,44.58,0,13.6,13.99,17.7,10.91,13,18.25,15.88,13th and 14th grade,343,53,5.490566038,5,0.0134,0.3619,0.6247,0.674816668,0.066106297,0.259076983
Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus but do not spread it to others.,1021,Human,FALSE,49.65,0,11.7,12.42,14.1,10.21,10,14.25,14.18,11th and 12th grade,268,43,5.255813953,3,0.023,0.5585,0.4185,0.672086775,0.067465514,0.260447741
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who were infected and took the vaccine are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,46.61,0,12.8,13.29,16,10.65,14,16.25,14.7,12th and 13th grade,310,49,5.346938776,4,0.0133,0.3146,0.6721,0.675884306,0.068197154,0.255918533
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are symptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,46.61,0,12.8,13.81,16.6,11.62,14,16.25,15.51,16th and 17th grade,316,49,5.469387755,5,0.0117,0.2987,0.6896,0.67250216,0.069524877,0.257973015
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-Cov-2 antibodies in their blood are symptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,46.61,0,12.8,13.81,16.6,11.62,14,16.25,15.51,16th and 17th grade,316,49,5.469387755,5,0.0117,0.2982,0.6901,0.67250216,0.069524877,0.257973015
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-Cov-2 antibodies in their blood are symptomatic. Those individuals carry the virus and potentially not spread it to others, who may not react with severe COVID-19 disease.",1021,Human,FALSE,45.59,0,13.2,13.29,16.6,11.4,14,16.75,15.69,16th and 17th grade,324,51,5.37254902,5,0.0262,0.5534,0.4204,0.672303319,0.069581367,0.258115351
"Many people who are infected with the virus do present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,47.12,0,12.7,14.22,16.7,11.74,14,16,15.43,15th and 16th grade,313,48,5.541666667,5,0.0116,0.2823,0.7062,0.664532304,0.067110933,0.2683568
"Many people who are infected with the virus sometimes present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,38.66,0,13.8,15.03,17.4,11.74,14,16,15.43,15th and 16th grade,320,48,5.6875,5,0.01,0.2588,0.7313,0.666285574,0.064009726,0.269704759
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are symptomatic. Those individuals carry the virus and improbably spread it to others, who may react with minor COVID-19 disease.",1021,Human,FALSE,46.61,0,12.8,13.58,16.4,11.62,14,16.25,15.51,15th and 16th grade,314,49,5.428571429,5,0.0133,0.3397,0.647,0.667971373,0.069275469,0.262753248
"Many people who are infected with the virus don't not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with lenient COVID-19 disease.",1021,Human,FALSE,46.61,0,12.8,14.28,17.1,11.62,14,16.25,15.51,15th and 16th grade,321,49,5.571428571,5,0.0133,0.3582,0.6285,0.669307768,0.072544433,0.258147836
"People who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 30% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,47.12,0,12.7,14.05,16.6,11.74,14,16,15.43,15th and 16th grade,312,48,5.520833333,5,0.0119,0.3215,0.6666,0.675100744,0.067518622,0.257380635
"All people who are infected with the virus do not present with any clinical symptoms; current estimates suggest a majority of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and spread it to others, who react with severe COVID-19 disease",1021,Human,FALSE,39.16,0,13.6,13.52,15.7,11.52,14,15.75,15.36,15th and 16th grade,299,47,5.382978723,3,0.0165,0.326,0.6575,0.681257367,0.064660341,0.254082352
"Many people who are infected with the virus do not present with any medical symptoms; current estimates suggest around 35% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,46.61,0,12.8,13.81,16.6,11.62,14,16.25,15.51,16th and 17th grade,316,49,5.469387755,5,0.012,0.3,0.688,0.668894768,0.072058238,0.259047031
"Many people who are infected with the virus do not present with any clinical symptoms; current estimates suggest around 95% of individuals who have SARS-CoV-2 antibodies in their blood are asymptomatic. Those individuals carry the virus and potentially spread it to others, who may react with severe COVID-19 disease.",1021,Human,FALSE,46.61,0,12.8,13.93,16.7,11.62,14,16.25,15.51,16th and 17th grade,317,49,5.489795918,5,0.0127,0.3107,0.6765,0.673344076,0.070433855,0.256222069
The findings support global recommendations to prioritize COVID-19 vaccine allocation for younger age groups. Relative differences between allocation strategies for older and younger age groups were increased as the speed of vaccine rollout was increased.,1022,Human,FALSE,36.79,0,12.5,18.56,17,12.17,13,11.75,12.71,12th and 13th grade,255,35,6.314285714,2,0.1514,0.8317,0.0169,0.727064073,0.105688632,0.167247295
The findings do not support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies were increased as the speed of vaccine rollout was increased.,1022,Human,FALSE,30.36,0,12.9,18.73,16.2,12.55,13,10.75,12.65,12th and 13th grade,227,31,6.35483871,2,0.0094,0.3157,0.6749,0.715079844,0.089923225,0.194996953
The findings support global recommendations to prioritize COVID-19 vaccine allocation for underserved groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,23.43,0,13.5,21.51,18,13.92,14,10.5,14.17,13th and 14th grade,220,28,6.892857143,2,0.2037,0.7725,0.0238,0.686188996,0.087566428,0.226244569
The findings support global recommendations to prioritize COVID-19 Petri dishes allocation for older age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,30.87,0,12.7,19.07,16.5,14.38,15,10.5,12.67,12th and 13th grade,223,30,6.466666667,2,0.1338,0.8387,0.0274,0.69265002,0.110569395,0.196780547
The findings support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies were increased as the speed of vaccine rollout was increased.,1022,Human,FALSE,22.92,0,13.7,19.94,17,13.07,13,10.25,12.7,12th and 13th grade,220,29,6.620689655,2,0.1153,0.8625,0.0223,0.719037652,0.098202243,0.182760164
The findings support global recommendations to prioritize COVID-19 vaccine allocation for younger age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,31.38,0,12.5,19.94,17,13.61,13,10.25,12.7,12th and 13th grade,220,29,6.620689655,2,0.2053,0.7733,0.0214,0.71739471,0.09544716,0.187158227
The findings support global recommendations to prioritize COVID-19 vaccine allocation for younger age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,31.38,0,12.5,19.94,17,13.61,13,10.25,12.7,12th and 13th grade,220,29,6.620689655,2,0.2053,0.7733,0.0214,0.71739471,0.09544716,0.187158227
The findings DO NOT support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,30.36,0,12.9,18.33,15.9,13.06,14,10.75,12.65,12th and 13th grade,225,31,6.290322581,2,0.0085,0.2099,0.7816,0.711785197,0.088563628,0.199651092
The findings support global recommendations to prioritize covid-19 vaccine allocation for older age groups. Relative differences between allocation strategies were increases as the speed of vaccine rollout was increased.,1022,Human,FALSE,22.92,0,13.7,19.94,17,13.61,14,10.75,14.08,13th and 14th grade,220,29,6.620689655,2,0.1094,0.8676,0.023,0.716759324,0.096370421,0.186870247
The findings support global recommendations to prioritize covid-19 vaccine allocation for younger age groups. Relative differences between allocation strategies were decreases as the speed of vaccine rollout was decreased.,1022,Human,FALSE,22.92,0,13.7,20.35,17.3,13.61,13,10.75,14.08,13th and 14th grade,222,29,6.689655172,2,0.064,0.8646,0.0714,0.717536807,0.094952874,0.187510356
The findings support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies were increased as the speed of vaccine rollout was increased.,1022,Human,FALSE,22.92,0,13.7,19.94,17,13.07,13,10.25,12.7,12th and 13th grade,220,29,6.620689655,2,0.1153,0.8625,0.0223,0.719037652,0.098202243,0.182760164
The findings do not support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,30.36,0,12.9,18.33,15.9,13.06,14,10.75,12.65,12th and 13th grade,225,31,6.290322581,2,0.01,0.3172,0.6728,0.711785197,0.088563628,0.199651092
The findings support global recommendations to prioritize COVID-19 vaccine allocation for younger age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,31.38,0,12.5,19.94,17,13.61,13,10.25,12.7,12th and 13th grade,220,29,6.620689655,2,0.2053,0.7733,0.0214,0.71739471,0.09544716,0.187158227
The findings support global recommendations to prioritize COVID-19 vaccine allocation for certain race groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,22.92,0,13.7,20.12,17.2,13.07,13,10.25,12.7,12th and 13th grade,221,29,6.655172414,2,0.1454,0.8279,0.0267,0.683879912,0.087414466,0.228705585
The findings support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies were emphasized as the speed of vaccine rollout was increased.,1022,Human,FALSE,22.92,0,13.7,20.12,17.2,13.61,14,10.75,14.08,13th and 14th grade,221,29,6.655172414,2,0.15,0.8294,0.0206,0.708259225,0.103025928,0.188714907
The findings support global recommendations to prioritize COVID-19 vaccine allocation for younger age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,31.38,0,12.5,19.94,17,13.61,13,10.25,12.7,12th and 13th grade,220,29,6.620689655,2,0.2053,0.7733,0.0214,0.71739471,0.09544716,0.187158227
The findings support global recommendations to prioritize COVID-19 vaccine allocation for young age groups. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,31.38,0,12.5,19.54,16.7,13.07,13,10.25,12.7,12th and 13th grade,218,29,6.551724138,2,0.2007,0.7782,0.0211,0.713281333,0.095646821,0.191071779
The findings support global recommendations to prioritize COVID-19 vaccine allocation for all age groups. male and female differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,38.82,0,11.7,17.98,15.7,12.55,13,10.25,11.36,11th and 12th grade,223,31,6.225806452,2,0.3507,0.6343,0.015,0.709234238,0.106060311,0.184705406
The findings support global recommendations to prioritize COVID-19 vaccine allocation for groups of people between the ages of 50-60. Relative differences between allocation strategies were reduced as the speed of vaccine rollout was increased.,1022,Human,FALSE,28.84,0,13.5,17.75,16.3,13.3,13,11.5,12.68,12th and 13th grade,244,34,6.205882353,6,0.1264,0.8501,0.0235,0.697353244,0.090520687,0.212126076
The findings support global recommendations to prioritize COVID-19 vaccine allocation for younger age groups. Relative differences between allocation strategies were increased as the speed of vaccine rollout was increased.,1022,Human,FALSE,31.38,0,12.5,20.35,17.3,13.07,12,10.25,12.7,12th and 13th grade,222,29,6.689655172,2,0.1418,0.8387,0.0195,0.720530868,0.09789829,0.181570888
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and less severe COVID-19 infections due to auto immunity.",1029,Human,FALSE,16.66,0,18.1,16.49,21,13.79,11,21.5,21.26,20th and 21st grade,200,29,5.931034483,4,0.015,0.2741,0.7109,0.726167858,0.065977745,0.20785445
"Down Syndrome, which is caused by covid 19 vaccinations, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and more sever COVID-19 infections.",1029,Human,FALSE,19.71,0,17,18.28,21.3,13.43,10,20,21.17,16th and 17th grade,189,26,6.307692308,4,0.0117,0.1989,0.7894,0.696449935,0.064286083,0.239263967
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the entire respiratory tract, and all COVID-19 infections.",1029,Human,FALSE,21.74,0,16.2,17.58,19.8,14.7,10,18,19.6,17th and 18th grade,172,24,6.208333333,4,0.0108,0.181,0.8083,0.727786064,0.064267546,0.20794633
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the entire respiratory tract, and more severe COVID-19 infections.",1029,Human,FALSE,20.72,0,16.6,17.82,20.5,14.98,11,18.5,19.6,16th and 17th grade,180,25,6.24,4,0.009,0.1467,0.8444,0.737245381,0.058125816,0.204628751
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the lower respiratory tract, and more sever COVID-19 infections.",1029,Human,FALSE,20.72,0,16.6,17.35,20.1,14.98,11,18.5,19.6,16th and 17th grade,178,25,6.16,4,0.0103,0.1813,0.8085,0.716527641,0.060520679,0.22295171
"Down Syndrome, which is caused by trisomy 21, is characterized by immune regulation, anatomical differences in the upper respiratory tract, and more sever COVID-19 infections.",1029,Human,FALSE,29.18,0,15.4,16.66,19.5,14.35,10,18.5,19.6,19th and 20th grade,175,25,6.04,4,0.0124,0.2214,0.7661,0.716020226,0.064609922,0.219369903
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the lower respiratory tract, and more severe COVID-19 infections.",1029,Human,FALSE,20.72,0,16.6,17.58,20.3,14.98,11,18.5,19.6,19th and 20th grade,179,25,6.2,4,0.0091,0.1568,0.834,0.739667654,0.05883472,0.201497525
"Down Syndrome, which is caused by fear of heights, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and more severe COVID-19 infections.",1029,Human,FALSE,28.17,0,15.8,17.12,20.4,13.43,9,19,19.63,19th and 20th grade,184,26,6.115384615,2,0.0102,0.1581,0.8317,0.687495291,0.068833195,0.243671462
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the lower respiratory tract, and more severe COVID-19 infections.",1029,Human,FALSE,20.72,0,16.6,17.58,20.3,14.98,11,18.5,19.6,19th and 20th grade,179,25,6.2,4,0.0091,0.1568,0.834,0.739667654,0.05883472,0.201497525
"Down Syndrome, which is caused by trisomy 21, is characterized by increased immune function, anatomical differences in the upper respiratory tract, and more minor COVID-19 infections.",1029,Human,FALSE,28.17,0,15.8,16.95,20.2,14.64,11,18,18.09,17th and 18th grade,183,26,6.076923077,4,0.0175,0.3187,0.6638,0.728575051,0.060443342,0.210981488
"Down syndrome, which is caused by trisomy 22, is chracterized by immune dysregulation, anatomical differences in the upper respiratory tract, and less sever covid-19 infections.",1029,Human,FALSE,29.18,0,15.4,17.12,19.9,14.35,10,18.5,19.6,19th and 20th grade,177,25,6.12,4,0.0235,0.3536,0.6229,0.677465975,0.069313586,0.253220409
"Down syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differnces in the lower respiractory tract, and less server covid-19 infections.",1029,Human,FALSE,29.18,0,15.4,17.58,20.3,14.98,11,18.5,19.6,14th and 15th grade,179,25,6.2,4,0.0109,0.2146,0.7745,0.679174423,0.066228323,0.254597336
"Down Syndrome, which is caused by Klinefelter 21, is characterized by immune regulation, anatomical differences in the lower respiratory tract, and more mild COVID-19 infections.",1029,Human,FALSE,29.18,0,15.4,17.35,20.1,14.98,10,19.5,21.2,14th and 15th grade,178,25,6.16,4,0.0127,0.2819,0.7054,0.732783794,0.068579771,0.198636398
"Down Syndrome, which is caused by trisomy 21, is characterized by immune regulation, anatomical differences in the upper respiratory tract, and lower COVID-19 infections.",1029,Human,FALSE,21.74,0,16.2,17.12,19.4,14.7,10,18,19.6,17th and 18th grade,170,24,6.125,4,0.0186,0.3265,0.6549,0.71747452,0.06823428,0.21429123
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and more sever COVID-19 infections.",1029,Human,FALSE,20.72,0,16.6,17.35,20.1,14.35,10,18.5,19.6,16th and 17th grade,178,25,6.16,4,0.0105,0.1859,0.8037,0.716592968,0.060649443,0.222757578
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and more sever COVID-19 infections.",1029,Human,FALSE,20.72,0,16.6,17.35,20.1,14.35,10,18.5,19.6,16th and 17th grade,178,25,6.16,4,0.0105,0.1859,0.8037,0.716592968,0.060649443,0.222757578
"Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the stem of the brain, and more severe COVID-19 infections.",1029,Human,FALSE,36.63,0,14.6,14.68,18.4,12.82,9,18,18.09,14th and 15th grade,173,26,5.692307692,4,0.0081,0.1427,0.8492,0.706714034,0.061811361,0.231474653
"Down Syndrome, which is caused by trisomy 21, is characterized by immune regulation, gastric differences in the upper respiratory tract, and more severe COVID-19 infections.",1029,Human,FALSE,29.18,0,15.4,16.19,19.1,14.35,10,17.5,18,17th and 18th grade,173,25,5.96,4,0.0107,0.178,0.8113,0.728966177,0.069242865,0.201790959
"Down syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and more sever COVID-19 infections.",1029,Human,FALSE,20.72,0,16.6,17.35,20.1,14.35,10,18.5,19.6,16th and 17th grade,178,25,6.16,4,0.0106,0.1936,0.7958,0.716592968,0.060649443,0.222757578
"Down syndrome, which is caused by trisomy 21, is characterized by immune difficulty accepting their emotional response, anatomical differences in the upper respiratory tract, and more severe COVID-19 infections.",1029,Human,FALSE,16.66,0,18.1,18.69,22.8,14.88,13,22.5,22.63,22nd and 23rd grade,211,29,6.310344828,4,0.0105,0.1757,0.8138,0.717229068,0.098029658,0.184741288
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among major agents that can hinder in recovery of patients with COVID19.",1033,Human,FALSE,33.92,0,17.7,14.69,23.2,12.73,13,22.5,19.12,22nd and 23rd grade,241,37,5.540540541,2,0.0108,0.1985,0.7906,0.660608828,0.078594998,0.26079616
"The presence of trapizoids, flavornoids and the rich amounts of phunky compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among major agents that can help in recovery of patients with COVID19.",1033,Human,FALSE,33.92,0,17.7,14.17,22.8,12.3,12,21.5,18.04,17th and 18th grade,238,37,5.459459459,2,0.6626,0.3268,0.0106,0.629797816,0.068317175,0.301885128
"The therapeutic potential of terpenoids, flavonoids, and phenolic compounds, which are present in rich amounts, have been scientifically proven to possess remarkable anti-inflammatory effects that aid in the up-regulation of the immune system, thereby contributing significantly to the recovery of COVID19 patients.",1033,Human,FALSE,-5,0,24.4,20.32,30.3,14.37,19,31,26.32,30th and 31st grade,315,42,6.523809524,2,0.9143,0.0809,0.0048,0.654160082,0.074230202,0.271609753
"The absence of terpenoids, flavonoids, and phenolic compounds, which do not have any anti-inflammatory effects or up-regulation of the immune system, are among the major factors that can help in the recovery of patients with COVID19.",1033,Human,FALSE,34.94,0,17.3,14.11,22.5,12,13,22,18.84,11th and 12th grade,233,36,5.5,2,0.4844,0.4817,0.0339,0.683731318,0.068001635,0.248266995
"The presence of terpenoids, flavonoids, and phenolic compounds in significant quantities, which are known for their anti-inflammatory effects and immune system up-regulation properties, are believed to play a pivotal role in facilitating the recovery of patients with COVID-19, according to current scientific understanding.",1033,Human,FALSE,-6.02,0,24.8,20.44,31,15.32,22,32.5,27.43,24th and 25th grade,324,43,6.558139535,2,0.7344,0.2586,0.007,0.6409356,0.063747704,0.295316726
"The presence of terpenoids, flavonoids, and phenolic compounds in significant quantities, which are known to have anti-inflammatory effects and up-regulate the immune system, are proven to be effective in aiding the recovery of patients with COVID-19, as demonstrated by robust scientific evidence and clinical trials",1033,Human,FALSE,0.42,0,24.4,17.77,29.7,14.99,22,33.5,27.78,-1th and 0th grade,317,45,6.066666667,2,0.8302,0.1605,0.0093,0.651413739,0.058178108,0.290408105
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among major agents that can help in preventing the spread of COVID19.",1033,Human,FALSE,33.92,0,17.7,14.17,22.8,11.87,11,22.5,19.12,22nd and 23rd grade,238,37,5.459459459,2,0.6662,0.3155,0.0183,0.66648674,0.078323491,0.255189747
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have inflammatory effects and also supress the immune system, are among major agents that can make patients with COVID19 take longer to recover.",1033,Human,FALSE,43.4,0,16.2,14.57,22.5,12.44,11,21,17.73,-1th and 0th grade,233,36,5.5,2,0.0097,0.1844,0.8059,0.618506253,0.068108395,0.313385338
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are merely minor agents have no real effect on recovery of patients with COVID19.",1033,Human,FALSE,24.45,0,19.3,14.46,23.5,13.42,15,23,19.41,18th and 19th grade,246,38,5.5,2,0.042,0.5015,0.4565,0.630407989,0.066763468,0.30282858
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have inflammatory effects and also up deterioration of the immune system, are among major agents that can help in recovery of patients with COVID19.",1033,Human,FALSE,33.92,0,17.7,14.17,22.6,11.87,11,22.5,19.12,22nd and 23rd grade,237,37,5.432432432,2,0.1228,0.7055,0.1717,0.658711791,0.078201473,0.263086826
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among minor agents that can help in recovery of patients with COVID19.",1033,Human,FALSE,33.92,0,17.7,14.34,22.9,12.73,13,22.5,19.12,22nd and 23rd grade,239,37,5.486486486,2,0.604,0.3842,0.0118,0.647738874,0.075519629,0.276741445
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among common agents that can help in recovery of patients with COVID19.",1033,Human,FALSE,33.92,0,17.7,14.52,23,12.73,13,22.5,19.12,22nd and 23rd grade,240,37,5.513513514,2,0.6417,0.3484,0.0099,0.659158587,0.077680692,0.263160706
"The presence of testosterone, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among major agents that can help in recovery of patients with COVID19",1033,Human,FALSE,33.92,0,17.7,14.69,23,12.3,12,22.5,19.12,22nd and 23rd grade,240,37,5.513513514,2,0.7272,0.2642,0.0086,0.659043133,0.083637983,0.257318884
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have inflammatory effects and also lower regulation of the immune system, are among major agents that can help in recovery of patients with COVID19",1033,Human,FALSE,33.92,0,17.7,14.17,22.6,12.3,12,22.5,19.12,22nd and 23rd grade,236,37,5.405405405,2,0.4903,0.491,0.0187,0.666585445,0.085832357,0.247582138
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among major agents that can help in recovery of patients with COVID19",1033,Human,FALSE,33.92,0,17.7,14.34,22.8,12.3,12,22.5,19.12,22nd and 23rd grade,238,37,5.459459459,2,0.7394,0.2524,0.0082,0.665992975,0.080257319,0.253749728
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among major agents that can help in recovery of patients with COVID19",1033,Human,FALSE,33.92,0,17.7,14.34,22.8,12.3,12,22.5,19.12,22nd and 23rd grade,238,37,5.459459459,2,0.7394,0.2524,0.0082,0.665992975,0.080257319,0.253749728
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among major agents that will help in recovery of patients with COVID19.",1033,Human,FALSE,33.92,0,17.7,14.52,23,12.3,12,22.5,19.12,22nd and 23rd grade,240,37,5.513513514,2,0.7769,0.2155,0.0076,0.663801312,0.080012605,0.256186128
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also up regulation of the immune system, are among major agents recover patients quickly with COVID19.",1033,Human,FALSE,29.52,0,17.3,16.55,22.8,12.93,12,20.5,18.05,16th and 17th grade,226,33,5.878787879,2,0.5923,0.3933,0.0145,0.617793798,0.07038644,0.311819792
"The presence of terpenoids, flavonoids and the subtle amounts of phenolic compounds, which have anti-inflammatory effects and also up possibility of the immune system regulation, are among major agents that can help in recovery of patients with COVID19.",1033,Human,FALSE,24.45,0,19.3,15.5,24.3,13,14,24,20.46,12th and 13th grade,253,38,5.684210526,2,0.6749,0.3161,0.009,0.654722691,0.080303952,0.264973313
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have inflammatory effects and also up regulation of the immune system, are among major agents that can help in recovery of patients with COVID19.",1033,Human,FALSE,42.38,0,16.5,13.7,22.3,11.87,11,22.5,19.12,22nd and 23rd grade,234,37,5.351351351,2,0.4436,0.5388,0.0175,0.659913421,0.080653235,0.259433329
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have also been tested with COVID-19 treatment. Despite an expected lowered tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic having little effectiveness has been confirmed in randomized trials.",1036,Human,FALSE,14.8,0,16.8,19.5,20.2,13.88,21,18.75,19.67,19th and 20th grade,334,45,6.444444444,4,0.0721,0.7069,0.221,0.661684453,0.159356028,0.178959534
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has been confirmed in trials.",1036,Human,FALSE,16.32,0,16.2,18.62,19,13.7,19,18,19.83,18th and 19th grade,308,42,6.357142857,4,0.4168,0.5653,0.0178,0.659612119,0.188734114,0.151653707
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin C, have been explored as potential treatments for COVID-19, given their excellent tolerance and plausible rationale for anti-COVID-19 activities. However, the effectiveness of these supplements in preventing or treating COVID-19 has not been confirmed in randomized trials, which makes it challenging to draw definitive conclusions about their efficacy.",1036,Human,FALSE,16.66,0,18.1,19.33,23.3,13.24,24,25,23.32,18th and 19th grade,429,58,6.413793103,6,0.5578,0.4242,0.018,0.722578704,0.10892538,0.168495834
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin C, have been proven to be highly effective in treating COVID-19, with randomized trials confirming their preventive and therapeutic effectiveness. These supplements are well-tolerated and their anti-COVID-19 activities are supported by compelling rationale.",1036,Human,FALSE,15.81,0,16.4,20.59,21.2,14.25,20,19.25,21.62,20th and 21st grade,333,43,6.76744186,4,0.9317,0.0636,0.0047,0.704573631,0.12131004,0.174116254
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have not been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trials.",1036,Human,FALSE,15.31,0,16.6,18.56,19.4,13.7,20,19,20.62,18th and 19th grade,322,44,6.340909091,4,0.0503,0.5471,0.4025,0.687921822,0.154654622,0.157423511
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have soly been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trials.",1036,Human,FALSE,15.31,0,16.6,18.68,19.5,14.06,20,19,20.62,18th and 19th grade,323,44,6.363636364,4,0.1672,0.7457,0.0871,0.681314349,0.167765588,0.150920063
"Dietary supplements and vitamins including vitamin D and low-dose vitamin C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trials.",1036,Human,FALSE,15.31,0,16.6,18.56,19.4,13.7,20,19,20.62,18th and 19th grade,322,44,6.340909091,4,0.2107,0.7422,0.0471,0.682254016,0.153678641,0.164067388
Dietary supplements and vitamins including vitamin A and high-dose vitamin B have also been used for COVID-19 treatment. Their preventive or therapeutic effectiveness has not been confirmed in randomized trials.,1036,Human,FALSE,30.87,0,12.7,16.52,14.7,12.8,12,12,16.67,12th and 13th grade,211,30,6.066666667,2,0.04,0.7473,0.2127,0.675288081,0.176609069,0.148102835
"Dietary supplements and vitamins including vitamin E and high-dose vitamin A have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trials.",1036,Human,FALSE,15.31,0,16.6,18.68,19.5,13.34,20,19,20.62,18th and 19th grade,323,44,6.363636364,4,0.1919,0.7527,0.0554,0.688468814,0.144727439,0.166803762
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have also been used for proving COVID-19 is not real. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trials.",1036,Human,FALSE,13.78,0,17.2,17.58,19.1,13.2,20,19.75,20.46,19th and 20th grade,333,47,6.106382979,4,0.0851,0.6014,0.3135,0.672622561,0.147292137,0.180085361
"Despite no accepted tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trials.",1036,Human,FALSE,3.8,0,18.9,21.06,22.7,14.35,13,22.5,22.8,22nd and 23rd grade,192,25,6.72,2,0.0262,0.3907,0.5831,0.635021329,0.066296704,0.298681915
"Dietary supplements and vitamins such as vitamin D and high-dose vitamin C , alone, have cured people of COVID-19.",1036,Human,FALSE,53.21,0,10.3,11.77,12.7,13.3,4,13.5,13.87,13th and 14th grade,114,19,5.052631579,2,0.7494,0.2393,0.0113,0.545227647,0.310140043,0.14463228
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have also been used for COVID-19 treatment. Despite their unexpected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has been constantly confirmed in randomized trials.",1036,Human,FALSE,6.84,0,17.8,20.3,20.8,14.06,21,19.5,21.53,19th and 20th grade,335,44,6.636363636,4,0.7118,0.2795,0.0087,0.679154992,0.144173145,0.176671833
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have not been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trials.",1036,Human,FALSE,15.31,0,16.6,18.56,19.4,13.7,20,19,20.62,18th and 19th grade,322,44,6.340909091,4,0.0503,0.5471,0.4025,0.687921822,0.154654622,0.157423511
"Home remedies including vitamin D and high-dose vitamin C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in trials.",1036,Human,FALSE,25.29,0,14.8,17.52,17.9,13.13,17,16.75,17.96,17th and 18th grade,293,41,6.170731707,4,0.2036,0.7332,0.0632,0.682324588,0.161475241,0.156200215
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have also been used to cure COVID- 19. Despite and expected excellent tolerance and an interesting rationale to support their anti-CODID-19 activities, their preventative and therapeutic effectiveness has been perceived favorably in cases.",1036,Human,FALSE,15.31,0,16.6,17.81,18.8,13.7,20,19,20.62,18th and 19th grade,316,44,6.204545455,4,0.8215,0.1706,0.008,0.649385691,0.155195877,0.195418432
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trails.",1036,Human,FALSE,15.31,0,16.6,18.68,19.5,13.7,19,19,20.62,18th and 19th grade,323,44,6.363636364,4,0.2202,0.7368,0.043,0.677060187,0.143558115,0.179381654
"Dietary supplements and vitamins including vitamin D and high-dose vitamin C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trails.",1036,Human,FALSE,15.31,0,16.6,18.68,19.5,13.7,19,19,20.62,18th and 19th grade,323,44,6.363636364,4,0.2202,0.7368,0.043,0.677060187,0.143558115,0.179381654
"Dietary supplements and vitamins including vitamin D and high-dose vitamin B have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trials",1036,Human,FALSE,15.31,0,16.6,18.68,19.4,13.7,20,19,20.62,18th and 19th grade,322,44,6.340909091,4,0.23,0.7269,0.0431,0.685100853,0.138623029,0.176276103
"Dietary supplements and vitamins including vitamin D and low-dose vitamin C have also been used for COVID-19 treatment. Despite an expected excellent tolerance and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic effectiveness has not been confirmed in randomized trials",1036,Human,FALSE,15.31,0,16.6,18.56,19.3,13.7,20,19,20.62,18th and 19th grade,321,44,6.318181818,4,0.2472,0.7145,0.0382,0.685679376,0.137970492,0.176350221
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients do not show neurological symptoms, later European studies showed less than 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,43.73,0,11.9,14.79,15,14.14,17,12.5,13.92,14th and 15th grade,254,38,5.710526316,6,0.0236,0.6064,0.3701,0.678830683,0.07817062,0.242998719
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological hemorrhaging, later European studies showed as much as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,35.78,0,12.9,15.49,15.3,14.37,17,12.75,14.97,14th and 15th grade,252,37,5.837837838,6,0.0222,0.5841,0.3937,0.668904126,0.082700349,0.248395592
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 39% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,44.24,0,11.7,14.85,14.8,14.37,17,12.25,13.89,14th and 15th grade,248,37,5.72972973,6,0.0319,0.7583,0.2098,0.669169486,0.082805209,0.248025313
"We addressed the infectability of the central nervous system. Early reports from Bejing suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,35.78,0,12.9,15.03,14.9,14.37,18,12.25,13.89,14th and 15th grade,249,37,5.756756757,6,0.0321,0.7592,0.2086,0.665333927,0.084124178,0.250541866
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 79% of COVID-19 patients show neurological symptoms, later European studies showed only 39%; cases of viral encephalitis have been reported.",1041,Human,FALSE,36.79,0,12.5,15.72,15.3,14.88,17,11.75,13.86,11th and 12th grade,242,35,5.942857143,6,0.0339,0.7621,0.204,0.677870989,0.08143609,0.240692943
"We addressed the infectability of the central nervous system. Early reports from Wuhan china report that no COVID-19 patients show neurological symptoms, later European studies showed only 2 cases of viral encephalitis that have been reported.",1041,Human,FALSE,36.28,0,12.7,15.31,14.8,13.74,16,11.5,12.76,12th and 13th grade,243,36,5.777777778,3,0.0379,0.7914,0.1707,0.65629065,0.081883408,0.261825979
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients do not show neurological symptoms, later European studies showed as little as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,43.22,0,12.1,14.27,14.8,13.92,17,12.75,13.95,13th and 14th grade,257,39,5.615384615,6,0.0215,0.6021,0.3764,0.672247946,0.079735398,0.248016596
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have not been reported.",1041,Human,FALSE,43.73,0,11.9,14.45,14.7,14.14,17,12.5,13.92,13th and 14th grade,252,38,5.657894737,6,0.0266,0.7429,0.2305,0.670877993,0.082647361,0.246474683
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neuroinfection symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,44.24,0,11.7,15.14,15,14.37,17,12.25,13.89,14th and 15th grade,250,37,5.783783784,6,0.0255,0.6819,0.2925,0.666488945,0.079250313,0.254260719
"We addressed the noninfectious of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been
reported.",1041,Human,FALSE,44.24,0,11.7,14.85,14.8,14.37,17,12.25,13.89,14th and 15th grade,248,37,5.756756757,6,0.0448,0.8178,0.1375,0.661305368,0.077497229,0.261197507
"We addressed the affectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,44.24,0,11.7,14.85,14.8,14.37,17,12.25,13.89,14th and 15th grade,248,37,5.72972973,6,0.0321,0.7863,0.1815,0.66640991,0.087304838,0.24628526
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 76% of COVID-19 patients show neurological symptoms, later European studies showed as much as 90%; cases of viral chickenpox have been reported.",1041,Human,FALSE,44.24,0,11.7,14.56,14.6,14.37,17,12.25,13.89,14th and 15th grade,246,37,5.675675676,6,0.0395,0.7514,0.2091,0.660905123,0.083764076,0.255330831
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,44.24,0,11.7,14.85,14.8,14.37,17,12.25,13.89,14th and 15th grade,248,37,5.72972973,6,0.0313,0.7578,0.2109,0.667154908,0.082881853,0.249963284
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,44.24,0,11.7,14.85,14.8,14.37,17,12.25,13.89,14th and 15th grade,248,37,5.72972973,6,0.0313,0.7578,0.2109,0.667154908,0.082881853,0.249963284
"We addressed the infectability of the central nervous system. Early reports from Wuhan mentioned that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,44.24,0,11.7,14.85,14.8,14.37,17,11.75,12.81,14th and 15th grade,248,37,5.72972973,6,0.0319,0.7661,0.202,0.658875644,0.086828917,0.254295498
"We addressed the infectability of the central nervous system. Early reports from Wuhan reported that 36% of COVID-19 patients show neurological symptoms, later European studies showed as little as 60%; cases of viral encephalitis have been reported.",1041,Human,FALSE,35.78,0,12.9,15.03,14.9,13.94,16,12.25,12.81,12th and 13th grade,249,37,5.756756757,6,0.025,0.6921,0.2829,0.668814003,0.082975246,0.248210758
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported. From these numbers we see that the CNS is easily infectable.",1041,Human,FALSE,55.24,11.9,9.5,13.11,12.3,13.31,20,10.333333333333334,12.23,9th and 10th grade,309,48,5.458333333,6,0.0324,0.722,0.2456,0.635822177,0.083413355,0.28076452
"We addressed the infectability of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported. From the studies we see that the CNS is obviously weaker than the brain and the brain has a strong capacity for pain and disease.",1041,Human,FALSE,50.46,12.5,11.4,11.6,13,11.79,21,13,13.44,12th and 13th grade,378,62,5.112903226,6,0.0259,0.6419,0.3322,0.636122763,0.086109377,0.277767926
"Early reports from Wuhan suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 10%; cases of viral encephalitis have been reported",1041,Human,FALSE,34.6,0,15.4,14.68,19.1,15.18,12,19,18.34,14th and 15th grade,185,28,5.642857143,6,0.0252,0.64,0.3348,0.681526899,0.086072609,0.232400477
"Early reports from North Korea suggested that 36% of COVID-19 patients show neurological symptoms, later European studies showed as much as 60%; cases of viral encephalitis have been reported",1041,Human,FALSE,33.58,0,15.8,14.92,19.5,14.88,13,19.5,18.5,14th and 15th grade,191,29,5.620689655,6,0.0243,0.6245,0.3512,0.663352132,0.090250619,0.246397212
"mRNA vaccines have shown to fight COVID-19 better than other vaccines, and this is why they were the first vaccines authorized world wide.",1042,Human,FALSE,73.51,0,8.7,11.49,13.8,8.9,3,12.5,10.94,8th and 9th grade,138,23,5.043478261,2,0.9249,0.0703,0.0047,0.61085695,0.098383553,0.290759474
mRNA vaccines will prevent you from getting COVID19.,1042,Human,FALSE,71.82,0,5.2,12.25,9.1,11.93,3,3,3.2,11th and 12th grade,52,8,5.625,2,0.0371,0.4562,0.5066,0.633077919,0.174371362,0.192550674
"Recent improvements in mRNA vaccines act to increase enzyme production, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,17.35,17.1,12.7,17,13.25,14.98,12th and 13th grade,276,39,6.102564103,2,0.733,0.2612,0.0057,0.628348887,0.068128988,0.30352214
"Recent improvements in DNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,17.52,17.2,13.11,17,13.25,14.98,12th and 13th grade,277,39,6.128205128,2,0.7112,0.2831,0.0057,0.632899046,0.070154816,0.296946108
"Recent scientific advancements in the field of mRNA technology have shown promising results in boosting protein translation, regulating innate and adaptive immunogenicity, and enhancing the delivery mechanism of vaccines. These vaccines are a novel class of immunization designed to safeguard against a wide range of infectious diseases, and were among the first vaccines to be authorized globally for use against the COVID-19 pandemic.",1042,Human,FALSE,22.58,0,17.9,17.18,22.3,12.97,27,22.75,21.49,17th and 18th grade,436,63,5.936507937,2,0.8383,0.157,0.0047,0.644660473,0.048792385,0.306547105
"Recent improvements in mRNA vaccines act to decrease protein translation, suppress innate and adaptive immunogenicity, and worsen delivery. mRNA vaccines are an old type of vaccine to protect against infectious diseases and were not the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.26,0,13.5,17.23,17.2,12.92,18,13,14,13th and 14th grade,282,40,6.075,2,0.0139,0.3515,0.6346,0.634301662,0.066987574,0.298710734
"Recent improvements in mRNA vaccines act to decrease protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,17.69,17.3,12.7,17,13.25,14.98,12th and 13th grade,278,39,6.153846154,2,0.6609,0.3316,0.0075,0.631053329,0.065555863,0.303390771
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are an established type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,19.03,18.4,13.11,18,13.75,16.01,13th and 14th grade,287,39,6.384615385,2,0.7243,0.2698,0.0059,0.62992233,0.061126698,0.308950961
"All improvements in mRNA vaccines act to decrease protein translation, modulate innate and adaptive immunogenicity, and in result improve delivery. mRNA vaccines are a traditional type of vaccine to protect against infectious diseases and were the third COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,33.75,0,13.6,17.81,17.9,12.74,18,14.25,16,17th and 18th grade,293,41,6.170731707,2,0.4746,0.5126,0.0128,0.630919158,0.057267904,0.311812878
"Recent improvements in mRNA vaccines act to decrease protein translation, modulate innate and adaptive immunogenicity, and deteriorate delivery. mRNA vaccines are a old type of vaccine that does not protect against infectious diseases and was the root cause of COVID-19 spreading worldwide.",1042,Human,FALSE,33.24,0,13.8,16.42,17,12.57,18,14,15.07,13th and 14th grade,290,42,5.928571429,2,0.0079,0.148,0.8441,0.645956576,0.071275987,0.282767385
"Recent improvements in mRNA vaccines act to decrease protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,17.69,17.3,12.7,17,13.25,14.98,12th and 13th grade,278,39,6.153846154,2,0.6609,0.3316,0.0075,0.631053329,0.065555863,0.303390771
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine that doesn't against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,17.81,17.6,12.7,17,13.25,14.98,12th and 13th grade,280,39,6.205128205,2,0.7141,0.28,0.0059,0.62812072,0.058423493,0.31345579
"Recent improvements in ivermectin vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,18.56,18,13.11,18,13.25,14.98,12th and 13th grade,284,39,6.307692308,2,0.7259,0.2687,0.0054,0.63384378,0.06131221,0.304843992
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide and it completely eradicated the COVID-19 virus.",1042,Human,FALSE,31.21,0,14.6,17.7,18.8,12.67,19,16,17.03,17th and 18th grade,326,46,6.108695652,4,0.8271,0.1672,0.0057,0.62859273,0.057008978,0.314398229
"Recent improvements in mRNA vaccines act to decrease protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,17.69,17.3,12.7,17,13.25,14.98,12th and 13th grade,278,39,6.153846154,2,0.6609,0.3316,0.0075,0.631053329,0.065555863,0.303390771
"Recent improvements in mRNA vaccines act to decrease protein translation, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,45.76,0,11.1,15.83,14.8,11.91,13,11,12.68,10th and 11th grade,233,34,5.882352941,2,0.7085,0.285,0.0065,0.629663944,0.070921808,0.299414217
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide",1042,Human,FALSE,34.76,0,13.3,17.69,17.2,12.7,17,13.25,14.98,12th and 13th grade,277,39,6.128205128,2,0.7615,0.233,0.0056,0.629881859,0.064400755,0.305717349
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide",1042,Human,FALSE,34.76,0,13.3,17.69,17.2,12.7,17,13.25,14.98,12th and 13th grade,277,39,6.128205128,2,0.7615,0.233,0.0056,0.629881859,0.064400755,0.305717349
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the second COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,17.81,17.4,12.7,17,13.25,14.98,12th and 13th grade,279,39,6.179487179,2,0.7437,0.2509,0.0054,0.626641631,0.062160943,0.31119743
"Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity, and decrease delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines authorized worldwide.",1042,Human,FALSE,34.76,0,13.3,17.81,17.4,13.11,18,13.25,14.98,12th and 13th grade,279,39,6.179487179,2,0.4666,0.5229,0.0105,0.630500674,0.058573667,0.310925633
"We noticed major influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies died in hospitals because they were not prescribed ivermectin.",1043,Human,FALSE,53.71,0,10.1,11.77,11.7,10.37,9,11.75,13.86,11th and 12th grade,215,35,5.171428571,2,0.018,0.3184,0.6636,0.679578781,0.111983053,0.208438113
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies died in 1 hour and very rapidly before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,58.11,0,10.5,9.28,11.3,9.84,9,14.25,15.11,9th and 10th grade,243,43,4.674418605,3,0.0233,0.4795,0.4972,0.672721148,0.106798671,0.220480189
"We noticed minor influence of age on COVID diagnosis. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,51.18,0,11.1,10.44,11.6,10.55,10,13.5,15,10th and 11th grade,234,40,4.875,2,0.0237,0.5128,0.4636,0.650644004,0.176938236,0.17241776
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of minors died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,59.64,0,9.9,9.86,11.1,10.55,10,13,14,9th and 10th grade,230,40,4.775,2,0.0172,0.4244,0.5583,0.671156049,0.109518416,0.219325513
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in France, a considerable number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,51.18,0,11.1,10.44,11.6,10.55,10,13.5,15,10th and 11th grade,234,40,4.875,2,0.0203,0.526,0.4536,0.645339072,0.163332224,0.191328719
"We noticed major influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,51.18,0,11.1,10.27,11.4,10.16,9,13.5,15,10th and 11th grade,233,40,4.85,2,0.0233,0.4498,0.527,0.673247874,0.132181317,0.194570825
"We noticed major influence of age on ICU admissions. This is probably because in the first wave of COVID 19 in Spain, a considerable number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU",1043,Human,FALSE,59.13,0,10.1,9.57,10.9,10.05,9,13.75,15.03,9th and 10th grade,232,41,4.682926829,2,0.0254,0.4656,0.509,0.665798604,0.128968909,0.205232531
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID 19 in Spain, a small number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU",1043,Human,FALSE,59.13,0,10.1,8.59,10.1,10.05,9,13.25,14.05,9th and 10th grade,225,41,4.512195122,2,0.025,0.5688,0.4062,0.667705953,0.121762671,0.210531414
"We noticed major influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,51.18,0,11.1,10.27,11.4,10.16,9,13.5,15,10th and 11th grade,233,40,4.85,2,0.0233,0.4498,0.527,0.673247874,0.132181317,0.194570825
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of children died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,59.64,0,9.9,10.1,11.3,10.16,9,13,14,9th and 10th grade,232,40,4.825,2,0.0202,0.4562,0.5236,0.670486152,0.136789143,0.192724645
We noticed a major influence of age on ICU admissions.,1043,Human,FALSE,61.33,0,7.2,6.76,4.8,10.45,3,6,12,6th and 7th grade,54,10,4.5,0,0.0441,0.807,0.149,0.678150713,0.159457341,0.162391871
"This is probably because in the first wave of COVID-19 in Spain, a considerable number of teenagers that died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,55.92,0,13.4,10.69,17.2,10.65,5,20,17.8,10th and 11th grade,185,32,4.8125,2,0.01,0.2236,0.7664,0.664225936,0.142263979,0.193510011
"We noticed major irrelevance of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of individuals died in their homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,51.18,0,11.1,10.56,11.6,9.76,8,13.5,15,10th and 11th grade,235,40,4.9,2,0.0135,0.2807,0.7058,0.668438077,0.106618553,0.22494331
"We noticed mild influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a low number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,59.64,0,9.9,8.82,10.2,10.16,8,13,14,9th and 10th grade,223,40,4.6,2,0.0311,0.6303,0.3386,0.675623,0.129214153,0.195162818
"We found that age was a significant predictor of ICU admissions in our study of COVID-19 patients in Spain, with older patients being more likely to require ICU care. This is likely due to the increased risk of severe illness and complications associated with COVID-19 in older individuals.",1043,Human,FALSE,47.12,0,12.7,11.78,14.4,10.42,12,15,14.6,14th and 15th grade,290,48,5.0625,4,0.0274,0.6248,0.3478,0.7200225,0.124123797,0.155853614
"Age was found to be a significant predictor of ICU admissions in our study of COVID-19 patients in Spain, with older patients being more likely to require ICU care. This finding is consistent with previous studies indicating that older age is a risk factor for severe illness and poor outcomes in COVID-19.",1043,Human,FALSE,53.55,0,12.3,10.91,14.6,11,15,16,15.02,10th and 11th grade,306,52,4.903846154,4,0.0292,0.6962,0.2746,0.733582497,0.120726071,0.14569144
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a vast number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,59.64,0,9.9,9.11,10.5,10.55,9,13,14,9th and 10th grade,225,40,4.65,2,0.0211,0.4726,0.5063,0.674676955,0.127906874,0.197416216
"We noticed strong influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a great number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,59.64,0,9.9,9.4,10.7,9.76,8,13,14,9th and 10th grade,227,40,4.7,2,0.0248,0.4679,0.5073,0.664512098,0.144994259,0.190493569
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU",1043,Human,FALSE,51.18,0,11.1,10.27,11.3,10.55,10,13.5,15,10th and 11th grade,232,40,4.825,2,0.0235,0.5288,0.4477,0.672240019,0.122642957,0.205117047
"We noticed minor influence of age on ICU admissions. This is probably because in the first wave of COVID-19 in Spain, a considerable number of elderlies died in nursing homes before they could even be hospitalized or admitted to ICU.",1043,Human,FALSE,51.18,0,11.1,10.27,11.4,10.55,10,13.5,15,10th and 11th grade,233,40,4.85,2,0.0225,0.522,0.4555,0.674980819,0.128608942,0.196410269
"Local and systemic reactions after a third Moderna vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and heartburn were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,31.58,13.6,12.4,16.64,15.6,13.53,19,10.5,12.23,13th and 14th grade,315,43,6.348837209,7,0.0188,0.421,0.5602,0.661168158,0.066832446,0.271999389
"Local and systemic reactions after a third Johnson and Johnson vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,39.33,13,11.5,15.88,15.3,12.8,18,10.5,11.33,11th and 12th grade,323,45,6.2,7,0.0216,0.4396,0.5388,0.657983303,0.065605283,0.276411414
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and seniors, were better than those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,40.04,12.5,11.2,16.12,15.2,12.79,17,8.833333333333334,10.37,12th and 13th grade,311,43,6.255813953,7,0.1571,0.6414,0.2015,0.666868031,0.066563487,0.266568482
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly results in hospitalization. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,39.33,13,11.5,16,15.3,13.15,19,10.5,12.22,11th and 12th grade,323,45,6.2,7,0.0137,0.2844,0.7019,0.653550565,0.064386658,0.282062739
"Local and systemic reactions after a third Pfizer vaccine, as reported by the immunocompromised and seniors, were generally consistent with the reactions observed following previous vaccines and were mostly self-resolving. Fatigue, myalgia, and fever were the most commonly reported systemic side effects, with frequencies of 19.6%, 9.2%, and 8.1% respectively, in line with the expected side effect profile of the vaccine.",1061,Human,FALSE,39.03,13.8,11.6,15.01,14.2,11.9,23,11.125,13.33,11th and 12th grade,423,61,5.950819672,7,0.0335,0.6346,0.3318,0.651409805,0.065374345,0.283215851
"Local and systemic reactions after a third Pfizer vaccine, as reported by the immunocompromised and seniors, were significantly more severe compared to reactions observed after previous vaccines and often required medical intervention. Fatigue, myalgia, and fever were reported as the most frequent and persistent systemic side effects, with much higher frequencies of 19.6%, 9.2%, and 8.1% respectively, indicating a heightened risk of adverse reactions in this population.",1061,Human,FALSE,29.04,14.2,13.4,16.35,15.6,12.95,29,12.125,13.88,12th and 13th grade,474,67,6.089552239,7,0.0134,0.2678,0.7187,0.678485453,0.062905006,0.258609593
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and seniors, were dissimilar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,31.58,13,12.4,16.41,15.4,13.16,18,10.166666666666666,11.3,12th and 13th grade,313,43,6.302325581,7,0.0199,0.4228,0.5573,0.656300664,0.06363523,0.280064076
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, new hair growth, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,39.33,13,11.5,15.25,14.8,12.8,17,10.5,11.33,11th and 12th grade,318,45,6.088888889,7,0.0195,0.4253,0.5552,0.657562554,0.064572968,0.277864546
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and diabetics, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,31.58,13.6,12.4,16.23,15.3,13.16,18,10.5,12.23,11th and 12th grade,312,43,6.279069767,7,0.022,0.4549,0.5231,0.666386127,0.065769479,0.267844379
"Local and systemic reactions after a third Pfizer vaccine, reported by the aliens that visited and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,39.33,13,11.5,14.49,14.1,13.15,18,10.5,11.33,11th and 12th grade,312,45,5.955555556,7,0.0227,0.4763,0.501,0.649045706,0.071623467,0.279330879
"Local and systemic reactions after a fourth Pfizer vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Transient, trauma, and fever were the most frequent systemic side effects reported (20.6%, 6.2%, and 7.1% respectively).",1061,Human,FALSE,40.04,13,11.2,16.23,15.3,12.79,18,10.166666666666666,11.3,10th and 11th grade,312,43,6.279069767,7,0.0245,0.5615,0.4141,0.653921068,0.065860704,0.280218244
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and seniors, were different from those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,40.04,13,11.2,16.52,15.5,12.79,17,10.166666666666666,10.37,10th and 11th grade,314,43,6.325581395,7,0.0217,0.4841,0.4942,0.6656124,0.065494381,0.268893182
"Local and systemic reactions after a fifth Pfizer vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,40.04,13,11.2,16,15.1,13.16,18,10.166666666666666,11.3,10th and 11th grade,310,43,6.23255814,7,0.0208,0.4463,0.5329,0.660725474,0.064790353,0.274484128
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and death were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,40.04,13,11.2,16,15.1,13.16,18,10.166666666666666,11.3,10th and 11th grade,310,43,6.23255814,7,0.0179,0.3816,0.6005,0.660059988,0.066579767,0.273360193
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, nausea, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,40.04,13,11.2,15.83,15,13.16,18,10.166666666666666,11.3,10th and 11th grade,309,43,6.209302326,7,0.0178,0.396,0.5862,0.674542487,0.065681227,0.259776235
"Local and systemic reactions after a third Moderna vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,31.58,13.6,12.4,16.12,15.2,13.16,18,10.5,12.23,11th and 12th grade,311,43,6.255813953,7,0.0206,0.4648,0.5146,0.669463456,0.065496661,0.265039861
"Local and systemic reactions after a Pfizer vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,31.89,13,12.3,16.12,15.1,13.35,18,9,11.31,12th and 13th grade,304,42,6.261904762,7,0.0202,0.4396,0.5402,0.672278941,0.066304252,0.261416823
"regional and systemic reactions after a fifth Pfizer vaccine, reported by the immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,31.58,13.6,12.4,16.41,15.4,13.16,18,10.5,12.23,11th and 12th grade,313,43,6.302325581,7,0.0204,0.4332,0.5464,0.665450215,0.063445166,0.271104693
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and seniors, were shown to be much higher than those observed following previous vaccines and mostly self-resolved. Fatigue, myalgia, and fever were the most frequent systemic side effects reported (19.6%, 9.2%, and 8.1% respectively).",1061,Human,FALSE,47.08,12.5,10.6,15.14,14.7,12.81,18,10.5,10.54,10th and 11th grade,328,47,6,7,0.0204,0.3368,0.6428,0.667133629,0.066434324,0.266432017
After clinical trials towards self-resolved cases and the immunocompromized showed that there was no significant differences from the symptoms. The third Pfizer vaccine was reported to be unnecessary for the immunocompromized and senior citizens.,1061,Human,FALSE,20.38,0,14.6,18.27,16.6,11.45,14,13,15.04,14th and 15th grade,246,34,6.264705882,0,0.0371,0.5882,0.3747,0.646538615,0.039945126,0.313516229
Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing capacity with only an 18% higher false-positive rate than individual testing.,1066,Human,FALSE,18.69,0,17.4,14.57,18.3,12.58,10,18.5,18.21,18th and 19th grade,176,27,5.555555556,2,0.0359,0.5534,0.4107,0.64732945,0.051268294,0.301402301
Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing capacity but a 62% higher rate of false-positives.,1066,Human,FALSE,38.66,0,13.8,12.77,15.3,12.72,9,16,16.27,12th and 13th grade,149,24,5.25,2,0.0227,0.5177,0.4596,0.623935103,0.060913153,0.315151662
Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing capacity with moderate loss of sensitivity compared with testing each sample individually,1066,Human,FALSE,9.22,0,18.9,16.37,19.7,12.92,12,20,19.77,19th and 20th grade,188,28,5.75,0,0.0292,0.6288,0.3419,0.660123229,0.05147431,0.288402498
Grouping samples into pools of thirty for PCR testing resulted in an increase in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually,1066,Human,FALSE,9.22,0,18.9,16.6,19.8,12.92,12,20,19.77,19th and 20th grade,189,28,5.785714286,0,0.1123,0.8066,0.0811,0.646377146,0.055158459,0.298464358
Grouping samples into pools of six for PCR testing resulted in an increase in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,9.22,0,18.9,15.96,19.5,12.92,12,20,19.77,19th and 20th grade,187,28,5.714285714,0,0.0953,0.826,0.0787,0.651554167,0.04904788,0.299397945
Grouping samples into pools of five for PCR testing resulted in a decrease in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,9.22,0,18.9,15.96,19.5,12.92,12,20,19.77,19th and 20th grade,187,28,5.714285714,0,0.0212,0.4919,0.487,0.653183162,0.049086057,0.297730863
Grouping samples into pools of five for saliva testing resulted in an increase in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,9.22,0,18.9,16.77,20.2,12.92,13,20,19.77,19th and 20th grade,191,28,5.857142857,0,0.0752,0.8207,0.1041,0.641082764,0.051153194,0.307763964
Grouping samples into pools of five for PCR testing resulted in an severe decrease in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,8.2,0,19.3,16.49,20.2,13.24,13,20.5,19.88,19th and 20th grade,195,29,5.75862069,0,0.0162,0.3695,0.6143,0.649156988,0.048823226,0.302019715
Grouping samples into pools of two for PCR testing resulted in an increase in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,9.22,0,18.9,15.96,19.5,12.92,12,20,19.77,19th and 20th grade,187,28,5.714285714,0,0.1027,0.8213,0.076,0.652964056,0.049303357,0.297732592
Grouping samples into pools of ten for PCR testing resulted in an increase in coronavirus testing capacity with heavy loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,17.68,0,17.8,15.55,19.1,12.36,11,19,18.34,18th and 19th grade,185,28,5.642857143,0,0.0165,0.4618,0.5218,0.647373796,0.052230127,0.300396085
Grouping samples into pools of five for PCR testing resulted in an decrease in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,9.22,0,18.9,16.13,19.7,12.92,12,20,19.77,19th and 20th grade,188,28,5.75,0,0.022,0.504,0.474,0.65293628,0.048798613,0.2982651
Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus and black plague testing capacity with minimal loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,14.63,0,18.9,15.85,20.7,12.81,12,21.5,20.14,12th and 13th grade,205,31,5.64516129,0,0.0343,0.6254,0.3403,0.645946383,0.049965695,0.304087967
Grouping samples into pools of five for PCR testing resulted in no results in coronavirus testing capacity with no loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,17.68,0,17.8,14.92,18.7,12.36,11,19,18.34,18th and 19th grade,182,28,5.535714286,0,0.0527,0.6884,0.2589,0.644664407,0.048920274,0.306415319
Grouping samples into pools of five for PCR testing resulted in a slight increase in coronavirus testing capacity with very minimal loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,15.65,0,18.5,15.97,20.3,13.02,12,21,20,19th and 20th grade,199,30,5.666666667,0,0.0626,0.7606,0.1768,0.649374664,0.049085513,0.301539838
Pooling samples for PCR testing is a cost-effective and efficient method that allows more people to be tested for coronavirus in a shorter amount of time while maintaining high levels of sensitivity.,1066,Human,FALSE,30.54,0,17,13.41,19.3,12.13,12,21,19.05,16th and 17th grade,199,32,5.25,0,0.51,0.47,0.0201,0.643969476,0.055242684,0.300787807
Pooling samples for PCR testing is a highly inefficient method that compromises the accuracy of coronavirus testing and should not be used.,1066,Human,FALSE,40.69,0,13.1,13.58,14.8,11.9,8,15,16.07,14th and 15th grade,139,22,5.363636364,0,0.0055,0.0868,0.9077,0.640950263,0.074036323,0.285013407
Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually,1066,Human,FALSE,9.22,0,18.9,16.13,19.5,12.92,12,20,19.77,19th and 20th grade,187,28,5.714285714,0,0.1225,0.8019,0.0756,0.660924494,0.052356251,0.286719233
Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually,1066,Human,FALSE,9.22,0,18.9,16.13,19.5,12.92,12,20,19.77,19th and 20th grade,187,28,5.714285714,0,0.1225,0.8019,0.0756,0.660924494,0.052356251,0.286719233
Grouping samples into pools of five for PCR testing resulted in an decrease in coronavirus testing capacity with minimal loss of sensitivity compared with testing each sample individually.,1066,Human,FALSE,9.22,0,18.9,16.13,19.7,12.92,12,20,19.77,19th and 20th grade,188,28,5.75,0,0.022,0.504,0.474,0.65293628,0.048798613,0.2982651
Grouping samples into pools of different for PCR testing resulted in an increase in coronavirus testing capacity with minimal gain of sensitivity compared with testing each sample individually.,1066,Human,FALSE,9.22,0,18.9,17.18,20.5,12.92,12,21,19.77,20th and 21st grade,193,28,5.928571429,0,0.0516,0.7544,0.194,0.638583243,0.053111434,0.308305264
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, sickle cell, and cardiovascular disease.",1081,Human,FALSE,33.92,11.9,11.5,15.82,14,15.2,14,7.333333333333334,12.58,11th and 12th grade,260,36,6.25,8,0.012,0.2583,0.7297,0.663672209,0.16864346,0.167684317
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, pregnancy and cardiovascular disease.",1081,Human,FALSE,34.22,12.5,11.4,16.34,14.4,15.5,14,7.5,13.82,15th and 16th grade,257,35,6.371428571,8,0.0116,0.2517,0.7367,0.64668262,0.187535897,0.165781409
There were no differences in the way Covid affected males and females.,1081,Human,FALSE,76.22,0,5.6,9.85,7.7,10.81,3,7,11.47,6th and 7th grade,70,12,4.916666667,0,0.0364,0.7567,0.2069,0.614380717,0.239818454,0.145800859
Men were entirely immune to Covid until they got cooties from women which is why women were more severely affected Covid than men.,1081,Human,FALSE,65.05,0,9.9,9.99,12.2,8.9,4,14.5,14.42,9th and 10th grade,130,23,4.695652174,0,0.0306,0.4422,0.5272,0.582045734,0.246381223,0.171572998
"Female COVID-19 patients had a higher risk of lost of taste and smell than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,42.07,11.9,10.4,14.43,12.9,14.06,13,7.5,12.49,11th and 12th grade,257,37,5.972972973,8,0.0135,0.2945,0.692,0.626072407,0.200758412,0.17316924
"Female COVID-19 patients had a higher risk of severe dengue than boy patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, high blood pressure, renal disease, and heart disease.",1081,Human,FALSE,50.84,10.5,9.2,13.38,11.9,14.32,12,6.666666666666667,10.36,9th and 10th grade,244,36,5.805555556,8,0.0117,0.2675,0.7208,0.662461996,0.178869903,0.158668011
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, cirrhosis, and cardiovascular disease.",1081,Human,FALSE,34.93,12.5,11.1,16.34,14.2,15.67,13,7.166666666666666,14.1,15th and 16th grade,243,33,6.393939394,8,0.0118,0.2542,0.734,0.664808154,0.168810502,0.166381285
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and vertigo.",1081,Human,FALSE,43.39,11.9,9.9,14.42,12.6,15.67,13,6.833333333333333,12.88,12th and 13th grade,232,33,6.060606061,8,0.0114,0.2409,0.7477,0.659971893,0.177404001,0.162624061
"Female COVID-19 patients had a higher risk of severe complications than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,26.17,12.5,12.4,17.03,14.9,15.34,14,7.333333333333334,13.93,12th and 13th grade,254,34,6.5,8,0.0122,0.26,0.7278,0.673878491,0.165179729,0.16094175
"Female COVID-19 patients had a higher risk of severe prostate complications than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,25.76,12.5,12.6,17.32,15.2,15.5,14,7.5,13.82,12th and 13th grade,263,35,6.542857143,8,0.0125,0.2674,0.7201,0.685519397,0.151574701,0.162905961
"Adolescent COVID-19 patients had a higher risk of severe dengue than adult patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,34.63,12.5,11.2,16.68,14.6,15.81,13,7.333333333333334,13.93,11th and 12th grade,252,34,6.441176471,8,0.011,0.2264,0.7626,0.68339473,0.154306039,0.162299275
"Female COVID-19 patients had no risk of severe dengue compared to male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,34.63,11.9,11.2,15.99,14,15.34,13,7,12.76,11th and 12th grade,248,34,6.323529412,8,0.0429,0.6369,0.3203,0.670048356,0.158876747,0.171074882
"Male COVID-19 patients had a higher risk of severe dengue than female patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,34.63,11.9,11.2,15.81,13.9,15.34,13,7,12.76,11th and 12th grade,247,34,6.294117647,8,0.0113,0.243,0.7457,0.658903599,0.177971721,0.163124636
Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes and arthritis.,1081,Human,FALSE,52.87,10.5,8.4,13.14,11,15.71,11,5.666666666666667,10.67,10th and 11th grade,204,30,5.833333333,8,0.0119,0.2549,0.7332,0.645287991,0.202156693,0.152555436
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing Inverse comorbidity associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,34.22,11.9,11.4,15.7,13.9,15.5,14,7.166666666666666,12.68,11th and 12th grade,253,35,6.257142857,8,0.0122,0.2683,0.7195,0.663751781,0.171807289,0.16444093
"Female COVID-19 patients had a higher risk of mild severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,34.22,11.9,11.4,15.52,13.7,15.5,13,7.166666666666666,12.68,11th and 12th grade,252,35,6.228571429,8,0.0133,0.3011,0.6857,0.671561003,0.166691914,0.161747098
"Female COVID-19 patients had a slight higher risk of severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,34.22,11.9,11.4,15.81,14,15.5,13,7.166666666666666,12.68,11th and 12th grade,254,35,6.285714286,8,0.0132,0.3113,0.6755,0.665471554,0.171655312,0.162873164
"Female COVID-19 patients had a moderately higher risk of severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease.",1081,Human,FALSE,25.76,12.5,12.6,16.51,14.5,15.5,14,7.5,13.82,12th and 13th grade,258,35,6.4,8,0.0144,0.3252,0.6604,0.671429932,0.166214883,0.16235517
"Female COVID-19 patients had a lower risk of severe dengue than male patients in the main analysis (16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease",1081,Human,FALSE,34.63,11.9,11.2,15.64,13.6,15.34,13,7,12.76,11th and 12th grade,245,34,6.235294118,8,0.0418,0.5428,0.4154,0.663482606,0.172882944,0.163634539
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis (66.2% vs 1.5%). Pre-existing comorbidities associated with severe disease were diabetes, hypertension, renal disease, and cardiovascular disease",1081,Human,FALSE,34.63,11.9,11.2,15.64,13.6,15.34,13,7,12.76,11th and 12th grade,245,34,6.235294118,7,0.0129,0.2552,0.7319,0.661385834,0.174661979,0.163952187
"Among 100,000 airline travelers, with testing and screening, there are 649 actively infectious passengers. A pre-travel PCR test will reduce the number of infected passengers to 500. A rapid antigen test on the day of travel would reduce th number of infected passengers to less than 500.",1082,Human,FALSE,55.54,13,9.4,11.42,10.7,10.8,11,10.833333333333334,10.54,10th and 11th grade,288,47,5.14893617,15,0.0284,0.6771,0.2945,0.61903441,0.050848849,0.330116808
"For every 100,000 travelers, a pre travel PCR test or a rapid antigen test will eliminate any infected passengers from flights.",1082,Human,FALSE,58.62,0,10.3,11.43,13.1,13.7,6,14.5,16.02,13th and 14th grade,127,21,5.095238095,6,0.0796,0.7435,0.1769,0.627390981,0.045013096,0.327595979
"We estimate that among 100,000 non-native travelers, with no testing or screening, there would be 649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,54.52,14.1,9.8,11.42,11.2,11.1,12,12,11.48,11th and 12th grade,307,50,5.16,15,0.015,0.6268,0.3582,0.631642163,0.04561545,0.322742403
"We estimate that among 100,000 public transit travelers, with no testing or screening, there would be 649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,54.22,13.6,9.9,11.31,11.2,10.67,12,11.833333333333334,11.51,11th and 12th grade,311,51,5.117647059,15,0.0161,0.6387,0.3453,0.619144678,0.051869523,0.32898581
"We estimate that among 100,000 airline travelers, with no testing or screening, there would only be 649 actively infectious passengers. A pre-travel PCR test would barely reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would slightly reduce the number of infected passengers to 560.",1082,Human,FALSE,53.51,13.6,10.2,11.54,11.7,10.77,13,12.166666666666666,11.61,11th and 12th grade,325,53,5.150943396,15,0.0239,0.6718,0.3043,0.61705327,0.063491657,0.319455057
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 649 actively infectious passengers. A post-travel PCR test would reduce the number of infected passengers to 569. A rapid antigen test the day after travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,54.93,13.6,9.6,12,11.4,10.57,12,11.5,11.42,11th and 12th grade,305,49,5.244897959,15,0.0171,0.6653,0.3176,0.62120837,0.054581426,0.324210167
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 569. A rapid antigen test the week of travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,54.93,13.6,9.6,11.66,11.1,10.89,12,11.5,11.42,11th and 12th grade,302,49,5.183673469,15,0.0167,0.6364,0.3469,0.618918896,0.054008685,0.327072352
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 649 actively infectious passengers. No pre-travel PCR test would reduce the number of infected passengers to 569. Taking a rapid antigen test on the day of travel would increase the number of infected passengers to 560.",1082,Human,FALSE,54.22,13.6,9.9,11.66,11.5,10.98,13,11.833333333333334,11.51,11th and 12th grade,314,51,5.176470588,15,0.0142,0.5105,0.4753,0.618586898,0.055706587,0.325706482
"We have proven that among 100,000 airline travelers, with no testing or screening, there would be 649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,62.68,13,8.7,10.84,10.8,10.67,11,11.5,10.72,10th and 11th grade,307,51,5.039215686,15,0.0195,0.4794,0.5011,0.635415852,0.043556046,0.321028173
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 569. A simple yes/no question on the day of travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,54.52,13.6,9.8,11.54,11.3,10.15,11,11.666666666666666,11.48,11th and 12th grade,308,50,5.18,15,0.0169,0.6287,0.3545,0.608860672,0.062125448,0.329013944
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 649 actively infectious passengers. A rapid antigen test would reduce the number of infected passengers to 569. A pre-travel PCR test on the day of travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,54.52,13.6,9.8,11.19,10.9,10.78,12,11.666666666666666,11.48,10th and 11th grade,304,50,5.1,15,0.0172,0.6575,0.3253,0.61665976,0.0589673,0.324372858
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 649 non-infected passengers. A pre-travel PCR test would reduce the number of uninfected passengers to 569. A rapid antigen test on the day of travel would reduce the number of uninfected passengers to 560.",1082,Human,FALSE,54.93,13,9.6,11.42,11,10.89,11,11.166666666666666,10.6,10th and 11th grade,301,49,5.163265306,15,0.0232,0.7783,0.1985,0.617895424,0.053509016,0.328595489
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 649 actively infectious passengers. A pre-travel PCR test would reduce the number of frequent flyer passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,54.22,13,9.9,11.19,11.1,11.29,14,11.5,11.51,11th and 12th grade,310,51,5.098039216,15,0.0187,0.665,0.3163,0.61634326,0.057577744,0.326079011
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 569. A rapid antigen test the next day of travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,54.52,13.6,9.8,11.42,11.1,10.78,12,11.666666666666666,11.48,10th and 11th grade,306,50,5.14,15,0.0168,0.6477,0.3354,0.617792308,0.059360921,0.32284674
"We estimate that among 231,098 airline travelers, with no testing or screening, there would be 543 actively infectious passengers. A pre-travel PCR test would reduce the number of infected passengers to 789. A rapid antigen test on the day of travel would increase the number of infected passengers to 987.",1082,Human,FALSE,54.52,13.6,9.8,11.42,11.1,11.1,13,11.666666666666666,11.48,11th and 12th grade,306,50,5.14,15,0.0171,0.6436,0.3394,0.609899938,0.057303045,0.33279708
"We estimate that among 100,000 airline travelers, with no testing or screening, there would be 649 actively infectious passengers. A pre-travel PCR test would increase the number of infected passengers to 786. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Human,FALSE,54.52,13.6,9.8,11.42,11.1,11.1,13,11.666666666666666,11.48,11th and 12th grade,306,50,5.14,15,0.0162,0.6147,0.3691,0.615920603,0.062050201,0.322029203
"We estimated that among 100,000 gym members, with full availability of the gym, there would be 649 actively infectious members. Shortening the open-hours for the gym would reduce the number of infected members to 569. Shutting down the steam room and showers in the gym would reduce the number of infected members to 560.",1082,Human,FALSE,61.67,11.9,9.1,10.44,10.9,9.5,10,11.333333333333334,11.64,11th and 12th grade,321,54,4.962962963,15,0.0177,0.5821,0.4002,0.598681509,0.068246238,0.333072245
Negative.,1082,Human,FALSE,-47.99,0,20.2,1,21.5,19.48,1,0.5,40.4,0th and 1st grade,9,1,9,0,0.0689,0.579,0.3521,0.526679933,0.166314393,0.307005703
"Our estimates show that just .6% of airline travelers are infections with COVID-19, making mandatory testing unnecessary.",1082,Human,FALSE,45.93,0,9,14.75,11.9,13.35,7,5.75,15.16,14th and 15th grade,121,17,6.176470588,3,0.0274,0.4236,0.549,0.635914564,0.09896867,0.265116751
"Under .6% of airline travelers are infections with COVID-19, making mandatory testing unhelpful and intrusive",1082,Human,FALSE,30.87,0,12.7,17.33,15.9,14.91,7,12.5,19.33,12th and 13th grade,109,15,6.333333333,3,0.0144,0.2302,0.7554,0.659846008,0.104397602,0.235756442
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants permanently after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,Human,FALSE,26.81,0,14.2,15.08,14.8,11.64,12,14,14.97,14th and 15th grade,253,38,5.684210526,2,0.5423,0.4366,0.021,0.677158713,0.071816385,0.251024961
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants permanently after the second vaccination. In the phase 2 trial, the potential vaccine formula showed similar safety outcomes.",1083,Human,FALSE,26.81,0,14.2,15.26,15,12.06,13,14.5,16.02,14th and 15th grade,254,38,5.710526316,2,0.1303,0.8281,0.0416,0.676999748,0.069661506,0.253338754
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 3 years after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,Human,FALSE,34.76,0,13.3,13.52,13.8,11.89,11,13.75,13.95,13th and 14th grade,249,39,5.41025641,3,0.5571,0.4233,0.0196,0.657462299,0.071886785,0.270650923
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed moderate/severe biohazards.",1083,Human,FALSE,26.81,0,14.2,15.08,15,12.89,13,14.5,16.02,14th and 15th grade,254,38,5.710526316,3,0.0414,0.7761,0.1825,0.658804476,0.073897563,0.267297983
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 4 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,Human,FALSE,34.76,0,13.3,13.63,13.9,11.89,11,13.75,13.95,13th and 14th grade,250,39,5.435897436,3,0.5506,0.4297,0.0197,0.658157885,0.069654852,0.272187233
"In the phase 1 trial, the potential vaccine formula caused a weak antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,Human,FALSE,34.76,0,13.3,13.34,13.7,11.89,11,13.75,13.95,13th and 14th grade,248,39,5.384615385,3,0.1843,0.6422,0.1735,0.664847374,0.070933521,0.264219105
"In the phase 1 trial, the potential vaccine formula cause a strong antibody response that remained stagnant in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,Human,FALSE,43.22,0,12.1,13.52,13.8,11.49,11,13.25,12.93,13th and 14th grade,249,39,5.41025641,3,0.3916,0.5645,0.0439,0.639912009,0.07030718,0.289780796
"In the phase 1 trial, the potential vaccine formula cause a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed worse safety outcomes.",1083,Human,FALSE,43.22,0,12.1,13.34,13.7,11.49,11,13.75,13.95,13th and 14th grade,248,39,5.384615385,3,0.0092,0.1395,0.8512,0.656082392,0.068813816,0.275103748
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that quickly disappeared from all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,Human,FALSE,43.22,0,12.1,14.27,14.4,11.49,10,13.75,13.95,13th and 14th grade,254,39,5.538461538,3,0.2466,0.6362,0.1172,0.63540709,0.07083261,0.293760359
"In the phase 1 trial, the potential vaccine formula caused a strong negative response that remained in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed even worse safety outcomes, yet the vaccine was still rolled out.",1083,Human,FALSE,48.13,0,12.3,12.42,14.4,10.96,10,15,13.55,10th and 11th grade,283,46,5.173913043,3,0.0088,0.111,0.8802,0.632889271,0.065304495,0.301806211
"In the phase 1 trial, the potential vaccine formula caused a negligible antibody response that showed little difference in participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,Human,FALSE,34.76,0,13.3,14.68,14.8,11.49,10,14.25,13.95,14th and 15th grade,257,39,5.615384615,3,0.2851,0.6056,0.1093,0.634699523,0.070584759,0.294715673
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 3 years after the second vaccination. In the phase 2 trial, the potential vaccine formula showed worse safety outcomes.",1083,Human,FALSE,43.22,0,12.1,13.34,13.7,11.89,11,13.75,13.95,13th and 14th grade,248,39,5.384615385,3,0.009,0.1314,0.8595,0.660316229,0.070441842,0.269241929
"In the phase 1 trial, the potential vaccine formula caused a weak antibody response that remained normal in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed decreased safety outcomes.",1083,Human,FALSE,43.22,0,12.1,13.52,13.8,12.3,12,13.25,12.93,12th and 13th grade,249,39,5.41025641,3,0.0123,0.2236,0.7641,0.659371734,0.072363742,0.268264532
"In the phase 1 trial, the official vaccine formula caused a strong antibody response that remained lethal in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed likely death of all participants.",1083,Human,FALSE,42.21,0,12.5,12.88,13.7,11.59,10,14.25,14.05,12th and 13th grade,257,41,5.292682927,3,0.0087,0.1867,0.8046,0.621258378,0.078274094,0.30046764
"In the phase 1 trial, the potential vaccine formula caused a weak antibody response that remained low in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed terrible safety outcomes.",1083,Human,FALSE,43.22,0,12.1,12.94,13.3,11.49,10,13.75,12.93,12th and 13th grade,245,39,5.307692308,3,0.0071,0.0865,0.9064,0.643013299,0.072208002,0.284778684
"In the phase 1 trial, the potential vaccine formula caused a non-existent antibody response that remained low in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed no safety outcomes.",1083,Human,FALSE,43.22,0,12.1,13.05,13.6,12.3,11,13.75,13.95,13th and 14th grade,247,39,5.358974359,3,0.0109,0.1846,0.8046,0.652624846,0.068258889,0.279116243
"In the phase 1 trial, the potential vaccine formula caused an accelerated heart rate response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes.",1083,Human,FALSE,34.26,0,13.5,13.92,14.4,11.73,11,14,14,13th and 14th grade,258,40,5.475,3,0.2064,0.6501,0.1434,0.65529114,0.066778697,0.27793017
"In the phase 1 trial, the potential vaccine formula caused no side effect responses in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula completely cured the virus.",1083,Human,FALSE,44.75,0,11.5,11.89,12,11.99,9,13,13.87,11th and 12th grade,222,36,5.194444444,3,0.5022,0.4751,0.0227,0.63226074,0.063128345,0.304610908
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed degraded safety outcomes.",1083,Human,FALSE,34.76,0,13.3,13.92,14.2,12.3,12,14.25,14.98,13th and 14th grade,252,39,5.487179487,3,0.0172,0.3236,0.6592,0.64438504,0.070251808,0.285363227
"In the phase 1 trial, the potential vaccine formula caused a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial, the potential vaccine formula showed better safety outcomes with and increased rate of serious side-effects.",1083,Human,FALSE,31.21,0,14.6,14.28,16,11.99,14,16.5,15.29,14th and 15th grade,298,46,5.5,3,0.385,0.574,0.041,0.654492915,0.069048673,0.276458472
We found that the number of cases of SARS-CoV-2 infection doubled every 3 days in barracks-style buildings. The corresponding doubling time for apartment-style buildings was 4 days.,1084,Human,FALSE,66.23,0,7.4,14.14,12.4,12.49,7,6.75,8.36,6th and 7th grade,181,27,5.740740741,3,0.0248,0.6857,0.2894,0.639253438,0.060376134,0.300370485
We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in apartment-style buildings. The corresponding doubling time for office-style buildings was 2.65 days.,1084,Human,FALSE,62.34,8.8,6.8,13.37,10.8,12.27,6,4.5,6.56,6th and 7th grade,185,27,5.888888889,7,0.0301,0.7682,0.2017,0.632241547,0.069901563,0.297856897
We found that the number of cases of SARS-CoV-2 infection had little to no effect every 1.56 days in barracks-style buildings. The same can be said for apartment-style buildings which was 2.65 days.,1084,Human,FALSE,85.69,6.4,4,9.32,7.8,10.4,5,4.833333333333333,5.61,5th and 6th grade,198,33,5.03030303,7,0.035,0.6767,0.2883,0.621431112,0.077216215,0.30135268
We found that the number of cases of SARS-CoV-2 infection had little to no effect every 1.56 days in barracks-style buildings. The corresponding doubling time for apartment-style buildings was 2.65 days.,1084,Human,FALSE,69.48,7.8,6.1,12.1,10,11.79,7,4.833333333333333,6.7,6th and 7th grade,203,31,5.580645161,7,0.0256,0.6276,0.3468,0.619435608,0.069455251,0.311109096
We found that the number of cases of SARS-CoV-2 infection more than doubled every 1.56 days in barracks-style buildings. The corresponding time for apartment-style buildings was 2.65 days.,1084,Human,FALSE,70.5,7.8,5.7,12.61,10.3,11.99,6,4.333333333333333,6.58,6th and 7th grade,188,28,5.75,7,0.0252,0.5557,0.4191,0.631183147,0.074254557,0.29456234
We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in barracks-style buildings. The corresponding doubling time for apartment-style buildings was 2.65 weeks.,1084,Human,FALSE,70.8,7.8,5.6,14,11.3,13.44,7,4.166666666666667,6.56,6th and 7th grade,188,27,6,7,0.026,0.6892,0.2848,0.640651107,0.061296389,0.29805246
We found that the number of cases of SARS-CoV-2 infection tripled every 1.56 days in barracks-style buildings. The corresponding quadrupled time for apartment-style buildings was 2.65 days.,1084,Human,FALSE,70.8,7.8,5.6,14.24,11.5,12.86,6,4.166666666666667,6.56,6th and 7th grade,189,27,6.037037037,7,0.0255,0.6851,0.2894,0.625492156,0.061205737,0.31330207
We found that the number of cases of SARS-CoV-2 infection decreased every 1.56 days in barracks-style buildings until it completely dissipated after a month. The corresponding time for apartment-style buildings was 10 days.,1084,Human,FALSE,60.31,9.7,7.6,13.9,11.3,11.84,8,5.833333333333333,9.25,7th and 8th grade,223,33,5.787878788,6,0.0582,0.8387,0.1031,0.621679723,0.064804919,0.313515335
We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in shared buildings. The corresponding doubling time for households was 2.65 days.,1084,Human,FALSE,71.1,7.8,5.5,10.34,8.1,13.18,7,4,6.56,6th and 7th grade,164,26,5.346153846,7,0.0289,0.8273,0.1438,0.637055814,0.073540755,0.289403468
We found that the number of cases of SARS-CoV-2 infection was likely to have doubled every 1.56 days in open-room buildings. The corresponding doubling time for apartment-style buildings was 2.65 days.,1084,Human,FALSE,69.48,7.8,6.1,11.75,9.7,11.28,6,4.833333333333333,6.7,6th and 7th grade,201,31,5.516129032,7,0.0256,0.8163,0.1581,0.620850682,0.067102149,0.312047184
We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in apartment-style buildings. The corresponding doubling time for barracks-style buildings was 2.65 days.,1084,Human,FALSE,70.8,7.8,5.6,13.83,11.1,12.86,7,4.166666666666667,6.56,6th and 7th grade,187,27,5.962962963,7,0.0243,0.695,0.2807,0.637188017,0.065059215,0.297752827
We found that the number of cases of SARS-CoV-2 infection stopped after 1.56 days in barracks-style buildings. The corresponding doubling time for apartment-style buildings was 2.65 days.,1084,Human,FALSE,70.8,7.8,5.6,13.83,11.1,12.27,6,4.166666666666667,6.56,6th and 7th grade,187,27,5.962962963,7,0.0325,0.8517,0.1159,0.622900009,0.062332887,0.314767182
We found that the number of cases of SARS-CoV-2 infection doubled every 2.65 days in barracks-style buildings. The corresponding single time for apartment-style buildings was 1.56 days.,1084,Human,FALSE,70.8,7.8,5.6,13.37,10.8,12.27,6,4.166666666666667,6.56,6th and 7th grade,185,27,5.888888889,7,0.0253,0.6339,0.3409,0.634104848,0.065566279,0.300328851
We found that the number of cases of SARS-CoV-2 infection tripled every 1.56 days in barracks-style buildings. The corresponding doubling time for apartment-style buildings was 2.65 days.,1084,Human,FALSE,70.8,7.8,5.6,13.83,11.1,12.86,6,4.166666666666667,6.56,6th and 7th grade,187,27,5.962962963,7,0.0252,0.6878,0.287,0.627866745,0.063225538,0.308907747
We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days.,1084,Human,FALSE,74.19,0,6.4,9.04,8.8,14.48,3,7,8.46,6th and 7th grade,82,14,4.928571429,4,0.0287,0.6744,0.2969,0.674281895,0.084712252,0.241005927
The number of cases of SARS-CoV-2 infection doubled almost every day.,1084,Human,FALSE,60.31,0,7.6,11.06,9.3,12.79,3,5.5,8.04,7th and 8th grade,69,11,5.363636364,1,0.0317,0.4668,0.5014,0.690013111,0.086250074,0.223736778
We found that the number of SARS-CoV-2 detections multiplied by 2 every 1.56 days in barracks-style buildings. The corresponding doubling time for apartment-style buildings was 2.56 days.,1084,Human,FALSE,70.8,8.8,5.6,13.83,11.1,11.69,6,4.5,8.04,8th and 9th grade,187,27,5.962962963,8,0.0387,0.8383,0.123,0.618857801,0.075088181,0.306054085
We found that the number of Covid cases doubled every 1.56 days in close work/store buildings. In apartment size buildings case was doubled again out coming in 2.65 days.,1084,Human,FALSE,87.01,3.1,3.5,8.62,6.5,9.02,3,3.833333333333333,3.88,3rd and 4th grade,170,29,4.896551724,6,0.0478,0.7109,0.2413,0.610978127,0.127995878,0.261025995
We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in barracks-style buildings. The corresponding doubling time for apartment-style buildings was 4 days.,1084,Human,FALSE,70.8,7.8,5.6,13.37,10.6,12.86,7,4.166666666666667,6.56,6th and 7th grade,184,27,5.851851852,5,0.0257,0.6853,0.289,0.640104651,0.063212447,0.296682864
We found that the number of cases of SARS-CoV-2 infection quadrupled every 1.56 days in barracks-style buildings. The corresponding doubling time for apartment-style buildings was 2.65 days.,1084,Human,FALSE,70.8,7.8,5.6,14.47,11.7,12.86,7,4.166666666666667,6.56,6th and 7th grade,190,27,6.074074074,7,0.0259,0.661,0.3131,0.6256392,0.063459538,0.310901284
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the United States over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.58,14.1,12.4,18.03,16,12.79,15,10.833333333333334,13.16,12th and 13th grade,318,43,6.418604651,9,0.0254,0.479,0.4957,0.644035757,0.043750249,0.312214017
"Without the initial lockdown, home remedies, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.58,13.6,12.4,16.81,15,13.53,16,10.5,13.16,13th and 14th grade,309,43,6.209302326,9,0.0235,0.4548,0.5217,0.636724472,0.047258716,0.316016823
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the US over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.89,14.1,12.3,17.51,15.4,12.98,15,10.666666666666666,13.22,12th and 13th grade,307,42,6.333333333,9,0.0263,0.4877,0.486,0.640377343,0.04510089,0.314521819
"If the initial lockdown, vaccination, and increased physical distancing did not occur, we estimated 148 million COVID-19 cases, and 3.1 million lives could have been saved within the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,38.62,14.1,11.8,16.12,14.8,12.81,16,11.5,13.09,11th and 12th grade,329,47,6.021276596,9,0.0644,0.6048,0.3307,0.653161526,0.04801517,0.298823357
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million lives would be saved in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.58,14.1,12.4,16.81,15,12.79,14,10.833333333333334,13.16,12th and 13th grade,309,43,6.209302326,9,0.0574,0.6318,0.3108,0.638003707,0.045325212,0.316671073
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the world over 10 years. In the least-likely scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,23.43,14.6,13.5,18.32,16.1,12.98,15,11,13.22,12th and 13th grade,313,42,6.476190476,9,0.0189,0.3954,0.5857,0.646431565,0.044601779,0.308966637
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 123 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.89,14.1,12.3,17.51,15.4,13.35,15,10.666666666666666,13.22,12th and 13th grade,307,42,6.333333333,9,0.024,0.476,0.5,0.648399711,0.045012109,0.306588173
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination maximizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.89,14.1,12.3,17.51,15.4,13.35,15,10.666666666666666,13.22,12th and 13th grade,307,42,6.333333333,9,0.0294,0.4966,0.474,0.651702821,0.04444617,0.303850979
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID 19 case, and 3.1 million deaths would occur in the UK one 10 years. In the best case scenario, lockdown minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,39.63,13.6,11.4,15.19,13.6,12.62,14,10.666666666666666,13.15,13th and 14th grade,302,44,5.886363636,9,0.024,0.4551,0.521,0.630223453,0.044017464,0.325759053
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID 19 case, and 3.1 million deaths would occur in the UK one 10 months. In the best case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,39.63,14.1,11.4,15.77,14.1,12.62,14,11,13.15,10th and 11th grade,306,44,5.977272727,9,0.0244,0.4576,0.518,0.63631767,0.043121245,0.320561022
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination eliminates community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.89,14.1,12.3,17.62,15.5,13.35,15,10.666666666666666,13.22,12th and 13th grade,308,42,6.357142857,9,0.0254,0.4445,0.5302,0.646135628,0.044664811,0.309199661
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, lockdowns minimize community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.89,13.6,12.3,17.04,15.1,13.73,16,10.333333333333334,13.22,13th and 14th grade,304,42,6.261904762,9,0.0242,0.4485,0.5273,0.634239793,0.044682033,0.321078211
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission combined with future periods of increased physical distancing",1095,Human,FALSE,31.58,14.1,12.4,17.33,15.3,13.53,16,10.833333333333334,13.16,13th and 14th grade,312,43,6.279069767,9,0.0277,0.47,0.5023,0.654434502,0.044448525,0.301116943
"With the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission with future periods of increased physical distancing",1095,Human,FALSE,31.89,14.1,12.3,16.64,14.6,13.35,15,10.666666666666666,13.22,12th and 13th grade,300,42,6.166666667,9,0.033,0.5278,0.4392,0.653169096,0.044500142,0.302330792
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination minimizes community transmission without future periods of decreased physical distancing.",1095,Human,FALSE,31.89,14.1,12.3,17.51,15.4,13.73,16,10.666666666666666,13.22,13th and 14th grade,307,42,6.333333333,9,0.023,0.4439,0.5331,0.648312747,0.045445513,0.306241721
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the worst-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.89,14.1,12.3,17.62,15.5,13.35,15,10.666666666666666,13.22,12th and 13th grade,308,42,6.357142857,9,0.0166,0.3727,0.6107,0.649868965,0.045082252,0.305048764
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination somewhat increases community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.58,14.1,12.4,17.74,15.7,13.53,16,10.833333333333334,13.16,13th and 14th grade,316,43,6.372093023,9,0.0179,0.3904,0.5917,0.652271807,0.045878194,0.301849991
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination greatly community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.89,13.6,12.3,17.22,15.2,13.35,15,10.333333333333334,12.27,11th and 12th grade,305,42,6.285714286,9,0.0177,0.3532,0.629,0.644406617,0.044888146,0.310705274
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 210 million COVID-19 cases, and 5.2 million deaths would occur in the UK over 9 years. In the best-case scenario, vaccination minimizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.89,14.1,12.3,17.33,15.3,13.35,15,10.666666666666666,13.22,12th and 13th grade,306,42,6.30952381,8,0.0224,0.4669,0.5108,0.647508621,0.044907935,0.307583451
"With the initial lockdown, vaccination, and increased physical distancing, we estimated 148 million COVID-19 cases, and 3.1 million deaths would occur in the UK over 10 years. In the best-case scenario, vaccination maximizes community transmission without future periods of increased physical distancing.",1095,Human,FALSE,31.89,14.1,12.3,17.04,15.1,13.35,15,10.666666666666666,13.22,12th and 13th grade,304,42,6.261904762,9,0.0366,0.5705,0.3929,0.655409038,0.045042444,0.299548477
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with the majority of deaths in this study.",1097,Human,FALSE,34.26,0,13.5,15.2,16.1,11.73,7,15,18,11th and 12th grade,136,20,5.85,0,0.013,0.3411,0.6459,0.718301356,0.120260209,0.16143845
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with deaths in this study.",1097,Human,FALSE,37.3,0,12.3,16.18,15.9,11.91,6,12.5,16.21,11th and 12th grade,120,17,6.117647059,0,0.0145,0.4402,0.5453,0.716723621,0.102608703,0.180667624
"After factoring in age, illness severity, and co-morbidities, this study did not establish a correlation between tocilizumab and a reduction in fatalities.",1097,Human,FALSE,15.31,0,16.6,16.71,18.3,11.9,9,18,21.53,16th and 17th grade,155,22,6.090909091,0,0.013,0.4271,0.5599,0.730751157,0.075366229,0.193882644
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with fewer deaths in this study.",1097,Human,FALSE,36.28,0,12.7,15.95,16.1,12.42,7,13,16.09,12th and 13th grade,126,18,6.055555556,0,0.2279,0.7155,0.0565,0.725184858,0.093362682,0.181452453
"In this study, after carefully controlling for age, severity of illness, and co-morbidities, tocilizumab did not demonstrate a statistically significant association with reduced mortality.",1097,Human,FALSE,-3.65,0,19.7,21.47,23,13.38,12,20,22.93,19th and 20th grade,188,24,6.875,0,0.0211,0.4974,0.4815,0.751497805,0.064754531,0.183747649
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was found to be strongly associated with reduced mortality in this study, with a significant decrease in the number of deaths observed.",1097,Human,FALSE,22.08,0,18.1,15.39,21.5,12.13,12,22,20.3,21st and 22nd grade,214,32,5.71875,0,0.3183,0.6406,0.0411,0.750112712,0.0889263,0.160961017
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with more deaths in this study.",1097,Human,FALSE,43.73,0,11.9,15.08,15.6,11.23,6,13.5,16.02,15th and 16th grade,129,19,5.842105263,0,0.0319,0.5804,0.3877,0.723956883,0.101085059,0.174958035
"When controlling for national origin, severity of illness, and co-morbidities, tocilizumab was not associated with fewer deaths in this study.",1097,Human,FALSE,25.8,0,14.6,16.94,17.5,13.31,9,15,18,14th and 15th grade,142,20,6.15,0,0.0255,0.5168,0.4577,0.705445886,0.089975707,0.204578415
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was directly associated with fewer deaths in this study.",1097,Human,FALSE,35.27,0,13.1,16.88,17.1,12.89,8,14.5,18.13,12th and 13th grade,135,19,6.157894737,0,0.2421,0.7007,0.0572,0.700753391,0.086470693,0.212775886
"When controlling for size, severity of health, and morbidities, tocilizumab was not associated with more deaths in this study.",1097,Human,FALSE,52.19,0,10.7,14.45,14.8,9.57,5,13.5,16.02,9th and 10th grade,126,19,5.684210526,0,0.027,0.5338,0.4392,0.714582503,0.086557321,0.198860273
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with fewer deaths in this study.",1097,Human,FALSE,36.28,0,12.7,15.95,16.1,12.42,7,13,16.09,12th and 13th grade,126,18,6.055555556,0,0.2279,0.7155,0.0565,0.725184858,0.093362682,0.181452453
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with some deaths in this study.",1097,Human,FALSE,43.73,0,11.9,15.08,15.6,11.23,6,13.5,16.02,15th and 16th grade,129,19,5.842105263,0,0.0244,0.5665,0.409,0.718621492,0.110628664,0.170749858
"tocilizumab did not demonstrate a significant reduction in mortality rates among patients with COVID-19 after controlling for age, severity of illness, and co-morbidities.",1097,Human,FALSE,22.75,0,15.8,19.32,20.6,14.39,10,17.5,19.63,19th and 20th grade,171,23,6.47826087,2,0.0127,0.3835,0.6037,0.744871318,0.103177778,0.151950866
"Tocilizumab was found to significantly reduce mortality rates among patients with COVID-19, even after controlling for age, severity of illness, and co-morbidities, according to this study.",1097,Human,FALSE,28.17,0,15.8,18.05,21.3,13.43,10,19,19.63,18th and 19th grade,189,26,6.307692308,2,0.5118,0.4676,0.0207,0.774653971,0.061225671,0.164120331
Tocilizumab was not associated with fewer deaths related to COVID-19 cases.,1097,Human,FALSE,43.39,0,9.9,14.77,11.9,15.67,5,6.5,11.67,11th and 12th grade,75,11,5.909090909,2,0.0191,0.4173,0.5636,0.656517029,0.066333346,0.277149647
Tocilizumab has no effects on COVID-19 mortality rates.,1097,Human,FALSE,63.36,0,6.4,13.7,10.8,15.88,3,4,8.2,7th and 8th grade,55,8,6,2,0.0192,0.4299,0.5508,0.757763207,0.063533381,0.178703368
"When controlling for age, severity of illness, and co-morbidities, tocilizumab was associated with fewer deaths in this study.",1097,Human,FALSE,36.28,0,12.7,15.95,16.1,12.42,7,13,16.09,12th and 13th grade,126,18,6.055555556,0,0.2279,0.7155,0.0565,0.725184858,0.093362682,0.181452453
"When controlling for height, severity of illness, and co-morbidities, tocilizumab was not associated with fewer deaths in this study.",1097,Human,FALSE,43.73,0,11.9,16.3,16.6,12.06,7,13.5,16.02,16th and 17th grade,133,19,6.052631579,0,0.0241,0.481,0.4949,0.706893563,0.111656457,0.181449935
"When controlling for age, severity of illness, and co-morbidities, tocilizumab were associated with the amount of deaths in this study.",1097,Human,FALSE,42.72,0,12.3,14.91,15.9,10.94,6,14,16,15th and 16th grade,135,20,5.8,0,0.015,0.4169,0.5681,0.730529487,0.096593864,0.172876686
When controlling for age there were no considerations that were associated with the few deaths in this study.,1097,Human,FALSE,53.21,0,10.3,11.77,11.6,8.04,3,12,13.87,11th and 12th grade,109,18,5.111111111,0,0.0266,0.6223,0.3511,0.677682936,0.106724478,0.215592578
"In Hawai'i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the Hawaiins was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,58.45,0,12.4,11.15,17.1,12.06,14,17.75,15.87,11th and 12th grade,356,59,5.050847458,13,0.0516,0.895,0.0534,0.615586042,0.063002408,0.32141155
"In Hawai'i, white Caucasians comprise 90%, Asians including Japanese, Chinese, and other Asians account for 2.5%, Hawaiians for 2.5%, and Pacific Islanders mostly from Micronesia and Samoa comprise 5%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other groups combined and they accounted for almost 90% of cases.",1099,Human,FALSE,73.17,10.1,6.8,9.79,9.9,10.96,14,8,10,9th and 10th grade,362,60,5.05,13,0.0558,0.8914,0.0528,0.608207583,0.069578588,0.322213769
"In Hawai'i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the former group was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,57.95,0,12.6,10.98,17.2,11.97,14,18,16,17th and 18th grade,360,60,5.016666667,13,0.0466,0.8947,0.0587,0.610993803,0.067811102,0.321195066
"In Hawai'i, white Caucasians comprise 25%, African Americans account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the Latino group was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,60.48,0,11.7,10.22,15.5,11.89,12,16.25,14.64,11th and 12th grade,325,55,4.927272727,13,0.0499,0.8804,0.0698,0.60132575,0.064965777,0.333708435
"In Hawai'i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was down to 10 times that in all of the other groups combined and they accounted for less than 30% of cases.",1099,Human,FALSE,57.44,0,12.8,10.86,17.4,11.88,14,18.25,16.13,12th and 13th grade,365,61,5,13,0.041,0.8667,0.0923,0.611068368,0.067492768,0.321438879
"In Hawai'i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,57.95,0,12.6,10.98,17.2,11.97,14,18,16,17th and 18th grade,360,60,5.016666667,13,0.046,0.8925,0.0615,0.611672461,0.067199193,0.321128398
"In Hawaii, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID 19 rate in the first group was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,57.44,0,12.8,10.4,16.9,11.62,13,18.25,16.13,16th and 17th grade,358,61,4.885245902,13,0.0528,0.9002,0.047,0.616827905,0.064437307,0.318734735
"In Hawaii, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID 19 rate in the latter group was up to 10 times less than that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,56.42,0,13.2,10.4,17.3,11.72,14,18.75,16.41,9th and 10th grade,369,63,4.873015873,13,0.0659,0.8916,0.0425,0.614425957,0.066204526,0.319369525
"In Hawaii, African Americans comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,49.99,0,13.6,11.33,17.2,12.33,14,18.25,16.55,16th and 17th grade,357,59,5.06779661,13,0.0596,0.8864,0.0539,0.608655334,0.065344408,0.326000303
"In Hawaii, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Californians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,49.99,0,13.6,11.5,17.3,12.06,14,18.25,16.55,11th and 12th grade,359,59,5.101694915,13,0.0478,0.8821,0.0701,0.614524961,0.063601375,0.321873665
"In Hawai'i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and Indians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,49.99,0,13.6,11.04,17,12.33,15,18.25,16.55,16th and 17th grade,355,59,5.033898305,13,0.044,0.8878,0.0682,0.610229969,0.068364903,0.321405143
"In Hawai'i, black Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,57.95,0,12.6,10.98,17.2,11.97,14,18,16,17th and 18th grade,360,60,5.016666667,13,0.0495,0.8937,0.0568,0.61308682,0.065752394,0.321160853
"There is a significant disparity in the COVID-19 rate among Pacific Islanders from Micronesia and Samoa compared to other ethnic groups in Hawai'i, with the former group experiencing up to 10 times the infection rate of all other groups combined and accounting for nearly 30% of all cases.",1099,Human,FALSE,22.76,0,22,12.26,26.3,12.93,13,31,25.03,12th and 13th grade,289,48,5.041666667,6,0.02,0.5286,0.4514,0.67815721,0.144419581,0.177423224
"The COVID-19 rate in Pacific Islanders from Micronesia and Samoa is not significantly different from that in other ethnic groups in Hawai'i, and they do not account for a disproportionate number of cases, according to this study.",1099,Human,FALSE,33.92,0,17.7,12.78,21.7,11.02,8,24.5,20.21,17th and 18th grade,229,37,5.216216216,2,0.0171,0.5578,0.4251,0.655090213,0.096513204,0.248396575
"In Hawai'i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20% and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the second group was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases",1099,Human,FALSE,57.95,0,12.6,10.98,17,11.7,13,18,16,12th and 13th grade,358,60,4.983333333,13,0.0508,0.8868,0.0624,0.61506635,0.065263726,0.319669992
"In Hawai'i, white Caucasians comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Africans for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,57.95,0,12.6,10.86,17.1,11.97,13,18,16,17th and 18th grade,359,60,5,13,0.0425,0.884,0.0735,0.612861216,0.065098412,0.32204029
"In Hawaii, COVID-19 cases in Pacific Islanders made up a majority of the cases, despite only being 4% of the population.",1099,Human,FALSE,41.7,0,12.7,8.94,11.5,12.2,6,13.5,14.11,12th and 13th grade,120,21,4.761904762,3,0.0766,0.7577,0.1657,0.665688813,0.131134033,0.203177124
Those from Micronesia and Samoa are more susceptible to COVID-19 and account for a large portion of overall cases relative to others.,1099,Human,FALSE,57.61,0,10.7,11.72,13.5,11.9,7,14,14.25,13th and 14th grade,133,22,5.090909091,2,0.015,0.3567,0.6283,0.668400466,0.093819603,0.237779856
"In Hawai'i, african americans comprise 25%, Asians including Japanese, Chinese, and other Asians account for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa comprise 4%. We discovered that the COVID-19 rate in the latter group was up to 10 times that in all of the other groups combined and they accounted for almost 30% of cases.",1099,Human,FALSE,49.49,0,13.8,11.04,17.3,12.23,14,18.5,16.67,16th and 17th grade,361,60,5.033333333,13,0.0581,0.8984,0.0435,0.609276056,0.06831114,0.322412848
asians catch covid 19 more then any other race on the in hawaii,1099,Human,FALSE,100.58,0,2.5,4.57,3.5,9.14,0,5.5,5.2,4th and 5th grade,63,13,3.923076923,2,0.0191,0.3514,0.6295,0.592777908,0.216874182,0.19034797
the number of negative cases in New York State,1166,Human,FALSE,79.26,0,4.4,5.42,2.9,9.35,2,4.5,8.04,4th and 5th grade,46,9,4.222222222,0,0.0589,0.8612,0.0799,0.635620713,0.108083047,0.256296277
The modeled results of COVID-20 spread,1166,Human,FALSE,90.77,0,2.1,10.08,7.5,14.46,2,2,2.4,1st and 2nd grade,38,6,5.5,2,0.0301,0.6202,0.3497,0.661866903,0.104913078,0.233220041
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of positive cases in New York State during March of 2021 is expected to remain stable, while in the UK it is projected to decrease",1166,Human,FALSE,34.6,0,21.6,9.88,26.6,11.33,12,31.5,24.97,21st and 22nd grade,295,53,4.58490566,6,0.1251,0.8504,0.0245,0.617691576,0.086938001,0.29537043
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of positive cases in New York State will remain unchanged during March of 2021, while in the UK it will decrease.",1166,Human,FALSE,38.66,0,20,10.35,25.2,11.22,11,27.5,22.05,19th and 20th grade,278,49,4.693877551,6,0.0424,0.8398,0.1178,0.614819944,0.088021837,0.297158241
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of positive cases in New York State increased drastically during March of 2021, while in the UK it will reduce.",1166,Human,FALSE,39.68,0,19.6,10.81,25,11.61,12,28,22.53,11th and 12th grade,276,48,4.770833333,6,0.0823,0.787,0.1308,0.613931894,0.086462386,0.299605727
"The modeled results of pneumococcal meningitis spread in New York State and the UK have demonstrated that if level of testing and containment measures is preserved, the number of positive cases in New York State remain the same during March of 2021, while in the UK it will reduce.",1166,Human,FALSE,38.66,0,20,10.81,25.5,10.9,12,29.5,23.68,10th and 11th grade,281,49,4.755102041,4,0.0532,0.8328,0.114,0.614249468,0.073110603,0.312639922
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is maintained, the number of cases in New York State will remain the same during March of 2021, while in the UK it will slightly decline.",1166,Human,FALSE,46.11,0,19.3,9.59,25,10.85,10,27,21.6,10th and 11th grade,277,50,4.56,6,0.0408,0.8474,0.1118,0.623161912,0.085054263,0.291783869
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of positive cases in New York State might remain the same during March of 2021, while in the UK it might reduce.",1166,Human,FALSE,46.11,0,19.3,9.59,25,10.85,10,28,22.4,10th and 11th grade,277,50,4.56,6,0.0477,0.8753,0.0769,0.608460844,0.078024179,0.313515007
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of negative cases in New York State remain the same during March of 2021, while in the UK it will increase.",1166,Human,FALSE,47.12,0,18.9,9.65,24.6,10.9,10,27.5,22.05,10th and 11th grade,272,49,4.571428571,6,0.042,0.8234,0.1345,0.609587312,0.089061268,0.301351458
"The modeled data of COVID-19 spread in New York State and the UK have demonstrated that the level of testing and containment measures is preserved, the number of positive cases in New York State remain the same during March of 2022, while in the UK it will reduce.",1166,Human,FALSE,39.68,0,19.6,9.36,23.9,10.95,10,27,21.7,19th and 20th grade,264,48,4.520833333,6,0.151,0.8208,0.0282,0.612160325,0.073266663,0.31457299
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures are not delivered, the number of positive cases in New York and UK will rise during March of 2021.",1166,Human,FALSE,44.75,0,17.7,9.65,21.5,10.91,9,25.5,20.92,10th and 11th grade,238,43,4.558139535,6,0.0165,0.4259,0.5576,0.619655848,0.071411692,0.308932424
The modeled results of COVID-19 spread in New York state and the UK have demonstrated that the level of testing and containment measures have no effect on the increase or decrease of cases in New York or the UK during March of 2021.,1166,Human,FALSE,53.21,0,16.5,8.95,20.9,11.28,10,23.5,19.06,16th and 17th grade,232,43,4.418604651,6,0.0245,0.7067,0.2688,0.6149562,0.070656218,0.31438753
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of negative cases inNew York State remain the same during March of 2021, while in the UK it will reduce.",1166,Human,FALSE,39.68,0,19.6,9.94,24.4,11.28,11,27,21.7,19th and 20th grade,269,48,4.625,6,0.0556,0.8275,0.117,0.604783714,0.071497679,0.323718548
"The modeled results of COVID-19 spread in New York State and not the UK have demonstrated that if the level of testing and containment measures is preserved, the number of positive cases in New York State increased during March of 2021, while in the UK it will reduce.",1166,Human,FALSE,39.68,0,19.6,9.82,24.2,11.28,11,27,21.7,19th and 20th grade,268,48,4.604166667,6,0.0358,0.6681,0.2961,0.611038983,0.092048757,0.296912283
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of containment but no testing measures is preserved, the number of positive cases in New York State decrease the same during March of 2021, while in the UK it will also reduce.",1166,Human,FALSE,36.63,0,20.8,9.3,25.3,11.12,11,28.5,22.75,20th and 21st grade,280,51,4.509803922,6,0.0689,0.838,0.0931,0.604839623,0.079871178,0.31528914
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is destroyed, the number of positive cases in New York State remain the same during March of 2021, while in the UK it will cause an increase in positive cases.",1166,Human,FALSE,33.59,0,22,9.59,27,10.7,10,31,23.82,21st and 22nd grade,299,54,4.555555556,6,0.0203,0.4777,0.502,0.62056464,0.054740097,0.32469523
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the level of testing and containment measures is preserved, the number of deaths in New York State will decrease the same during March of 2021, while in the UK it will reduce.",1166,Human,FALSE,47.12,0,18.9,9.3,24.3,10.9,9,26.5,21.23,10th and 11th grade,269,49,4.510204082,6,0.0668,0.8401,0.0931,0.609252632,0.085534565,0.305212915
"The modeled results of COVID-19 spread in New York State and the UK have demonstrated that if the United States enacts a travel ban from certain regions of the world, the number of positive cases in New York State remains the same during March of 2021, while in the UK it will reduce.",1166,Human,FALSE,43.06,0,20.4,8.55,25.7,11.03,10,28.5,22.71,10th and 11th grade,284,53,4.377358491,6,0.0353,0.8333,0.1313,0.638483286,0.054937359,0.306579292
The UK handled testing preservation and usage better than New York as cases decreased during the month of March while they remained the same for New York in the same month.,1166,Human,FALSE,65.39,0,11.8,9.7,15.6,9.76,7,16.5,13.69,9th and 10th grade,172,31,4.580645161,0,0.3422,0.6387,0.0191,0.624320507,0.058559276,0.317120224
UK is cleaner and more capable of testing and controlling the spread of COVID 19 than New York as seen in the difference in results in March.,1166,Human,FALSE,69.45,0,10.3,7.49,12.1,9.65,4,16.5,13.76,9th and 10th grade,141,27,4.259259259,2,0.3912,0.576,0.0328,0.606734037,0.081210576,0.312055379
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, a vaccine is unnecessary to obtain a protective immune response.",1170,Human,FALSE,28.03,15.9,13.8,13.63,13.4,10.3,21,13.875,14.44,13th and 14th grade,462,71,5.521126761,2,0.0282,0.7786,0.1933,0.636713445,0.071699671,0.291586876
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 65% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, a vaccine is unnecessary to obtain a protective immune response.",1170,Human,FALSE,28.03,15.9,13.8,13.69,13.5,10.3,21,13.875,14.44,13th and 14th grade,463,71,5.535211268,3,0.0279,0.7853,0.1868,0.63691473,0.073937319,0.289147884
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, two doses of vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,35.78,15.9,12.9,13.52,13.5,10.1,21,14.25,14.43,13th and 14th grade,476,74,5.445945946,2,0.0426,0.8836,0.0738,0.63769877,0.062284596,0.300016582
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, no vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,36.28,15.9,12.7,13.45,13.4,10.23,21,14,14.42,13th and 14th grade,466,72,5.486111111,2,0.0301,0.8217,0.1482,0.636728048,0.073374398,0.289897591
"Different amounts of antibodies produced after the full doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, no dose of vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,35.78,15.9,12.9,13.46,13.4,10.32,21,14.25,14.43,12th and 13th grade,475,74,5.432432432,2,0.031,0.8149,0.1541,0.639794528,0.075890809,0.284314662
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, it is recommended that you get no vaccinations for COVID-19.",1170,Human,FALSE,36.49,15.9,12.6,13.22,13.2,10.08,18,13.875,14.44,13th and 14th grade,458,71,5.464788732,4,0.0262,0.7577,0.2161,0.635369956,0.071522862,0.293107122
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals without a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,35.78,15.9,12.9,13.69,13.6,10.32,21,14.25,14.43,13th and 14th grade,478,74,5.472972973,2,0.0408,0.878,0.0812,0.637482524,0.067303456,0.295214057
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher alcohol tolerance level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,35.47,16.2,13,13.63,13.7,10.67,23,14.625,15.52,13th and 14th grade,484,75,5.466666667,2,0.0477,0.8833,0.069,0.630827904,0.064123742,0.305048376
"Differing amounts of antibodies produced after the two doses of vaccine were found. Individuals with previous infections developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired immunity in an asymptomatic way. In such individuals, one dose of vaccine may be enough to maintain a protective immune response.",1170,Human,FALSE,36.49,15.2,12.6,13.4,13.3,10.75,22,13.375,15.01,12th and 13th grade,459,71,5.478873239,2,0.0449,0.8881,0.067,0.640124798,0.076007493,0.283867747
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a better antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,35.78,15.9,12.9,13.46,13.4,10.1,20,14.25,14.43,12th and 13th grade,475,74,5.432432432,2,0.1301,0.8361,0.0339,0.636735022,0.064931177,0.298333853
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,35.78,15.9,12.9,13.34,13.3,10.32,21,14.25,14.43,12th and 13th grade,474,74,5.418918919,2,0.0331,0.8478,0.1191,0.638527036,0.068031937,0.293441057
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in a symptomatic way. In such individuals, one dose of vaccine may be superficial to obtain a protective immune response.",1170,Human,FALSE,35.78,15.9,12.9,13.34,13.3,10.32,21,14.25,14.43,12th and 13th grade,474,74,5.418918919,2,0.0352,0.8607,0.1041,0.637746394,0.059351217,0.3029024
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with a history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,35.78,15.9,12.9,13.34,13.3,10.32,21,14.25,14.43,12th and 13th grade,474,74,5.418918919,2,0.042,0.8877,0.0703,0.637763381,0.066142321,0.296094239
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of SARS-CoV-2 infection, 65% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In these individuals, one dose of vaccine is always enough to obtain a protective immune response.",1170,Human,FALSE,35.98,15.6,12.8,13.63,13.5,10.17,20,13.875,13.9,13th and 14th grade,471,73,5.465753425,3,0.0468,0.8822,0.071,0.635491431,0.069067746,0.295440882
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous neurological infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,27.32,15.9,14,13.81,13.7,10.32,21,14.25,14.43,13th and 14th grade,480,74,5.5,2,0.0397,0.8776,0.0827,0.639243543,0.066811919,0.293944448
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, five doses of vaccine may be sufficient to obtain a protective immune response.",1170,Human,FALSE,35.78,15.9,12.9,13.58,13.5,10.1,21,14.25,14.43,13th and 14th grade,477,74,5.459459459,2,0.0433,0.8846,0.0722,0.638034523,0.066042833,0.295922697
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection had a lower antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, more than one dose of vaccine is needed to be sufficient enough to obtain a protective immune response.",1170,Human,FALSE,34.46,15.6,13.4,12.53,13.3,10.02,21,14.625,14,12th and 13th grade,494,79,5.265822785,2,0.0305,0.8192,0.1503,0.637638509,0.065408669,0.296952754
"Different amounts of antibodies produced after the two doses of vaccine were found. Individuals with a previous natural infection developed a higher antibody level. Among the individuals with no history of past SARS-CoV-2 infection, 5% had an antibody level at the same order of magnitude of infected people, suggesting that they acquired the infection in an asymptomatic way. In such individuals, almost three doses of vaccines may be sufficient to obtain a protective immune response.",1170,Human,FALSE,35.47,15.9,13,13.81,13.8,10.25,22,14.375,14.45,13th and 14th grade,486,75,5.493333333,2,0.0465,0.884,0.0694,0.636736453,0.063649923,0.299613655
"When someone gets vaccinated twice, their body produces different levels of antibodies. People who had COVID-19 before getting vaccinated had slightly higher levels of antibodies. For those who never had COVID-19, 5% of them had antibody levels similar to those who had the virus before but didn't show any symptoms. This suggests that they may have had an asymptomatic infection. These people might only need one vaccine dose to have a strong immune response.",1170,Human,FALSE,56.45,10.8,9.1,11.59,10.6,8.85,15,8.2,9.16,8th and 9th grade,460,74,5.22972973,5,0.0519,0.8222,0.126,0.65150547,0.086491413,0.262003124
"When someone gets vaccinated twice, their body produces the same levels of antibodies. People who had COVID-19 before getting vaccinated had lower levels of antibodies. For those who never had COVID-19, 95% of them had antibody levels similar to those who had the virus before and showed symptoms. This suggests that they may have had a symptomatic infection. These people might need three vaccine doses to have a stronger immune response.",1170,Human,FALSE,65.52,10.4,7.6,11.48,10.2,9.23,15,7.699999999999999,9.06,7th and 8th grade,439,71,5.197183099,6,0.0438,0.7633,0.1929,0.636742532,0.082035176,0.281222284
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for blood-based point-of-care COVID-19 diagnosis",1171,Human,FALSE,22.92,0,13.7,19.94,17.8,13.07,12,10.25,14.08,13th and 14th grade,225,29,6.793103448,2,0.8577,0.1377,0.0046,0.620180726,0.097695589,0.282123744
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for urine-based point-of-care COVID-19 diagnosis",1171,Human,FALSE,31.38,0,12.5,19.94,17.8,13.61,12,10.25,14.08,13th and 14th grade,225,29,6.793103448,2,0.8623,0.1332,0.0045,0.61724776,0.09907835,0.283673912
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, high cost which will raise taxes as magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,36.79,0,12.5,17.57,16.9,12.63,14,11.75,13.86,12th and 13th grade,254,35,6.285714286,2,0.6146,0.3664,0.019,0.613716185,0.091139629,0.295144171
"The proposed technique exhibited terrible similarity with the PCR testing technique. The results obtained will be sent to china and sold to their laboratorys which point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,25.8,0,14.6,17.52,17.9,11.73,14,14,15,14th and 15th grade,288,40,6.225,2,0.0136,0.2002,0.7862,0.616088271,0.068197727,0.315713972
"The proposed technique exhibited great similarity with the AIDS testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,22.92,0,13.7,20.35,18.3,13.61,13,10.25,14.08,13th and 14th grade,228,29,6.896551724,2,0.7894,0.2046,0.006,0.622750282,0.093099438,0.284150243
"The proposed technique exhibited great similarity with the MCR testing technique. The results obtained point to the application potential of this simple, low-cost magenta-purple for saliva-based point-of-sale COVID-19 diagnosis.",1171,Human,FALSE,22.92,0,13.7,20.35,18.3,13.07,12,10.25,14.08,13th and 14th grade,228,29,6.896551724,2,0.7827,0.2119,0.0054,0.614948273,0.102947958,0.282103688
"The proposed technique exhibited very little similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,22.41,0,13.9,19.83,18.1,13.33,13,10.5,14,13th and 14th grade,233,30,6.8,2,0.0552,0.7372,0.2076,0.63176465,0.09273272,0.275502652
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, high-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,22.92,0,13.7,20.35,18.3,13.61,13,10.25,14.08,13th and 14th grade,228,29,6.896551724,2,0.8287,0.1664,0.0049,0.619242966,0.090234876,0.290522099
"The proposed technique exhibited no differences with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,31.38,0,12.5,19.71,17.8,13.61,13,10.25,14.08,13th and 14th grade,225,29,6.793103448,2,0.4584,0.528,0.0136,0.632488012,0.094724432,0.272787601
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,22.92,0,13.7,20.12,18.1,13.61,13,10.25,14.08,13th and 14th grade,227,29,6.862068966,2,0.8489,0.1466,0.0045,0.621642292,0.090606034,0.287751704
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 treatment.",1171,Human,FALSE,31.38,0,12.5,20.12,18.1,13.61,13,8.75,12.7,12th and 13th grade,227,29,6.862068966,2,0.8591,0.1365,0.0044,0.618797183,0.089322522,0.291880339
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the money making potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,30.87,0,12.7,18.84,17.3,12.8,12,9,12.67,12th and 13th grade,228,30,6.633333333,2,0.8378,0.1567,0.0055,0.6195485,0.093689628,0.28676182
The proposed technique exhibited near-similarity with the PCR testing technique. The results obtained point to the application potential of this decreased-cost magneto-assay for saliva-based clinical COVID-19 diagnosis.,1171,Human,FALSE,15.47,0,14.5,22.09,19,15.42,15,10.75,15.77,14th and 15th grade,219,27,7.148148148,2,0.3134,0.6791,0.0075,0.625474989,0.085232161,0.289292783
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this complex, magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,23.43,0,13.5,20.23,17.9,14.48,14,9,14.17,13th and 14th grade,219,28,6.857142857,2,0.8159,0.1794,0.0048,0.62144047,0.093089744,0.28546977
"The proposed technique exhibited great popularity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,22.92,0,13.7,20.12,18.1,13.61,13,10.25,14.08,13th and 14th grade,227,29,6.862068966,2,0.9086,0.0877,0.0037,0.619681656,0.091989346,0.288329065
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, high-cost magneto-essay for saliva-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,22.92,0,13.7,20.35,18.3,13.61,13,10.25,14.08,13th and 14th grade,228,29,6.896551724,2,0.8256,0.1696,0.0049,0.615974247,0.094303012,0.289722711
"The proposed technique exhibited no similarity with the PCR testing technique. The results obtained point to the application potential of this complex, high-cost for saliva-based point-of-care in COVID-19 diagnosis.",1171,Human,FALSE,31.38,0,12.5,17.91,16.2,13.07,12,8.75,12.7,12th and 13th grade,215,29,6.448275862,2,0.0235,0.5464,0.4301,0.618727624,0.09550444,0.285767943
"The proposed technique exhibited opposite in similarity with the PCR testing. The results obtained point to the TERRIBLE application potential of this simple, low-cost for saliva-based point-of-care in COVID-19 diagnosis.",1171,Human,FALSE,30.87,0,12.7,17.68,16.2,12.8,12,11,14,12th and 13th grade,221,30,6.4,2,0.0098,0.1867,0.8035,0.622097671,0.096271761,0.281630605
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, low-cost magneto-assay for sweat-based point-of-care COVID-19 diagnosis.",1171,Human,FALSE,22.92,0,13.7,19.94,18,13.07,12,10.25,14.08,13th and 14th grade,226,29,6.827586207,2,0.8542,0.1413,0.0046,0.619596422,0.089887083,0.290516466
"The proposed technique exhibited great similarity with the PCR testing technique. The results obtained point to the application potential of this simple, high-cost magneto-assay for saliva-based point-of-care COVID-19 treatment.",1171,Human,FALSE,31.38,0,12.5,20.35,18.3,13.61,13,8.75,12.7,12th and 13th grade,228,29,6.896551724,2,0.837,0.1582,0.0049,0.616662681,0.088896386,0.294440985
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to expedite elective tests and procedures. There was a 17% increase in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,50.67,0,11.3,13.87,14.9,12.36,12,13.25,12.1,11th and 12th grade,267,41,5.536585366,4,0.0482,0.6964,0.2554,0.627534747,0.082710735,0.28975448
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to increase elective tests and procedures. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,50.67,0,11.3,13.87,14.9,12.36,12,12.75,11.13,11th and 12th grade,267,41,5.536585366,4,0.0199,0.4396,0.5404,0.632914484,0.086731054,0.28035447
"During the final phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to postpone elective tests and procedures. There was about a 15% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,58.62,0,10.3,13.52,14.9,12.2,12,13,11.26,12th and 13th grade,271,42,5.476190476,4,0.0126,0.345,0.6425,0.616033018,0.073397577,0.310569435
"During the final phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to postpone elective tests and procedures. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,50.67,0,11.3,13.58,14.7,12.36,12,12.75,11.13,11th and 12th grade,265,41,5.487804878,4,0.0116,0.2985,0.6899,0.621198654,0.075782493,0.303018808
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to postpone unnecessary tests and procedures. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,50.67,0,11.3,14.27,15.2,12.36,12,13.25,12.1,11th and 12th grade,270,41,5.609756098,4,0.011,0.2536,0.7355,0.623241186,0.079875387,0.296883464
"During the initial phase of the Bird Flu pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to postpone elective tests and procedures. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,58.62,0,10.3,13.11,14.4,11.82,12,13,11.26,12th and 13th grade,267,42,5.380952381,2,0.0107,0.3096,0.6797,0.610913217,0.056972876,0.332113981
"During the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to postpone elective tests and procedures. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,52.7,0,10.5,14.56,14.6,12.24,11,11.75,10.64,10th and 11th grade,246,37,5.675675676,4,0.0112,0.2842,0.7046,0.62764746,0.086723916,0.285628617
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines helped United States health systems to postpone elective tests and procedures. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,50.67,0,11.3,13.87,14.9,12.36,12,12.75,11.13,11th and 12th grade,267,41,5.536585366,4,0.0581,0.6702,0.2717,0.634659946,0.088179663,0.277160406
"During the middle phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines allowed United States health systems to continue elective tests and procedures. There was a 17% Increase in the volume of brain MRI scans during the middle of the pandemic.",1172,Human,FALSE,49.65,0,11.7,13.23,14.8,11.68,12,13.75,12.32,11th and 12th grade,275,43,5.418604651,4,0.0579,0.801,0.1411,0.621287584,0.082164302,0.296548158
"During the end phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to postpone elective tests and procedures. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,59.13,0,10.1,13.29,14.4,11.97,11,12.75,11.13,12th and 13th grade,263,41,5.43902439,4,0.0118,0.3192,0.669,0.628833711,0.081696704,0.28946963
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines persauded United States health systems to stop elective tests and procedures. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,50.67,0,11.3,13.69,14.8,11.97,12,13.25,12.1,11th and 12th grade,266,41,5.512195122,4,0.0142,0.3844,0.6014,0.638030112,0.086751938,0.27521795
"During the initial phase of the COVID-19 pandemic, no one followed the stay-at-home orders and social distancing guidelines thus allowing United States health systems to increase elective tests and procedures. There was a 17% increase in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,48.13,0,12.3,13.52,15.6,11.99,13,14.5,12.68,11th and 12th grade,294,46,5.413043478,4,0.0185,0.4815,0.5,0.641687453,0.085104436,0.273208112
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to find alternatives for elective tests and procedures. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,49.65,0,11.7,13.87,15.4,12.05,12,13.75,12.32,11th and 12th grade,280,43,5.534883721,4,0.0183,0.4484,0.5333,0.621686101,0.077864468,0.300449491
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to perform elective tests and procedures virtually. There was a 17% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,50.16,0,11.5,14.21,15.4,12.57,13,13.5,12.21,11th and 12th grade,276,42,5.595238095,4,0.016,0.4086,0.5754,0.624471962,0.07245259,0.303075522
"As the outbreak of COVID-19 pandemic progressed and social distancing rules continued, the United States orders of MRIS were 17% less than usual during the middle of the pandemic.",1172,Human,FALSE,42.04,0,14.6,12.72,17.6,12.15,8,18.5,15.74,12th and 13th grade,179,29,5.206896552,4,0.0258,0.5454,0.4288,0.630257487,0.099776454,0.269966036
"As the outbreak of COVID-19 pandemic progressed and social distancing rules continued, the United States orders of MRIS were 17% more than usual with the pandemic targeting people with underlying health issues.",1172,Human,FALSE,30.54,0,17,15.04,20.9,13.12,11,22,19.05,16th and 17th grade,210,32,5.59375,4,0.0221,0.4162,0.5617,0.634144545,0.097466633,0.268388778
Patient health has decreased due to stay-at-home orders and social distancing because the inability to complete elective tests and procedures as seen with the 17% decrease in brain MRI scan volume since the start of the pandemic.,1172,Human,FALSE,42.38,0,16.5,12.95,21.7,12.3,12,23.5,19.12,12th and 13th grade,229,37,5.216216216,2,0.0113,0.2047,0.784,0.647118628,0.103215307,0.249666005
Hospitals decreased the ability to obtain elective tests and procedures by 17% to meet the social distancing guidelines forced by the United States Government.,1172,Human,FALSE,38.66,0,13.8,15.38,17.3,12.72,9,17,16.27,16th and 17th grade,159,24,5.666666667,2,0.0138,0.3049,0.6813,0.609625041,0.09369427,0.296680599
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to postpone elective tests and procedures. There was a 25% decrease in the volume of brain MRI scans during the early pandemic.",1172,Human,FALSE,50.67,0,11.3,13.87,14.9,12.36,12,12.75,11.13,11th and 12th grade,267,41,5.536585366,4,0.0122,0.3226,0.6652,0.625758171,0.08148095,0.292760879
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing guidelines forced United States health systems to postpone elective tests and procedures. There was a 17% decrease in the volume of spinal cord MRI scans during the early pandemic.",1172,Human,FALSE,58.62,0,10.3,13.81,15.1,12.57,12,13,11.26,12th and 13th grade,273,42,5.523809524,4,0.0111,0.3018,0.6871,0.630516768,0.083569616,0.285913706
"It seems that the virus traveled by car on highways and motorways; and that ?carpooling?, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,66.57,0,9.3,9.17,11.8,9.84,10,13.75,13.25,9th and 10th grade,247,43,4.76744186,0,0.0191,0.562,0.419,0.629923224,0.047109336,0.32296744
"The virus traveled by car on highways and motorways; and that ?solo? driving, i.e. traveling only with one's family, that now seems to be perceived by the public as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,58.62,0,10.3,8.82,11.4,10.32,11,13,12.21,9th and 10th grade,240,42,4.738095238,0,0.0219,0.556,0.4221,0.620862186,0.047180336,0.331957459
"The evidence suggests that the virus may have spread through transportation on highways and motorways, including individuals traveling alone in passenger cars, which some members of the public have recently suggested as a potential solution. This mode of transportation may have actually contributed to the initial spread of the virus.",1182,Human,FALSE,37.64,0,14.2,15.73,18,10.88,16,19.5,19.6,19th and 20th grade,335,50,5.72,0,0.0087,0.3061,0.6852,0.650995314,0.046201456,0.302803189
"It is a well-known fact that the virus does not spread through transportation on highways and motorways, and there is no evidence to support the idea that traveling alone in passenger cars contributed to the initial spread of the virus.",1182,Human,FALSE,47.8,0,16.5,11.44,21.8,9.57,8,26,21,16th and 17th grade,236,40,4.925,0,0.0136,0.3983,0.5882,0.617167115,0.068480149,0.314352751
"It seems that the virus traveled by car on highways and motorways. Traveling by passenger cars, that now seems to be perceived by the public as a main method to spread COVID-19.",1182,Human,FALSE,80.62,0,6,8.18,8,10.35,5,8.5,8.9,8th and 9th grade,177,32,4.5625,2,0.0168,0.4033,0.5798,0.632979512,0.06401322,0.303007245
"It seems that the virus traveled by car on highways and motorways. Traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,68.6,0,8.5,9.05,10.2,9.46,9,12.25,11.9,8th and 9th grade,219,39,4.641025641,0,0.026,0.6245,0.3495,0.632669389,0.048235212,0.319095343
"It seems that the virus traveled by car on highways and motorways; and that ?solo? driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,66.07,0,9.5,8.7,11.6,10.11,11,13.5,12.44,9th and 10th grade,249,44,4.681818182,0,0.0204,0.5457,0.4339,0.62558043,0.048017822,0.3264018
"It seems that the virus traveled by car on highways and motorways; and that ?solo? driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,66.07,0,9.5,8.7,11.6,10.11,11,13.5,12.44,9th and 10th grade,249,44,4.681818182,0,0.0204,0.5457,0.4339,0.62558043,0.048017822,0.3264018
"It seems that the virus traveled by car on highways and motorways; and that driving alone, which seemed to be perceived by the public as a solution, was one of the means which increased the initial spread.",1182,Human,FALSE,59.3,0,14.2,9.18,18.6,10.17,8,20.5,16.96,9th and 10th grade,205,37,4.567567568,0,0.0144,0.4046,0.581,0.626189351,0.047735728,0.326074868
"It seems that the virus traveled by car on highways and motorways; and that ""solo"" driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the biggest factors that favored the initial spread.",1182,Human,FALSE,65.56,0,9.7,9.46,12.2,10.72,13,13.75,12.56,9th and 10th grade,258,45,4.755555556,0,0.0203,0.4722,0.5075,0.637773275,0.049004976,0.313221693
"We now know it is not true that the virus traveled by car on highways and motorways; and that ?solo? driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was unlikely one of the means which favored the initial spread.",1182,Human,FALSE,63.53,0,10.5,7.9,11.9,9.69,11,14.75,13.07,7th and 8th grade,267,49,4.469387755,0,0.0137,0.3776,0.6087,0.642874897,0.047381517,0.309743524
"It seems that the virus traveled by car on highways and motorways; and that ?solo? driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means that prevented the initial spread.",1182,Human,FALSE,66.07,0,9.5,8.82,11.7,10.11,11,14,13.35,9th and 10th grade,250,44,4.704545455,0,0.0426,0.6593,0.2981,0.624511123,0.048316523,0.327172428
"some would say, it seems that the virus likely traveled with its host by car via highways and motorways; and that ?solo? driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,62.51,0,10.9,8.83,13.2,9.86,11,15.25,13.34,8th and 9th grade,287,51,4.647058824,0,0.0276,0.7111,0.2613,0.631002426,0.047981706,0.321015865
"It seems that the virus only traveled with its host by car via highways and motorways; and that ?solo? driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,64.04,0,10.3,8.77,12.4,10.09,11,14.5,12.93,8th and 9th grade,269,48,4.625,0,0.0178,0.5089,0.4733,0.629387319,0.047096536,0.32351616
"It seems that the virus never traveled by car on highways and motorways; and that solo driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means which didn’t change the initial spread.",1182,Human,FALSE,65.05,0,9.9,9,12,9.93,11,14,12.68,9th and 10th grade,259,46,4.652173913,0,0.013,0.3691,0.6179,0.630961478,0.047677387,0.321361095
"It seems that the virus never traveled by car on highways and motorways; and that solo driving, i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably never the means which favored the initial spread.",1182,Human,FALSE,57.61,0,10.7,9.34,11.9,10.11,11,13.5,12.44,10th and 11th grade,252,44,4.75,0,0.0168,0.4123,0.571,0.63264209,0.047444195,0.319913745
"It seems that the virus traveled by car on highways and motorways; and that ?solo? driving, i.e. traveling by passenger cars, that now seems to be perceived by government authorities as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,57.61,0,10.7,10.27,12.9,10.47,12,14.5,13.35,10th and 11th grade,261,44,4.954545455,0,0.0167,0.4906,0.4927,0.624495387,0.048059106,0.327445507
"It seems that the virus traveled by car on highways and motorways; and that car pooling, i.e. traveling by public transportation, that now seems to be perceived by the public as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,66.07,0,9.5,9.46,12,9.75,11,13.5,13.35,9th and 10th grade,253,44,4.772727273,0,0.0237,0.6457,0.3306,0.636101246,0.047661595,0.316237122
"It seems that the virus traveled by car on highways and motorways; and that ?solo? driving i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means which inhibited the initial spread.",1182,Human,FALSE,57.61,0,10.7,8.94,11.7,10.11,11,14,13.35,10th and 11th grade,250,44,4.704545455,0,0.0283,0.6565,0.3152,0.623972833,0.048319533,0.327707648
"It seems that the virus traveled by car exclusively in residential areas; and that ?solo? driving i.e. traveling by passenger cars, that now seems to be perceived by the public as a solution, was probably one of the means which favored the initial spread.",1182,Human,FALSE,57.61,0,10.7,9.63,12.3,10.47,12,14,13.35,9th and 10th grade,255,44,4.818181818,0,0.0179,0.5039,0.4783,0.625068486,0.047401451,0.327529997
"Pure Silver and silver contained in stainless steel surfaces actively inhibit the spread of SARS-CoV-2 and H1N1 viruses. On the other hand, surfaces high in copper contact do not.",1186,Human,FALSE,65.22,0,7.8,11.3,10.4,10.35,7,7.25,8.56,7th and 8th grade,179,29,5.206896552,3,0.0424,0.6612,0.2965,0.631056666,0.04911714,0.319826186
Steel surface stop the spread of covid. Copper surfaces increase the rate viruses spread.,1186,Human,FALSE,81.29,0,3.7,10.74,7.6,8.5,3,2.5,2.8,2nd and 3rd grade,89,14,5.428571429,0,0.033,0.4454,0.5215,0.635212362,0.062280711,0.302506924
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and stainless steel exhibit significant antiviral properties.",1186,Human,FALSE,37.81,0,12.1,17.75,16.4,12.59,13,12.25,15.08,12th and 13th grade,239,33,6.272727273,3,0.143,0.7763,0.0807,0.640489936,0.046226121,0.31328389
"It is discovered that pure silver, pure copper. and most commonly used stainless steel surfaces do not display inhibitory effects on SARS-CoV-2 and H1N1 viruses.",1186,Human,FALSE,67.25,0,7,12.46,10.6,11.84,8,6.75,9.8,6th and 7th grade,161,25,5.48,3,0.0612,0.7833,0.1556,0.63260448,0.048534226,0.318861276
"It is discovered that pure silver and silver-contained stainless steel surfaces do display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and copper-contained stainless steel with a high copper content exhibit significant antiviral properties.",1186,Human,FALSE,35.27,0,13.1,18.56,18.1,12.06,14,14,14.97,13th and 14th grade,279,38,6.368421053,3,0.0498,0.78,0.1701,0.628118217,0.0457724,0.32610938
"It is discovered that pure gold and titanium-contained stainless steel surfaces do not display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and copper-contained stainless steel with a high copper content exhibit significant antiviral properties.",1186,Human,FALSE,34.76,0,13.3,18.1,17.9,12.3,15,14.25,16.01,17th and 18th grade,283,39,6.282051282,3,0.1345,0.7966,0.069,0.634848714,0.045667797,0.319483459
"It is discovered that pure silver and silver-contained stainless steel surfaces do display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and copper-contained stainless steel with a high copper content exhibit non-significant antiviral properties.",1186,Human,FALSE,35.27,0,13.1,19.03,18.5,12.47,14,14,14.97,13th and 14th grade,283,38,6.473684211,3,0.0293,0.6434,0.3273,0.629677117,0.045683704,0.324639171
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure tin and tin-contained stainless steel with a high tin content exhibit significant antiviral properties.",1186,Human,FALSE,43.22,0,12.1,16.77,16.8,11.89,14,14.25,14.98,16th and 17th grade,274,39,6.051282051,3,0.1425,0.7741,0.0835,0.633861244,0.045101341,0.321037412
"It is discovered that pure silver and silver contained stainless steel surfaces do not display transmission effects on SARS CoV 2 and H1N1 viruses. In comparison, both pure copper and copper contained stainless steel with a high copper content exhibit significant antiviral properties",1186,Human,FALSE,41.19,0,12.9,15.08,15.8,11.31,14,14.25,15.11,15th and 16th grade,284,43,5.627906977,3,0.1156,0.7965,0.0879,0.633575559,0.04778162,0.318642825
"It is discovered that pure silver and silver contained stainless steel surfaces do not display inhibitory effects on SARS CoV 2 and H1N1 viruses. In comparison, both pure copper and copper contained stainless steel with a high copper content exhibit significant vaccination properties",1186,Human,FALSE,41.19,0,12.9,15.08,15.8,11.31,14,14.25,15.11,15th and 16th grade,284,43,5.627906977,3,0.1137,0.8082,0.0781,0.625027061,0.047818303,0.327154666
"It is discovered that wood and concrete surfaces do not display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and copper-contained stainless steel with a high copper content exhibit significant antiviral properties.",1186,Human,FALSE,36.28,0,12.7,16.41,16,12.86,15,13,14.98,12th and 13th grade,252,36,6.027777778,3,0.1657,0.7744,0.0599,0.637747228,0.047574326,0.31467846
"It is discovered that pure silver and silver-contained stainless steel surfaces are extremely effective at preventing the spread of SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and copper-contained stainless steel with a high copper content exhibit no antiviral benefits.",1186,Human,FALSE,33.75,0,13.6,16.65,17.2,11.2,13,15.25,16,16th and 17th grade,287,41,6.024390244,3,0.3715,0.567,0.0615,0.637375295,0.044589251,0.318035424
"It is discovered that pure sliver and sliver-contained stainless steel surfaces display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and copper-contained stainless steel with a high copper content exhibit significant increase of viral properties.",1186,Human,FALSE,34.76,0,13.3,18.27,18,12.7,16,13.75,13.95,13th and 14th grade,284,39,6.307692308,3,0.0219,0.5754,0.4027,0.626016617,0.045755405,0.328227997
"It is discovered that pure and sliver-contained stainless steel surfaces display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In contrast, both pure copper and copper-contained stainless steel with a high copper content exhibit significant viral properties.",1186,Human,FALSE,36.28,0,12.7,18.04,17.4,12.86,15,12.5,12.76,12th and 13th grade,263,36,6.333333333,3,0.0253,0.6574,0.3173,0.632842362,0.045935113,0.321222484
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and copper-contained stainless steel with a high copper content exhibit light to moderate antiviral properties.",1186,Human,FALSE,33.75,0,13.6,16.94,17.4,11.59,14,14.75,15.03,11th and 12th grade,289,41,6.073170732,3,0.0935,0.8047,0.1018,0.634749174,0.045543782,0.319706976
"It is discovered that pure silver and silver-contained stainless steel surfaces do not display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure gold and gold-contained stainless steel with a high gold content exhibit significant antiviral properties.",1186,Human,FALSE,43.22,0,12.1,17.23,17.2,11.89,14,14.25,14.98,11th and 12th grade,277,39,6.128205128,3,0.1329,0.7831,0.084,0.634649575,0.046069231,0.31928122
"It is discovered that pure copper and copper-contained stainless steel surfaces do not display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure silver and silver-contained stainless steel with a high silver content exhibit significant antiviral properties.",1186,Human,FALSE,34.76,0,13.3,18.1,17.9,11.89,14,14.25,14.98,11th and 12th grade,283,39,6.282051282,3,0.1193,0.7925,0.0882,0.632076025,0.045818653,0.322105378
"It is discovered that pure silver and silver-contained stainless steel surfaces do display inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and copper-contained stain steel with a high copper content exhibit significant viral properties.",1186,Human,FALSE,35.27,0,13.1,17.35,17.1,12.47,14,13.5,13.92,13th and 14th grade,271,38,6.157894737,3,0.0241,0.6154,0.3606,0.627704382,0.046186309,0.32610935
"According to this study, silver and silver-contained stainless steel surfaces do not possess antiviral properties against SARS-CoV-2 and H1N1 viruses, whereas pure copper and copper-contained stainless steel with a high copper content exhibit significant inhibitory effects on these viruses.",1186,Human,FALSE,14.97,0,20.9,19.91,28.6,12.86,14,27.5,21.75,12th and 13th grade,291,39,6.487179487,3,0.02,0.4166,0.5634,0.630790293,0.044256978,0.324952781
"The study found that silver and silver-contained stainless steel surfaces exhibit strong antiviral properties against SARS-CoV-2 and H1N1 viruses, while pure copper and copper-contained stainless steel with a high copper content do not show any inhibitory effects against these viruses.",1186,Human,FALSE,30.88,0,18.9,18.29,27.7,11.15,10,26,20,18th and 19th grade,286,40,6.175,3,0.256,0.7146,0.0294,0.645897806,0.044923622,0.30917865
Results from hospitalized patients indicate that viral shedding in fecal matter occurs for three weeks following a positive PCR test from a nasal swab and two weeks following a negative result from a nasal swab.,1194,Human,FALSE,35.95,0,16.9,12.49,19.9,12.14,11,23.5,18.57,11th and 12th grade,211,35,5.057142857,0,0.0175,0.8249,0.1576,0.652291894,0.043647062,0.304061085
Viral shedding of fecal matter following a positive PCR test can last for a month.,1194,Human,FALSE,64.71,0,8,8.05,7.4,9.64,4,8.5,8.67,8th and 9th grade,82,15,4.533333333,0,0.0209,0.4767,0.5024,0.636116505,0.088157222,0.275726259
Results from hospitalized patients indicate that viral shedding in fecal matter does not occur ~3-7 days after a negative PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a positive nasal swab.,1194,Human,FALSE,27.83,0,20.1,11.51,23.2,13.48,13,27.5,21.85,12th and 13th grade,253,43,4.906976744,5,0.0278,0.8837,0.0886,0.639422297,0.0570767,0.303500921
Results from hospitalized patients indicate that viral shedding in fecal matter does not occur ~3-7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a negative nasal swab.,1194,Human,FALSE,27.83,0,20.1,11.51,23.2,13.48,13,27.5,21.85,12th and 13th grade,253,43,4.906976744,5,0.024,0.8526,0.1234,0.639971256,0.056983784,0.303045034
"It has been reported based on studies conducted on hospitalized patients that viral shedding in fecal matter may occur within the range of 3 to 7 days subsequent to obtaining a positive PCR test from a nasal swab. Furthermore, it has also been observed that shedding in feces might persist for a duration of 6 to 10 days even after a negative result is obtained from a nasal swab.",1194,Human,FALSE,44.92,0,15.6,9.3,17.1,12.44,21,21.75,19.02,15th and 16th grade,380,69,4.52173913,5,0.0143,0.7122,0.2735,0.648237169,0.047729328,0.304033577
Results from hospitalized patients indicate that viral shedding in fecal matter occurs exactly 2 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for a lifetime following a negative nasal swab.,1194,Human,FALSE,28.85,0,19.7,12.49,23.1,13.24,15,28,22.51,12th and 13th grade,251,42,5,1,0.0157,0.7556,0.2287,0.655349553,0.044892214,0.299758166
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~4-8 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a negative nasal swab.,1194,Human,FALSE,29.86,0,19.3,12.03,22.6,13.76,13,26.5,21.28,12th and 13th grade,245,41,5,5,0.0151,0.8624,0.1225,0.642535031,0.059497941,0.297966987
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3-7 days after a negative PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a negative nasal swab.,1194,Human,FALSE,29.86,0,19.3,12.03,22.6,13.37,12,26.5,20.3,12th and 13th grade,245,41,5,5,0.0149,0.8569,0.1283,0.641350031,0.058626845,0.300023168
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3-7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a positive nasal swab.,1194,Human,FALSE,29.86,0,19.3,12.03,22.6,13.37,12,26.5,20.3,12th and 13th grade,245,41,5,5,0.016,0.8949,0.0891,0.640608847,0.059578519,0.299812675
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3-7 days after a negative PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a negative nasal swab.,1194,Human,FALSE,29.86,0,19.3,12.03,22.6,13.37,12,26.5,20.3,12th and 13th grade,245,41,5,5,0.0149,0.8569,0.1283,0.641350031,0.058626845,0.300023168
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3-7 days after a negative PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a positive nasal swab.,1194,Human,FALSE,29.86,0,19.3,12.03,22.6,13.76,13,26.5,21.28,12th and 13th grade,245,41,5,5,0.0159,0.8874,0.0968,0.640682697,0.058818411,0.300498903
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3-7 days after a positive PCR test can be obtained from an anal swab and that shedding in feces could continue for 6-10 days following a negative nasal swab.,1194,Human,FALSE,29.86,0,19.3,12.03,22.6,14.14,13,26.5,21.28,12th and 13th grade,245,41,5,5,0.015,0.8554,0.1295,0.640121222,0.058657523,0.301221311
Results from non-hospitalized patients indicate that viral shedding in fecal matter occurs ~3-7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a negative nasal swab.,1194,Human,FALSE,29.86,0,19.3,12.49,23.1,14.14,13,26.5,21.28,12th and 13th grade,249,41,5.097560976,5,0.0169,0.8821,0.101,0.639606774,0.05650413,0.303889126
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3-7 days after a patient is infected and that shedding in feces could continue for 6-10 days following a negative nasal swab.,1194,Human,FALSE,28.51,0,17.7,13.36,20.5,14.61,13,23,19.48,17th and 18th grade,213,34,5.294117647,5,0.0134,0.7548,0.2318,0.639152765,0.061473284,0.299373925
Results from hospitalized patients indicate that blood found in fecal matter occurs ~3-7 days after a positive PCR test can be obtained from a nasal swab and that blood found in feces could continue for 6-10 days following a negative nasal swab,1194,Human,FALSE,37.31,0,18.5,11.22,22.3,12.86,11,27,21.56,21st and 22nd grade,244,42,4.833333333,5,0.0237,0.924,0.0523,0.633825243,0.057193566,0.30898115
Results from hospitalized patients indicate that internal bleeding in fecal matter occurs ~3-7 days after a negative PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a negative nasal swab,1194,Human,FALSE,29.86,0,19.3,12.49,22.9,13.76,13,27.5,21.28,12th and 13th grade,247,41,5.048780488,5,0.0155,0.8022,0.1823,0.639190257,0.055165738,0.305644065
Results from hospitalized patients indicate that viral shedding in fecal matter does not occur for ~3-7 days after a negative PCR test can be obtained from a nasal swab and that shedding in feces could occur 6-10 days following a positive nasal swab.,1194,Human,FALSE,36.29,0,18.9,11.1,22.9,13.11,12,26.5,20.92,18th and 19th grade,250,43,4.837209302,5,0.0296,0.8906,0.0798,0.636257291,0.055126593,0.308616102
Results from hospitalized patients indicate that viral shedding in fecal matter does not occur for ~3-7 days after a positve PCR test can be obtained from a nasal swab and that shedding in feces could continue 6-10 days following a negative nasal swab.,1194,Human,FALSE,36.29,0,18.9,11.39,23.1,13.48,12,26.5,20.92,18th and 19th grade,252,43,4.88372093,5,0.0287,0.8738,0.0975,0.63508606,0.054547455,0.310366511
Results from hospitalized patients indicate that viral shedding in fecal matter occurs ~3-7 days after a positive PCR test can be obtained from a anal swab and that shedding in feces could continue for 6-10 days following a negative nasal swab.,1194,Human,FALSE,29.86,0,19.3,11.91,22.5,14.14,13,26.5,21.28,-1th and 0th grade,244,41,4.975609756,5,0.0152,0.8548,0.13,0.640897989,0.058274217,0.300827801
Results from at home volunteers indicate that viral shedding in fecal matter occurs ~3-7 days after a positive PCR test can be obtained from a nasal swab and that shedding in feces could continue for 6-10 days following a negative nasal swab.,1194,Human,FALSE,37.31,0,18.5,10.81,22.1,13.24,12,27,21.56,21st and 22nd grade,242,42,4.785714286,5,0.017,0.8928,0.0901,0.626687706,0.065395981,0.307916284
COVID-19 patients with asthma have a significant mortality rate regardless of country.,1195,Human,FALSE,33.92,0,11.5,17.1,14,13.44,5,8,14.8,11th and 12th grade,86,12,6.25,2,0.0148,0.3277,0.6576,0.693688035,0.149000451,0.157311484
"If you have asthma and contract COVID-19, you will die.",1195,Human,FALSE,95.17,0,2.5,6.18,5.2,10.45,2,4,4,3rd and 4th grade,55,10,4.6,2,0.0117,0.1092,0.8792,0.632965684,0.172853634,0.194180638
"COVID-19 patients with asthma had a significantly increased risk for re-infection in Asia, but not in Europe, North America, and South America.",1195,Human,FALSE,40.69,0,13.1,13.29,15.7,12.62,6,15,12.44,12th and 13th grade,143,22,5.545454545,2,0.0217,0.5917,0.3866,0.69327271,0.112293713,0.194433585
"COVID-19 patients with eczema had a significantly increased risk for mortality in Asia, but not in Europe, North America, and South America.",1195,Human,FALSE,49.15,0,11.9,12.76,15.1,11.9,5,15,12.44,11th and 12th grade,140,22,5.409090909,2,0.0208,0.5732,0.406,0.66730994,0.156275958,0.176414102
"COVID-19 patients with asthma no significantly increased risk for mortality in Asia, unlike in Europe, North America, and South America.",1195,Human,FALSE,34.26,0,13.5,15.2,16.1,13.31,7,14,12,13th and 14th grade,136,20,5.85,2,0.0639,0.7806,0.1555,0.66410929,0.117201269,0.218689471
"COVID-19 patients with asthma had no significantly increased risk for mortality in Asia, but did in Europe, North America, and South America.",1195,Human,FALSE,40.69,0,13.1,13.05,15.2,11.9,6,15,12.44,12th and 13th grade,141,22,5.454545455,2,0.0702,0.8085,0.1213,0.678389907,0.121993288,0.199616805
"Based on the available data, COVID-19 patients with asthma were found to have a statistically significant increased risk for mortality in Asia, while the association between asthma and mortality was not consistently observed in Europe, North America, and South America.",1195,Human,FALSE,13.96,0,21.3,15.79,25.7,12.33,12,28,21,20th and 21st grade,269,40,5.75,2,0.0172,0.6011,0.3817,0.658931077,0.077895567,0.263173312
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, but not in Europe, North America, and South America, based on the findings of a peer-reviewed study published in a reputable medical journal.",1195,Human,FALSE,34.94,0,17.3,13.41,22,13.32,12,24,17.73,17th and 18th grade,229,36,5.388888889,2,0.026,0.7193,0.2548,0.642707109,0.085350968,0.27194199
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, Europe, North America, but not South America.",1195,Human,FALSE,34.26,0,13.5,14.33,15.4,12.52,6,14,12,13th and 14th grade,133,20,5.7,2,0.0204,0.5131,0.4664,0.682568848,0.12948285,0.187948301
"COVID-19 patients with asthma had no noticeable risk for mortality in Asia, Europe, North America, and South America.",1195,Human,FALSE,44.75,0,11.5,13.05,13.8,12.42,5,13,11.64,11th and 12th grade,117,18,5.555555556,2,0.0849,0.8266,0.0885,0.654090405,0.143806159,0.202103406
"COVID-19 patients with diabetes had a significantly increased risk for mortality in Asia, but not in Europe, North America, and South America.",1195,Human,FALSE,40.69,0,13.1,13.29,15.5,11.9,6,16,14.25,15th and 16th grade,142,22,5.5,2,0.0256,0.6282,0.3462,0.65355134,0.158958212,0.187490433
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, but not in Asia.",1195,Human,FALSE,54.22,0,9.9,11.42,11.5,12.84,5,10.5,11.51,11th and 12th grade,104,17,5.176470588,2,0.0196,0.5304,0.45,0.718576133,0.123447388,0.157976508
"COVID-19 patients with asthma had a minor risk for mortality in neither Asia, Europe, North America, or South America.",1195,Human,FALSE,52.19,0,10.7,11.72,12.8,12.06,5,12.5,9.71,12th and 13th grade,118,19,5.263157895,2,0.0209,0.5296,0.4494,0.661544621,0.105720229,0.232735127
"COVID-19 patients with asthma had no risk for death in Asia, but not in Europe, North America, and South America.",1195,Human,FALSE,68.1,0,8.7,8.53,10.7,10.16,3,12,8,8th and 9th grade,113,20,4.7,2,0.0638,0.732,0.2041,0.637152255,0.144552425,0.218295291
"COVID-19 patients with asthma had a significantly increased risk for mortality, regardless of location.",1195,Human,FALSE,23.43,0,13.5,18.15,15.9,15.61,7,11,17.03,15th and 16th grade,103,14,6.428571429,2,0.0158,0.4066,0.5776,0.723339677,0.121923439,0.154736862
"COVID-19 patients had a significantly increased risk for mortality in Asia, but not in Europe, North America, and South America.",1195,Human,FALSE,42.72,0,12.3,12.88,14.2,11.73,5,14,12,11th and 12th grade,128,20,5.45,2,0.0221,0.6041,0.3738,0.671212256,0.131060854,0.197726876
COVID-19 patients with asthma did not have an increased risk for mortality in the Americas.,1195,Human,FALSE,56.25,0,9.1,11.13,10.2,12.8,5,8.5,11.33,8th and 9th grade,91,15,5.133333333,2,0.0481,0.7903,0.1616,0.719444513,0.110828117,0.169727355
Asia was the only continent with increased mortality rates of COVID-19 patients with asthma.,1195,Human,FALSE,57.27,0,8.8,14.03,12.1,14.48,5,8,11.31,8th and 9th grade,92,14,5.642857143,2,0.0147,0.3207,0.6646,0.689154267,0.121043399,0.189802274
"COVID-19 patients with asthma had a significantly increased risk for mortality in Asia, but not in Europe, North America, and South America.",1195,Human,FALSE,40.69,0,13.1,12.76,15.1,11.9,6,15,12.44,12th and 13th grade,140,22,5.409090909,2,0.0226,0.5766,0.4008,0.684019089,0.126049042,0.18993187
"COVID-19 patients with asthma had a risk increase for morality in Asia, but not in Europe, North America, and South America.",1195,Human,FALSE,58.62,0,10.3,10.04,12.4,11.45,5,13.5,10.3,9th and 10th grade,124,21,4.952380952,2,0.0268,0.6981,0.2751,0.644358277,0.147218853,0.208422855
"The evaluation results show high diagnosis accuracy, from 95% to 100%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,14.97,17.6,13.23,19,17.25,17.15,17th and 18th grade,327,49,5.693877551,7,0.8326,0.1618,0.0055,0.62634778,0.089704514,0.283947676
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method for early detection and classification of COVID-19 through image processing using Shutterstock images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,15.79,18.2,13.23,20,17.75,17.96,17th and 18th grade,333,49,5.816326531,6,0.7903,0.2031,0.0066,0.631138504,0.091814987,0.277046502
"The evaluation results reveal an impressive degree of precision in diagnosis, ranging from 89% to 99%. Through cutting-edge image processing techniques utilizing X-ray images, the proposed method has demonstrated its efficacy in early detection and classification of COVID-19. This approach boasts an end-to-end architecture that eliminates the need for manual feature extraction or manual selection methods, establishing its reliability and efficiency.",1199,Human,FALSE,17.03,17.5,15.9,18.85,19.1,13.96,29,16.5,19.92,18th and 19th grade,453,61,6.442622951,6,0.889,0.1061,0.0049,0.632470548,0.079632208,0.287897259
"The evaluation results show high diagnosis accuracy, from 99% to 100%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,14.97,17.6,13.23,19,17.25,17.15,17th and 18th grade,327,49,5.693877551,7,0.8227,0.1716,0.0057,0.630597532,0.088093624,0.28130883
"The evaluation results show high diagnosis accuracy, from 91% to 99%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,14.86,17.5,13.23,19,17.25,17.15,17th and 18th grade,326,49,5.673469388,6,0.801,0.193,0.0059,0.632725716,0.091841988,0.275432289
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure with the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,14.51,17.2,13.23,19,17.25,17.15,14th and 15th grade,323,49,5.612244898,6,0.7949,0.1991,0.006,0.633007824,0.091574878,0.275417298
"The evaluation results show low diagnosis accuracy, from 89% to 99%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,14.74,17.4,13.23,19,17.25,17.15,14th and 15th grade,325,49,5.653061224,6,0.0668,0.6802,0.253,0.637979448,0.093252905,0.268767625
"The evaluation results show high diagnosis accuracy, from .05% to 1%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images hs not been proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,45.76,13.6,11.1,13.69,13.4,12.84,19,11.833333333333334,13.86,13th and 14th grade,335,51,5.588235294,5,0.162,0.7288,0.1092,0.624792218,0.093919389,0.281288356
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for automatic feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,15.21,17.8,13.55,20,17.25,17.96,17th and 18th grade,329,49,5.734693878,6,0.8045,0.1895,0.006,0.633118093,0.09301611,0.273865819
"The evaluation results show low diagnosis accuracy, from 89% to 99%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,14.74,17.4,13.23,19,17.25,17.15,14th and 15th grade,325,49,5.653061224,6,0.0668,0.6802,0.253,0.637979448,0.093252905,0.268767625
The proposed method for early detection and classification of COVID-19 through image processing using MRI imaging is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.,1199,Human,FALSE,24.45,0,19.3,15.97,24.6,13.83,15,26,21.52,-1th and 0th grade,255,38,5.736842105,2,0.5161,0.4741,0.0099,0.626912236,0.065203771,0.307883978
"The evaluation results show high diagnosis accuracy, from 0% to 9%.",1199,Human,FALSE,34.93,0,11.1,9.49,8.5,12.79,4,7.5,15.31,8th and 9th grade,67,11,5.181818182,2,0.6532,0.3381,0.0087,0.67733103,0.12062373,0.202045247
"The evaluation results show low diagnosis accuracy, from 89% to 59%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods",1199,Human,FALSE,29.69,0,15.2,14.74,17.3,13.23,19,17.25,17.15,14th and 15th grade,324,49,5.632653061,6,0.0613,0.6482,0.2905,0.63484937,0.095657684,0.269492954
"The evaluation results show low diagnosis accuracy, from 89% to 99%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods",1199,Human,FALSE,29.69,0,15.2,14.74,17.3,13.23,19,17.25,17.15,14th and 15th grade,324,49,5.632653061,6,0.06,0.6313,0.3086,0.635190248,0.094593257,0.270216465
"The evaluation results show early diagnosis accuracy, from 89% to 99%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,14.97,17.6,13.23,19,17.25,17.15,17th and 18th grade,327,49,5.693877551,6,0.7044,0.2885,0.0072,0.640213966,0.090605937,0.269180119
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method for late detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,14.74,17.4,13.23,19,17.25,17.15,14th and 15th grade,325,49,5.653061224,6,0.7897,0.2038,0.0065,0.629823864,0.09212739,0.278048813
"The evaluation results show moderate diagnosis accuracy, from 59% to 69%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,15.32,17.9,13.55,20,17.75,17.96,17th and 18th grade,330,49,5.755102041,6,0.3252,0.6522,0.0227,0.636779785,0.089819007,0.273401231
"The evaluation results show low diagnosis accuracy, from 39% to 79%. The proposed method for early detection and classification of COVID-19 through image processing using X-ray images is proven to be usable since it provides an end-to-end structure without the need for manual feature extraction and manual selection methods.",1199,Human,FALSE,29.69,0,15.2,14.74,17.4,13.23,19,17.25,17.15,14th and 15th grade,325,49,5.653061224,6,0.0686,0.6933,0.2381,0.638914168,0.093167342,0.267918557
"The evaluation of a method for early detection and classification of COVID-19 using X-ray images showed moderate accuracy, ranging from 80% to 95%. This method is considered useful because it provides an end-to-end structure that eliminates the need for manual feature extraction and manual selection methods, making it more efficient.",1199,Human,FALSE,29.18,0,15.4,15.03,18,12.77,18,18.5,18.8,18th and 19th grade,335,50,5.72,6,0.6559,0.3331,0.011,0.651001692,0.07769534,0.271302968
"The evaluation of a method for early detection and classification of COVID-19 using X-ray images showed low accuracy, ranging from 20% to 35%. This method is considered ineffective because it requires extensive manual feature extraction and manual selection methods, making it inefficient.",1199,Human,FALSE,24.78,0,15,15.84,16.9,13.7,17,16.5,18.88,16th and 17th grade,289,42,5.904761905,6,0.0069,0.1634,0.8297,0.691761792,0.077707715,0.230530515
"A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group.
band. Successful weaning from supplemental oxygen was achieved in 63% of anakinra-treated subjects.
group compared to 27% of the control group.",1012,Translated,TRUE,58.28,11.2,8.4,12.34,11,11.16,12,7.5,9.3,10th and 11th grade,253,39,5.564102564,8,0.1224,0.8177,0.06,0.76689899,0.090061747,0.143039197
"Mechanical ventilation was required in 31% of patients treated with anakinra and 75% of the control group. 63% of patients treated with anakinra were successfully weaned from oxygen, compared with 27% of the control group.",1012,Translated,TRUE,53.71,0,10.1,12.41,12.6,11.27,10,10.25,10.43,9th and 10th grade,222,35,5.371428571,8,0.1924,0.7932,0.0145,0.736101687,0.094069794,0.169828624
"In the anakinra group, 31% required mechanical ventilation, compared with 75% in the control group.
Group. 63% of patients treated with anakinra achieved oxygen supplementation.
Group compared with 27% in the control group.",1012,Translated,TRUE,60.31,8.8,7.6,13.32,11.3,11.36,10,5.5,8.04,7th and 8th grade,223,33,5.848484848,8,0.07,0.8838,0.0462,0.705106974,0.10627611,0.188617021
"The need for mechanical ventilation occurred in 31% of the anakinra group and in 75% of the control group.
group. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
group compared to 27% of the control group.",1012,Translated,TRUE,58.62,0,10.3,11.31,13.1,11.07,12,12.5,12.21,12th and 13th grade,255,42,5.142857143,8,0.1624,0.7899,0.0477,0.779892564,0.089814231,0.130293101
"Mechanical ventilation was required in 31% of patients treated with anakinra and 75% of the control group. 63% of patients treated with anakinra were successfully weaned off oxygen, compared with 27% of the control group.",1012,Translated,TRUE,53.71,0,10.1,12.24,12.5,11.27,10,10.25,10.43,9th and 10th grade,221,35,5.342857143,8,0.1748,0.8091,0.016,0.734229326,0.093810178,0.171960562
"Mechanical ventilation was required in 31% of patients in the anakinra group and 75% in the control group.
group. 63% of patients treated with anakinra achieved successful oxygen supplementation.
The group was compared to 27% of the control group.",1012,Translated,TRUE,58.28,9.7,8.4,11.7,10.3,10.76,11,6.833333333333333,9.3,9th and 10th grade,247,39,5.41025641,8,0.1458,0.8325,0.0218,0.740291774,0.106061295,0.153647006
"The need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group
group. Successful withdrawal from supplemental oxygen was achieved in 63% of patients treated with anakinra
group compared to 27% of the control group.",1012,Translated,TRUE,50.67,0,11.3,13.11,14.3,11.2,12,13.25,13.08,13th and 14th grade,262,41,5.463414634,8,0.1555,0.8103,0.0342,0.777313948,0.091064036,0.131622046
"Mechanical ventilation was required in 31% of the anakinra-treated group and 75% of the control
club. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
compared to 27% of the control group.",1012,Translated,TRUE,52.7,0,10.5,13.11,13.4,11.81,12,11.75,11.72,11th and 12th grade,237,37,5.486486486,8,0.3005,0.6851,0.0144,0.76197356,0.091377616,0.146648869
"A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control
group. Successful weaning from supplemental oxygen was achieved in 63% of anakinra-treated
group compared to 27% of the control group.",1012,Translated,TRUE,52.7,0,10.5,13,13.4,11.38,11,12.25,11.72,12th and 13th grade,237,37,5.486486486,8,0.2176,0.7488,0.0336,0.782995462,0.088548295,0.12845619
Mechanical ventilation was required in 31% of patients treated with anakinra and 75% of the control group. 63% of patients treated with anakinra were successfully weaned from oxygen compared to 27% of the control group.,1012,Translated,TRUE,53.71,0,10.1,12.06,12.2,11.27,10,10.25,10.43,9th and 10th grade,219,35,5.285714286,8,0.1815,0.8031,0.0154,0.734002113,0.096199334,0.169798523
"Mechanical ventilation was required in 31% of the anakinra-treated group and 75% of the control
Club. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
compared to 27% of the control group.",1012,Translated,TRUE,52.7,0,10.5,13.11,13.4,11.81,12,11.75,11.72,11th and 12th grade,237,37,5.486486486,8,0.2641,0.72,0.0159,0.76197356,0.091377616,0.146648869
Mechanical ventilation was required in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra-treated group compared with 27% of the control group.,1012,Translated,TRUE,43.73,0,11.9,14.62,15,11.64,12,12.5,11.81,11th and 12th grade,254,38,5.710526316,8,0.4018,0.5879,0.0103,0.766692758,0.093171448,0.14013581
"The need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group
group. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
group compared to 27% of the control group.",1012,Translated,TRUE,50.67,0,11.3,12.71,14,11.2,12,12.75,12.1,12th and 13th grade,259,41,5.390243902,8,0.2095,0.7629,0.0276,0.787917733,0.086679593,0.125402629
"Mechanical ventilation was required in 31% of the anakinra-treated group and 75% of the control group
The club. Successful weaning from supplemental oxygen was achieved in 63% of patients treated with anakinra
Compared to 27% of the control group.",1012,Translated,TRUE,51.68,0,10.9,12.76,13.6,11.49,12,12.25,11.9,11th and 12th grade,247,39,5.41025641,8,0.333,0.6541,0.0129,0.759031773,0.091119237,0.149849072
"Mechanical ventilation was required in 31% of anakinra-treated patients and 75% in the control group. Sixty-three percent of patients treated with anakinra were successfully weaned off oxygen, compared with 27% in the control group.",1012,Translated,TRUE,45.76,0,11.1,15.02,14.6,11.45,11,10.5,10.33,10th and 11th grade,232,34,5.852941176,6,0.1897,0.796,0.0143,0.732194304,0.087780312,0.180025369
"Mechanical ventilation was required in 31% of anakinra-treated patients and 75% of controls. Sixty-three percent of patients treated with anakinra were successfully taken off oxygen, compared with 27% in the control group.",1012,Translated,TRUE,38.32,0,11.9,15.6,14.7,11.83,12,9,10.15,11th and 12th grade,222,32,5.96875,6,0.1834,0.8024,0.0143,0.712769806,0.091670193,0.195559978
Mechanical ventilation was required in 31% of anakinra-treated patients and 75% in the control group. Sixty-three percent of patients treated with anakinra were successfully weaned from oxygen compared with 27% in the control group.,1012,Translated,TRUE,45.76,0,11.1,15.19,14.6,11.45,11,10.5,10.33,10th and 11th grade,232,34,5.852941176,6,0.1781,0.808,0.0139,0.730200171,0.089443363,0.180356428
"Mechanical ventilation was required in 31% of patients treated with anakinra and in 75% of the control group. 63% of patients treated with anakinra were successfully weaned from oxygen, compared with 27% of the control group.",1012,Translated,TRUE,53.21,0,10.3,11.89,12.4,11.11,10,10.5,10.53,10th and 11th grade,225,36,5.277777778,8,0.1962,0.7895,0.0143,0.736573696,0.092256598,0.171169683
"Mechanical ventilation was required in 31% of patients in the anakinra group and 75% in the control group.
Group. 63% of patients treated with anakinra achieved successful oxygen supplementation.
This group was compared to a 27% control group.",1012,Translated,TRUE,58.58,9.7,8.2,12.05,10.4,10.91,11,6.666666666666667,9.29,9th and 10th grade,243,38,5.473684211,8,0.1036,0.8709,0.0256,0.740087867,0.105111957,0.154800177
"Many people who are infected with the virus do not have any clinical symptoms; current
Estimates suggest that around 30% of people who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These people carry the virus and potentially transmit it to other people, who may react with
severe COVID-19 illness.",1021,Translated,TRUE,54.56,0,11.9,12.6,15.8,11.19,13,15.5,14.8,15th and 16th grade,312,50,5.32,5,0.0133,0.3117,0.675,0.663411558,0.069810644,0.266777903
"Many people infected with the virus show no clinical symptoms. drift
Estimates show that about 30% of people who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These people carry the virus and potentially spread it to others, who may react
severe disease COVID-19.",1021,Translated,TRUE,65.01,11.2,7.8,11.94,11,10.83,11,8.333333333333334,11.33,10th and 11th grade,277,44,5.386363636,5,0.012,0.2395,0.7485,0.645689368,0.07014896,0.284161597
"Many people infected with the virus have no clinical symptoms; the current one
it is estimated that about 30% of people have antibodies to SARS-CoV-2 in their blood.
asymptomatic. These individuals carry the virus and can spread it to others who may react to it
severe COVID-19 disease.",1021,Translated,TRUE,55.58,0,11.5,10.91,14,11.08,12,15,14.6,14th and 15th grade,286,48,5.041666667,5,0.0183,0.3438,0.638,0.672704101,0.049336419,0.277959526
"Many people infected with the virus do not have clinical symptoms; the current
It is estimated that around 30% of people have antibodies against SARS-CoV-2 in their blood.
asymptomatic. These people are carriers of the virus and can transmit it to others who may react to it.
severe COVID-19 disease.",1021,Translated,TRUE,62.98,11.2,8.6,10.5,10.5,10.78,13,10.333333333333334,11.48,10th and 11th grade,300,50,5.08,5,0.0167,0.2984,0.685,0.656750023,0.066545531,0.276704371
"Many people who are infected with the virus show no clinical symptoms; current
estimates suggest that about 30% of individuals who have antibodies to SARS-CoV-2 in their blood
asymptomatic. These individuals carry the virus and potentially transmit it to others who may react with it
severe disease of COVID-19.",1021,Translated,TRUE,38.15,0,14,13.29,16.1,11.94,15,16.25,15.51,15th and 16th grade,311,49,5.428571429,5,0.0142,0.3509,0.635,0.653903902,0.069420211,0.27667591
"Many people who are infected with the virus do not have any clinical symptoms; current
Estimates suggest that about 30% of people who have antibodies against SARS-CoV-2 in their blood are
asymptomatic. These people carry the virus and potentially transmit it to others, who may react with
severe COVID-19 disease.",1021,Translated,TRUE,54.56,0,11.9,12.71,15.9,11.51,14,15.5,14.8,11th and 12th grade,313,50,5.34,5,0.0133,0.3044,0.6823,0.662637055,0.066968754,0.270394236
"Many people infected with the virus do not show any clinical symptoms; current
estimates suggest that about 30% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These individuals carry the virus and potentially spread it to others, who may react with it
severe covid-19 disease.",1021,Translated,TRUE,47.12,0,12.7,13.58,16.2,11.74,14,16,15.43,15th and 16th grade,308,48,5.5,5,0.0104,0.2636,0.726,0.656053662,0.065070502,0.278875768
"Many people infected with the virus have no clinical symptoms; present
estimates suggest that about 30% of individuals who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These individuals carry the virus and potentially spread it to others who may react
severe COVID-19 disease.",1021,Translated,TRUE,40.69,0,13.1,14.5,16.1,11.9,13,15,15.16,14th and 15th grade,291,44,5.704545455,5,0.0112,0.2798,0.7091,0.659081399,0.063685104,0.277233481
"Many people infected with the virus show no clinical symptoms. drift
estimates show that about 30% of people who have antibodies against SARS-CoV-2 in their blood
asymptomatic. These people carry the virus and potentially spread it to others who may react to it
severe disease of COVID-19.",1021,Translated,TRUE,64,11.2,8.2,11.54,10.8,10.46,11,8.833333333333334,11.39,10th and 11th grade,289,47,5.234042553,5,0.0121,0.2491,0.7388,0.644968152,0.066926114,0.288105756
"Many people infected with the virus have no clinical symptoms; current
estimates suggest that around 30% of people who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These people carry the virus and can transmit it to others, who may react by
severe illness from COVID-19.",1021,Translated,TRUE,56.59,0,11.1,12.25,14.7,11.64,13,14,13.55,11th and 12th grade,285,46,5.282608696,5,0.0158,0.3664,0.6178,0.654694915,0.06977389,0.275531173
"Many people infected with the virus do not show any clinical symptoms; current
According to estimates, about 30% of people who have antibodies to SARS-CoV-2 in their blood,
asymptomatic. These people carry the virus and potentially spread it to others who may react
severe disease of COVID-19.",1021,Translated,TRUE,47.62,0,12.5,12.36,15.1,11.52,13,15.25,15.36,12th and 13th grade,293,47,5.319148936,5,0.0119,0.2688,0.7193,0.652180851,0.067296781,0.280522436
"Many people infected with the virus do not show any clinical symptoms. the point
It is estimated that about 30% of people who have SARS-CoV-2 antibodies in their blood have the disease.
No apparent symptoms. These people carry the virus and potentially transmit it to others who may interact with it
Serious illness Covid-19.",1021,Translated,TRUE,66.23,11.2,7.4,10.49,9.1,10.15,13,7.75,11.33,7th and 8th grade,325,54,5.092592593,5,0.0134,0.2891,0.6975,0.648982108,0.083281077,0.267736793
"Many people infected with the virus show no clinical symptoms. drift
estimates show that about 30% of people who have SARS-CoV-2 antibodies in their blood are
asymptomatic. These people carry the virus and potentially spread it to others, who may react to it
severe disease covid-19.",1021,Translated,TRUE,64.41,11.2,8.1,11.13,10.6,10.57,11,8.666666666666666,11.34,10th and 11th grade,283,46,5.239130435,5,0.0123,0.2505,0.7372,0.639759898,0.0685651,0.291675001
"Many people infected with the virus do not show any clinical symptoms; Present
It is estimated that about 30% of individuals who have SARS-CoV-2 antibodies in their blood are infected with the virus.
No apparent symptoms. These individuals carry the virus and potentially transmit it to others who may interact with it
Severe COVID-19 illness.",1021,Translated,TRUE,52.9,13.6,10.4,12.36,12.5,10.29,13,12.5,13.14,12th and 13th grade,343,55,5.309090909,5,0.0125,0.2873,0.7002,0.650255144,0.068593897,0.281150967
"Many people infected with the virus do not show any clinical symptoms. point
It is estimated that about 30% of people who have antibodies to SARS-CoV-2 in their blood have this disease.
No noticeable symptoms. These people carry the virus and potentially pass it on to others who may interact with it
Severe disease Covid-19.",1021,Translated,TRUE,65.93,10.7,7.5,9.85,8.7,9.49,11,7.625,10.61,7th and 8th grade,325,55,4.981818182,5,0.0163,0.3207,0.663,0.639887929,0.067397267,0.292714834
"Many people infected with the virus do not have clinical symptoms; the actual
It is estimated that around 30% of people have antibodies to SARS-CoV-2 in their blood.
asymptomatic. These people carry the virus and can transmit it to other people who may react to it.
severe COVID-19 illness.",1021,Translated,TRUE,63.39,11.2,8.5,10.03,10,10.25,11,10.166666666666666,11.42,10th and 11th grade,290,49,5,5,0.0167,0.3005,0.6828,0.64452374,0.07437741,0.281098872
"Many people infected with the virus do not show clinical symptoms. drift
Estimates show that about 30% of people who have antibodies to SARS-CoV-2 in their blood,
asymptomatic. These people carry the virus and potentially spread it to others who may react
severe disease of COVID-19.",1021,Translated,TRUE,64.41,11.2,8.1,11.13,10.6,10.57,11,8.666666666666666,11.34,10th and 11th grade,283,46,5.239130435,5,0.0111,0.2403,0.7485,0.64973861,0.071826972,0.278434396
"Many people infected with the virus do not show clinical symptoms. Current estimates suggest that about 30% of people who have SARS-CoV-2 antibodies in their blood are asymptomatic. These people carry the virus and may spread it to others, who may respond with severe COVID-19 disease.",1021,Translated,TRUE,64.41,10.5,8.1,11.36,10.8,10.92,12,8.333333333333334,10.47,10th and 11th grade,285,46,5.217391304,5,0.0085,0.2155,0.7759,0.650494576,0.068232842,0.281272501
"Many people infected with the virus have no clinical symptoms; current
According to estimates, about 30% of people who have antibodies to SARS-CoV-2 in their blood,
asymptomatic. These people carry the virus and potentially pass it on to other people who may react
severe disease of COVID-19.",1021,Translated,TRUE,47.62,0,12.5,12.25,15,11.19,12,15.25,15.36,14th and 15th grade,292,47,5.29787234,5,0.0152,0.317,0.6678,0.643057764,0.062266514,0.294675738
"The findings support global recommendations to prioritize the allocation of COVID-19 vaccines to the elderly
groups. The relative differences between allocation strategies decreased with the rate of vaccine introduction
was increased.",1022,Translated,TRUE,21.9,0,14.1,20.01,17.3,13.57,15,11.75,15.23,13th and 14th grade,234,31,6.64516129,2,0.1173,0.8473,0.0354,0.729795456,0.091086686,0.179117858
"The findings support global recommendations to prioritize COVID-19 vaccine allocation to older age
groups. Relative differences between allocation strategies were reduced as the rate of vaccine rollout
was increased.",1022,Translated,TRUE,22.92,0,13.7,19.13,16.3,13.61,14,10.25,12.7,13th and 14th grade,216,29,6.551724138,2,0.1559,0.8159,0.0282,0.732419431,0.093222596,0.174357966
"The findings support global recommendations for prioritizing the distribution of the COVID-19 vaccine in the elderly
groups. The relative differences between distribution strategies were reduced as the rate of vaccine distribution increased
was increased.",1022,Translated,TRUE,20.38,0,14.6,19.78,17.8,11.91,13,12.5,13.86,12th and 13th grade,255,34,6.588235294,2,0.1745,0.804,0.0215,0.734463811,0.074722931,0.190813184
"Findings support global recommendations to prioritize COVID-19 vaccine allocation to older people
groups. Relative differences between allocation strategies decreased as the speed of vaccine rollout increased.
was increased.",1022,Translated,TRUE,14.97,0,14.7,22.09,18.7,13.92,14,9,12.74,12th and 13th grade,224,28,7.107142857,2,0.0894,0.842,0.0686,0.708723962,0.11049705,0.180778936
The results support global recommendations to prioritize COVID-19 vaccine allocation to older age groups. Relative differences between allocation strategies decreased as vaccine distribution increased.,1022,Translated,TRUE,0.08,0,16.2,24.11,19.5,15.42,14,8.5,14.8,14th and 15th grade,201,24,7.416666667,2,0.0959,0.8664,0.0377,0.721778035,0.115003698,0.16321823
"The results support global recommendations to prioritize covid-19 vaccine allocation for older age
groups. Relative differences between allocation strategies decreased as the vaccine evolved
was increased.",1022,Translated,TRUE,24.44,0,13.1,21.33,17.7,14.61,13,8.5,12.89,12th and 13th grade,205,26,7,2,0.1287,0.839,0.0324,0.719652414,0.102833174,0.177514434
"The findings support global recommendations to prioritize the distribution of the COVID-19 vaccine for older age groups
groups. The relative differences between distribution strategies decreased as the speed of vaccine circulation
Increased.",1022,Translated,TRUE,29.86,0,13.1,19.95,17.5,12.82,14,11.5,13.9,12th and 13th grade,241,32,6.625,2,0.0626,0.8601,0.0773,0.730732858,0.087859623,0.181407526
"The results support global recommendations to prioritize the allocation of the Covid-19 vaccine to older people
groups. The relative differences between allocation strategies have been reduced with the speed of the vaccine rollout
has been increased.",1022,Translated,TRUE,36.28,0,12.7,16.59,15.7,11.99,14,12,12.76,11th and 12th grade,250,36,6.027777778,2,0.1941,0.7818,0.0241,0.663600028,0.09047164,0.245928228
"The results support global recommendations to prioritize the allocation of the Covid-19 vaccine to older people
groups. The relative differences between allocation strategies decreased as the vaccine developed
has been increased.",1022,Translated,TRUE,21.9,0,14.1,19.08,16.6,13.06,14,11.25,13.94,13th and 14th grade,229,31,6.483870968,2,0.1103,0.8512,0.0385,0.70480001,0.097495288,0.197704703
"The findings support global recommendations to prioritize distribution of the COVID-19 vaccine to older age groups
groups. The relative differences between distribution strategies decreased with the rate of vaccine circulation
Increased.",1022,Translated,TRUE,21.9,0,14.1,20.59,17.8,13.06,14,11.25,13.94,13th and 14th grade,237,31,6.741935484,2,0.0856,0.8634,0.0509,0.739173293,0.086874112,0.173952535
"The findings support global recommendations for prioritizing COVID-19 vaccine allocation to older people.
groups. As the pace of vaccine rollout has accelerated, the relative differences between allocation strategies have decreased.
has increased.",1022,Translated,TRUE,12.94,0,15.4,20.47,18.4,13.31,15,11.5,13.9,13th and 14th grade,247,32,6.8125,2,0.1263,0.8359,0.0377,0.712800562,0.093734607,0.193464801
"The findings support global recommendations for prioritizing the distribution of the COVID-19 vaccine for the elderly
groups. The relative differences between distribution strategies decreased as the rate of vaccine distribution increased
was increased.",1022,Translated,TRUE,20.89,0,14.4,20.76,18.4,12.11,13,12.25,13.87,13th and 14th grade,253,33,6.757575758,2,0.1014,0.8642,0.0344,0.732101142,0.07840915,0.189489722
"The findings support global recommendations to prioritize the allocation of COVID-19 vaccines to older adults
groups. The relative differences between allocation strategies decreased with the rate of vaccine introduction
was increased.",1022,Translated,TRUE,21.9,0,14.1,20.24,17.5,14.08,15,11.25,13.94,13th and 14th grade,235,31,6.677419355,2,0.1128,0.8499,0.0373,0.726805329,0.093928665,0.179265961
The results support global recommendations to prioritize COVID-19 vaccine distribution to older age groups. The relative differences between distribution strategies decreased as the rate of vaccine circulation increased.,1022,Translated,TRUE,14.97,0,14.7,21.51,18,13.92,14,10.5,14.17,14th and 15th grade,220,28,6.892857143,2,0.0894,0.8627,0.0478,0.721832633,0.095157094,0.18301031
"The results support global recommendations for prioritizing covid-19 vaccine allocation to older people.
groups. As the rate of vaccine deployment has increased, the relative differences between distribution strategies have decreased.
has increased.",1022,Translated,TRUE,21.4,0,14.3,20.88,18.6,13.31,15,11.5,15.15,13th and 14th grade,249,32,6.875,2,0.1397,0.8191,0.0412,0.697695255,0.095589921,0.206714794
"Findings support global recommendations to prioritize COVID-19 vaccine allocation to older adults
groups. Relative differences between allocation strategies have been reduced as the speed of vaccine deployment
was increased.",1022,Translated,TRUE,22.92,0,13.7,20.76,17.7,14.16,14,10.75,14.08,13th and 14th grade,224,29,6.827586207,2,0.0815,0.8644,0.0541,0.691894174,0.09131217,0.216793597
The results support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Relative differences between allocation strategies decreased as the pace of vaccine rollout increased.,1022,Translated,TRUE,23.93,0,13.3,20.81,17.3,14.25,14,8.75,12.81,12th and 13th grade,209,27,6.777777778,2,0.1024,0.8615,0.0361,0.715508699,0.113607548,0.170883775
The findings support global recommendations to prioritize COVID-19 vaccine allocation to older age groups. The relative differences between allocation strategies decreased as the pace of vaccine deployment increased.,1022,Translated,TRUE,23.43,0,13.5,20.64,17.4,13.92,14,10.5,14.17,13th and 14th grade,216,28,6.75,2,0.063,0.877,0.0599,0.731193841,0.098832615,0.169973582
"Findings Support Global Recommendations to Prioritize COVID-19 Vaccine Distribution for Older People
groups. Relative differences between distribution strategies decrease as vaccine distribution rate increases
was increased.",1022,Translated,TRUE,-0.95,0,16.6,25.56,21.1,14.61,14,10.5,14.43,14th and 15th grade,224,26,7.730769231,2,0.0931,0.8736,0.0333,0.717672408,0.093512498,0.188815102
"Down syndrome, which is caused by trisomy 21, is characterized by immune disorders, anatomically
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,29.18,0,15.4,17.12,19.7,14.35,10,18.5,19.6,19th and 20th grade,176,25,6.12,4,0.0096,0.1735,0.8168,0.721787453,0.067500018,0.210712463
"Down syndrome, caused by Down syndrome, is characterized by immune dysregulation, anatomical problems
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,13.28,0,17.4,20.02,21.6,14.04,10,18,19.6,17th and 18th grade,181,24,6.625,2,0.0088,0.1299,0.8614,0.732856214,0.079421923,0.187721848
"Down syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical
upper respiratory tract differences and more severe COVID-19 infection.",1029,Translated,TRUE,14.29,0,17,19.09,20.4,15.08,10,17.5,19.63,19th and 20th grade,170,23,6.47826087,4,0.0096,0.1616,0.8287,0.744807839,0.06176931,0.193422958
"Down syndrome, which is caused by trisomy 21, is characterized by immune disorders, anatomically
upper respiratory tract differences and more severe COVID-19 infection.",1029,Translated,TRUE,22.75,0,15.8,18.57,20,15.08,10,17.5,19.63,19th and 20th grade,168,23,6.391304348,4,0.0109,0.1893,0.7997,0.724459767,0.070463672,0.205076575
"Down syndrome, which is caused by trisomy 21, is characterized by immune dysfunction, anatomical
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,29.18,0,15.4,17.12,19.7,14.35,10,18.5,19.6,19th and 20th grade,176,25,6.12,4,0.0093,0.1453,0.8454,0.748679042,0.065673538,0.185647413
"Down syndrome, caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and more severe COVID-19 infections.",1029,Translated,TRUE,14.29,0,17,18.8,20.4,15.08,10,17.5,19.63,19th and 20th grade,170,23,6.434782609,4,0.01,0.1756,0.8144,0.745874703,0.061837099,0.192288175
"Down syndrome, which is caused by trisomy 21, is characterized by immunodeficiency, anatomical
differences in the upper respiratory tract and more severe covid-19 infections.",1029,Translated,TRUE,13.28,0,17.4,18.28,20.2,14.04,9,18,19.6,17th and 18th grade,174,24,6.333333333,4,0.0106,0.1717,0.8177,0.740157008,0.071979873,0.187863082
"Down syndrome caused by trisomy 21 is characterized by immune system disorders, anatomical differences in the upper respiratory tract, and more severe COVID-19 infections.",1029,Translated,TRUE,21.74,0,16.2,17.82,19.6,15.35,11,18,19.6,17th and 18th grade,171,24,6.166666667,4,0.0084,0.1585,0.8331,0.741229832,0.069854714,0.188915476
"Down syndrome, which results from trisomy 21, is characterized by an immunological and anatomical defect
Differences in upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,20.72,0,16.6,18.28,20.5,14.35,11,18.5,19.6,18th and 19th grade,180,25,6.28,4,0.0124,0.2442,0.7433,0.741634965,0.06798692,0.19037804
"Down syndrome, caused by trisomy 21, is characterized by dysregulation of the immune system, anatomical
upper respiratory tract differences and more severe COVID-19 infection.",1029,Translated,TRUE,13.28,0,17.4,18.57,20.4,15.35,11,18,19.6,17th and 18th grade,175,24,6.375,4,0.0088,0.1472,0.844,0.748223126,0.062519886,0.189256981
"Down syndrome, caused by trisomy 21, is characterized by immune, anatomical dysregulation
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,14.29,0,17,18.8,20.2,15.08,10,17.5,19.63,19th and 20th grade,169,23,6.434782609,4,0.0112,0.1934,0.7955,0.737432361,0.068129376,0.194438219
"Down syndrome, caused by trisomy 21, is characterized by dysregulation of the immune system, anatomical
differences in upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,20.72,0,16.6,17.82,20.3,14.98,11,18.5,19.6,19th and 20th grade,179,25,6.24,4,0.0082,0.1352,0.8566,0.740787864,0.063015945,0.196196154
"Down syndrome, caused by trisomy 21, is characterized by dysregulation of the immune system, anatomically
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,19.71,0,17,17.58,20.5,14.64,11,19,19.63,16th and 17th grade,185,26,6.192307692,4,0.0085,0.1519,0.8396,0.738445938,0.063106537,0.19844754
"Down syndrome is caused by Down syndrome, immune dysregulation, and anatomical problems.
It is characterized by upper respiratory tract differences and more severe COVID-19 infections.",1029,Translated,TRUE,33.41,0,11.7,17.79,15,13.1,10,8.25,14.6,14th and 15th grade,184,25,6.44,2,0.008,0.1235,0.8685,0.728160322,0.084583543,0.187256083
"Down syndrome, caused by trisomy 21, is characterized by dysregulation of the immune system, anatomical differences of the upper respiratory tract and a more severe course of COVID-19 infection.",1029,Translated,TRUE,25.12,0,17,15.5,20,13.79,11,20.5,19.88,19th and 20th grade,194,29,5.724137931,4,0.0088,0.1754,0.8158,0.739144504,0.056759011,0.204096511
"Down syndrome, caused by trisomy 21, is characterized by immunodeficiency, anatomical
differences in the upper respiratory tract and more severe Covid-19 infections.",1029,Translated,TRUE,15.31,0,16.6,19.38,20.4,14.78,9,17,19.71,16th and 17th grade,165,22,6.590909091,4,0.0108,0.1786,0.8106,0.740211129,0.075585149,0.18420361
"Down syndrome, caused by trisomy 21, is characterized by immune dysfunction, anatomical
differences in upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,23.77,0,15.4,18.85,19.9,15.49,10,17,19.71,19th and 20th grade,163,22,6.5,4,0.0097,0.1472,0.8432,0.750929952,0.067403048,0.181666955
"Down syndrome, caused by trisomy 21, is characterized by immune disorders, anatomically
differences in the upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,22.75,0,15.8,18.34,19.7,15.08,10,17.5,19.63,19th and 20th grade,167,23,6.347826087,4,0.0101,0.1801,0.8098,0.734120905,0.06895595,0.196923107
"Down syndrome, caused by trisomy 21, is characterized by anatomical dysregulation of the immune system
differences in upper respiratory tract and more severe COVID-19 infections.",1029,Translated,TRUE,20.72,0,16.6,17.82,20.1,14.98,11,18.5,19.6,19th and 20th grade,178,25,6.2,4,0.0084,0.1629,0.8287,0.738442242,0.066687539,0.194870144
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds
It has anti-inflammatory effects and also regulates the immune system, and is among the main elements
Factors that can help in the recovery of patients infected with COVID19.",1033,Translated,TRUE,31.89,0,18.5,14.52,23.9,13.26,15,25.5,21.75,18th and 19th grade,252,39,5.538461538,2,0.4494,0.5265,0.0241,0.634675503,0.067629345,0.29769513
"The presence of terpenoids, flavonoids and rich phenolic compounds which
which has an anti-inflammatory effect and also regulates the immune system, are some of the most important
substances that can help patients with COVID19 recover.",1033,Translated,TRUE,27.49,0,18.1,15.97,23.1,12.14,13,22.5,18.57,18th and 19th grade,235,35,5.8,2,0.7129,0.2728,0.0143,0.644797623,0.074510098,0.280692339
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which
they have anti-inflammatory effects and also enhance the regulation of the immune system, they are among the most important
factors that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,27.83,0,20.1,14.52,25.7,12.01,14,26.5,20.92,20th and 21st grade,276,43,5.488372093,2,0.8452,0.1463,0.0084,0.648526073,0.082341194,0.269132733
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which
has anti-inflammatory effects and also upregulation of the immune system, is among the biggest
agents that can help recover patients with covid19.",1033,Translated,TRUE,27.49,0,18.1,15.79,23.1,13.04,13,21.5,18.57,18th and 19th grade,235,35,5.8,2,0.4612,0.5094,0.0294,0.636611521,0.076905012,0.286483467
"The presence of terpenoids, flavonoids and a large number of phenolic compounds which
they have anti-inflammatory effects and also enhance the regulation of the immune system, they are among the most important
factors that may aid in the recovery of patients with COVID19.",1033,Translated,TRUE,27.83,0,20.1,14.12,25.3,11.64,14,26.5,20.92,20th and 21st grade,272,43,5.395348837,2,0.8281,0.1637,0.0081,0.667991519,0.075977035,0.256031513
"The presence of terpenoids, flavonoids and rich phenolic compounds
It has an anti-inflammatory effect and also regulates the immune system and is one of the main elements
Factors that may contribute to the recovery of patients infected with COVID19.",1033,Translated,TRUE,23.43,0,19.7,14.23,23.6,13.26,16,26.5,22.78,19th and 20th grade,249,39,5.461538462,2,0.2397,0.7144,0.046,0.638371587,0.066651225,0.294977218
"The presence of terpenoids, flavonoids and a rich amount of phenolic compounds which
they have anti-inflammatory effects and also increase the regulation of the immune system, they are among the main ones
substances that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,36.29,0,18.9,13.94,25.2,12.38,14,25.5,20.92,25th and 26th grade,271,43,5.372093023,2,0.7266,0.2628,0.0106,0.636214316,0.072049364,0.291736275
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which
They have anti-inflammatory effects and also increase the regulation of the immune system, they are among the main
Agents that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,37.31,0,18.5,14,24.8,12.49,13,25,20.61,24th and 25th grade,266,42,5.404761905,2,0.6634,0.323,0.0136,0.642689288,0.078122914,0.279187799
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds
It has anti-inflammatory effects and also regulates the immune system, and is one of the main elements
Factors that may contribute to the recovery of patients infected with COVID19.",1033,Translated,TRUE,22.42,0,20.1,14.63,24.5,13.52,16,27,23,-1th and 0th grade,259,40,5.55,2,0.2319,0.7227,0.0454,0.635050178,0.067925848,0.297023922
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds.
It has anti-inflammatory effects and also regulates the immune system, and is among the main elements.
Factors that can help in the recovery of patients infected with COVID19.",1033,Translated,TRUE,58.28,11.2,8.4,13.04,11.2,11.97,15,7.5,11.35,11th and 12th grade,254,39,5.58974359,2,0.3742,0.607,0.0188,0.645422518,0.073033385,0.28154406
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds, which
have anti-inflammatory effects and also regulate the immune system, are among the main
agents that can aid in the recovery of COVID19 patients.",1033,Translated,TRUE,35.95,0,16.9,14.63,22.2,13.04,12,21.5,18.57,21st and 22nd grade,228,35,5.6,2,0.4541,0.5229,0.023,0.659292281,0.079617687,0.26109007
"The presence of terpenoids, flavonoids and large amounts of phenolic compounds, which have anti-inflammatory effects and also regulate the immune system, are among the most important active ingredients that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,24.45,0,19.3,16.14,24.8,12.59,14,25,20.46,24th and 25th grade,257,38,5.789473684,2,0.8476,0.1463,0.0061,0.661681175,0.077516586,0.260802209
"The presence of terpenoids, flavonoids and a rich amount of phenolic compounds which
they have anti-inflammatory effects and also increase the regulation of the immune system, they are among the main
substances that can aid the recovery of COVID19 patients.",1033,Translated,TRUE,30.88,0,18.9,14.34,24.2,12.33,14,24,20,23rd and 24th grade,257,40,5.5,2,0.7274,0.2612,0.0114,0.651781738,0.086088613,0.262129664
"Terpenoids, flavonoids and abundant amounts of phenolic compounds are present.
They have an anti-inflammatory effect and also increase the regulation of the immune system, which is one of their main effects.
A substance that can help COVID-19 patients recover.",1033,Translated,TRUE,58.28,9.7,8.4,13.79,11.9,12.38,15,6.833333333333333,9.3,9th and 10th grade,260,39,5.743589744,2,0.8058,0.1883,0.0059,0.610779405,0.091765344,0.297455281
"The presence of terpenoids, flavonoids and the rich amounts of phenolic compounds, which have anti-inflammatory effects and also improve the regulation of the immune system, are among the most important factors that can help in the recovery of patients with COVID19.",1033,Translated,TRUE,29.86,0,19.3,14.87,25,11.83,13,25.5,20.3,19th and 20th grade,266,41,5.512195122,2,0.9033,0.0911,0.0056,0.66511178,0.080247857,0.2546404
"Terpenoids, flavonoids and abundant amounts of phenolic compounds are present.
It has an anti-inflammatory effect and regulates the immune system, which is one of the main factors.
A medication that can help COVID-19 patients recover.",1033,Translated,TRUE,51.14,10.5,9,13.49,11.3,12.79,14,6.5,10.39,10th and 11th grade,234,35,5.771428571,2,0.6432,0.3481,0.0087,0.622857094,0.09423358,0.282909334
"The presence of terpenoids, flavonoids and rich amounts of phenolic compounds, which have anti-inflammatory effects and also enhance the regulation of the immune system, are among the key factors that can aid in the recovery of patients infected with COVID19.",1033,Translated,TRUE,30.88,0,18.9,14.52,24.5,12.73,15,25,21,24th and 25th grade,259,40,5.5,2,0.6847,0.3033,0.012,0.655922413,0.067495696,0.276581913
"The presence of terpenoids, flavonoids and rich phenolic compounds which
which are anti-inflammatory and also regulate the immune system, are some of the most important
substances that can help patients with COVID19 recover.",1033,Translated,TRUE,29.52,0,17.3,16.37,22.5,11.97,12,21.5,18.05,16th and 17th grade,224,33,5.878787879,2,0.7496,0.2372,0.0132,0.646108329,0.074581936,0.27930975
"The presence of terpenoids, flavonoids and rich phenolic compounds which
they have an anti-inflammatory effect and also increase the regulation of the immune system, are among the main ones
substances that may contribute to the recovery of COVID19 patients.",1033,Translated,TRUE,31.89,0,18.5,15.27,24.5,13.26,15,24.5,20.73,24th and 25th grade,257,39,5.666666667,2,0.2131,0.7308,0.056,0.647560656,0.077387497,0.275051862
"Dietary supplements and vitamins including vitamin D and high dose vitamin
C have also been used to treat COVID-19. Despite the expected excellent tolerance and
interesting rationale to support their activities against COVID-19, their preventive or therapeutic
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,23.26,0,15.6,17.18,18.1,12.82,18,18.75,20.56,12th and 13th grade,314,45,6.066666667,4,0.1775,0.7489,0.0736,0.691022575,0.15235725,0.156620115
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin
C have also been used to treat COVID-19. Despite an expected excellent tolerance and a
interesting reasoning to support their activities against COVID-19, their preventive or therapeutic activities
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.29,0,17,17.7,18.9,12.67,18,19.5,20.5,12th and 13th grade,327,46,6.195652174,4,0.1862,0.7556,0.0582,0.667158782,0.154521883,0.178319305
"Dietary supplements and vitamins including vitamin D and high dose vitamin
C has also been used for COVID-19 treatment. Despite an expected excellent tolerance and a
interesting justification to support their anti-COVID-19 activities, their preventive or therapeutic
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.8,0,16.8,17.82,18.7,13.52,20,19.25,20.56,18th and 19th grade,320,45,6.2,4,0.1618,0.7705,0.0678,0.671762109,0.171339154,0.156898752
"Dietary supplements and vitamins including vitamin D and high doses of the vitamin
C is also used to treat COVID-19. Despite the expected excellent tolerance and
interesting rationale for supporting their activities against COVID-19, their preventive or therapeutic activities
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,13.78,0,17.2,17.47,18.8,12.53,19,20.25,21.31,12th and 13th grade,330,47,6.106382979,4,0.1893,0.7549,0.0558,0.64730233,0.185116827,0.167580828
"Dietary supplements and vitamins, including vitamin D and high-dose vitamins
C was also used to treat COVID-19. Excellent resistance and
Interesting evidence supporting anti-COVID-19 activity, prevention or treatment
Randomized trials have not confirmed effectiveness.",1036,Translated,TRUE,11.92,0,15.8,21.17,19.6,14.7,17,16,20.92,15th and 16th grade,268,34,7,4,0.5732,0.4035,0.0233,0.684036613,0.153318599,0.162644759
"Supplements and vitamins including vitamin D and high doses of vitamin D
C has also been used to treat COVID-19. Despite the expected excellent tolerance and
An interesting justification to support their activities against Covid-19, whether preventive or therapeutic
Its effectiveness has not been confirmed in randomized trials.",1036,Translated,TRUE,21.74,0,16.2,16.48,18.3,12.39,18,19.5,20.43,19th and 20th grade,329,48,5.9375,4,0.3229,0.6427,0.0345,0.644998729,0.19712244,0.157878742
"Dietary supplements and vitamins, including high-dose vitamin D and vitamin C, have also been used for the treatment of COVID-19. Despite expected excellent tolerability and an interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.8,0,16.8,18.34,19.4,13.52,20,19.25,20.56,18th and 19th grade,327,45,6.288888889,4,0.2894,0.6849,0.0257,0.693069398,0.132191539,0.174739093
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin
C have also been used for the treatment of COVID-19. Despite excellent expected tolerance and
interesting justification to support their anti-COVID-19 activities, their preventive or therapeutic actions
effectiveness has not been confirmed in randomized trials.",1036,Translated,TRUE,14.8,0,16.8,19.73,20.5,13.88,21,19.25,20.56,20th and 21st grade,337,45,6.577777778,4,0.1255,0.7975,0.077,0.680937946,0.149367526,0.169694528
"Supplements and vitamins including vitamin D and high doses of vitamin D
C has also been used to treat COVID-19. Despite the expected excellent tolerance and
An interesting justification to support their anti-COVID-19 activities, preventive or therapeutic
Its effectiveness has not been confirmed in randomized trials.",1036,Translated,TRUE,14.29,0,17,16.66,18,12.67,19,19.5,20.5,16th and 17th grade,318,46,6,4,0.1848,0.7467,0.0684,0.657909632,0.182072431,0.160017863
"Dietary supplements and vitamins including vitamin D and high-dose vitamin
C has also been used for covid-19 treatment. Despite an expected excellent tolerance and a
interesting justification to support their anti-COVID-19 activities, their preventive or therapeutic
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,15.31,0,16.6,18.33,19.2,13.7,20,19,20.62,18th and 19th grade,320,44,6.363636364,4,0.1448,0.7693,0.0859,0.674759328,0.164743036,0.16049771
"Dietary supplements and vitamins, including vitamin D and high-dose vitamins
C have also been used for the treatment of COVID-19. Despite the expected excellent tolerability and
interesting rationale to support their anti-COVID-19 activities, their preventive or therapeutic
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.8,0,16.8,18.57,19.5,13.52,20,19.25,20.56,18th and 19th grade,328,45,6.377777778,4,0.1177,0.7976,0.0847,0.701049209,0.123494253,0.175456583
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin C, have also been used to treat COVID-19. Despite expected excellent tolerability and an interesting rationale for their anti-COVID-19 activities, their preventive or therapeutic efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,7.86,0,17.4,18.33,19,13.33,18,18.5,20.78,18th and 19th grade,308,42,6.357142857,4,0.344,0.6307,0.0253,0.677954555,0.137961552,0.184084013
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin C, have also been used to treat COVID-19. Despite expected excellent tolerability and an interesting rationale for their anti-COVID-19 effects, their preventive or therapeutic efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,16.32,0,16.2,17.93,18.7,13.33,18,18,19.83,17th and 18th grade,305,42,6.285714286,4,0.3426,0.6329,0.0245,0.694155931,0.113823473,0.192020535
"Dietary supplements and vitamins, including vitamin D and high doses of vitamin.
C have also been used to treat COVID-19. Despite the expected excellent tolerance and
interesting foundation to support your activities against COVID-19, its preventive or therapeutic nature
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,30.16,15.9,13,16.01,14.4,12.48,20,12.833333333333334,17.34,12th and 13th grade,325,47,6,4,0.2425,0.6921,0.0654,0.653218746,0.177101061,0.169680178
"Dietary supplements and vitamins, including vitamin D and a high-dose vitamin
C have also been used to treat COVID-19. Despite the excellent expected tolerance and
interesting rationale to support their activities in the fight against COVID-19, their preventive or therapeutic actions
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,21.23,0,16.4,16.54,18.7,12.59,19,19.75,20.41,16th and 17th grade,338,49,5.979591837,4,0.1929,0.7496,0.0575,0.665370524,0.151229277,0.183400244
"Dietary supplements and vitamins, including vitamin D and high-dose vitamins
C has also been used to treat covid-19. Despite excellent expected tolerance and
interesting justification to support their anti-COVID-19 activities, their preventive or therapeutic measures
Efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,7.35,0,17.6,19.26,19.9,13.88,20,18.75,20.69,18th and 19th grade,321,43,6.558139535,4,0.1371,0.7463,0.1166,0.673089981,0.155036896,0.171873108
"Dietary supplements including vitamin D and high-dose vitamins and vitamin C have also been used to treat COVID-19. Expected excellent tolerability and
interesting evidence supporting anti-COVID-19 activity, prevention or treatment
Randomized trials have not shown efficacy",1036,Translated,TRUE,2.44,0,17.4,19.78,18.7,14.62,17,17,21.64,16th and 17th grade,273,36,6.666666667,4,0.4784,0.4959,0.0257,0.669178188,0.131815597,0.19900623
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin
C has also been used to treat COVID-19. Despite the expected excellent tolerability and an
an interesting rationale to support their anti-COVID-19 activity, their preventive or curative activity
efficacy has not been confirmed in randomized trials.",1036,Translated,TRUE,14.29,0,17,17.18,18.7,13.02,19,20,20.5,16th and 17th grade,324,46,6.130434783,4,0.2093,0.7416,0.0492,0.691435218,0.123086147,0.185478598
"Dietary supplements and vitamins, including vitamin D and high-dose vitamin C, have also been used to treat COVID-19. Despite the expected excellent tolerability and an interesting rationale for their anti-COVID-19 effect, their preventive or curative effect has not been confirmed in randomized trials.",1036,Translated,TRUE,24.27,0,15.2,16.71,17.9,12.78,17,17.75,18.83,17th and 18th grade,303,43,6.069767442,4,0.3362,0.6409,0.0229,0.684803307,0.125484765,0.189711958
"We addressed the infectivity of the central nervous system. First reports from Wuhan
claimed that 36% of COVID-19 patients show neurological symptoms, later European studies showed
showed as much as 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,43.73,0,11.9,14.33,14.6,14.14,16,12,12.86,11th and 12th grade,251,38,5.684210526,6,0.0271,0.7012,0.2717,0.650590479,0.085564286,0.263845235
"We have looked at the contagiousness of the central nervous system. Early reports from Wuhan
suggested that 36% of COVID-19 patients had neurological symptoms, later European studies
showed that this figure was as high as 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,49.65,0,11.7,13.05,14.8,13.15,16,13.75,14.18,13th and 14th grade,274,43,5.441860465,6,0.028,0.7638,0.2082,0.654639304,0.085369579,0.259991109
"We addressed the infectivity of the central nervous system. Early reports from Wuhan
suggested that 36% of covid-19 patients show neurological symptoms, later European studies
showed as much as 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,35.78,0,12.9,14.56,14.6,14.37,17,12.25,13.89,14th and 15th grade,246,37,5.72972973,6,0.0292,0.7182,0.2527,0.670684159,0.083115742,0.246200159
"We have addressed susceptibility to CNS infection. Initial reports from Wuhan
Subsequent European studies indicated that 36% of COVID-19 patients develop neurological symptoms
Show up to 60%; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,28.84,0,13.5,16.53,15.6,15.16,17,13,17.39,12th and 13th grade,239,34,6.117647059,6,0.0337,0.8171,0.1492,0.67101711,0.07339602,0.255586922
"We turned to infection of the central nervous system. First reports from Wuhan
suggested that 36% of patients with COVID-19 show neurological symptoms, later European studies
showed as much as 60%; reported cases of viral encephalitis.",1041,Translated,TRUE,44.75,0,11.5,13.51,13.8,14.62,16,12,13.87,13th and 14th grade,235,36,5.611111111,6,0.0181,0.514,0.4679,0.643073142,0.083544835,0.273382038
"We have dealt with infectivity of the central nervous system. Initial reports from Wuhan
A subsequent European study suggested that 36% of COVID-19 patients had neurological symptoms.
A whopping 60% showed up; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,49.82,11.9,9.5,13.38,11.5,14,17,7.833333333333334,12.38,11th and 12th grade,257,39,5.666666667,6,0.0221,0.5121,0.4658,0.643446863,0.079782203,0.27677092
"We discussed the infectious power of the central nervous system. First reports from Wuhan
suggested that 36% of covid-19 patients have neurological symptoms, later European studies
shown up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,44.24,0,11.7,14.39,14.4,14.37,17,12.25,13.89,13th and 14th grade,245,37,5.702702703,6,0.0385,0.7786,0.1828,0.649113119,0.082032755,0.268854231
"We looked at the transmissibility of the central nervous system. Early reports from Wuhan suggested that 36% of COVID-19 patients had neurological symptoms, and later European studies suggested that this figure was as high as 60%. Cases of viral encephalitis have been reported.",1041,Translated,TRUE,48.5,11.9,10,13.04,11.6,12.42,16,8.5,11.3,11th and 12th grade,278,43,5.488372093,6,0.0283,0.8553,0.1164,0.657121837,0.0839421,0.258936018
"We have studied CNS infectivity. First reports from Wuhan
claimed that 36% of COVID-19 patients had neurological symptoms, later European studies showed
showed that this figure was as high as 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,52.19,0,10.7,13.23,13.7,13.3,13,12,12.86,12th and 13th grade,244,38,5.5,6,0.0254,0.7388,0.2358,0.627390921,0.082486808,0.2901223
"We address the infectability of the central nervous system. First reports from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, subsequent European studies
showed up to 60%; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,36.28,0,12.7,15.31,15.2,14.18,16,12.5,14.98,14th and 15th grade,246,36,5.916666667,6,0.0228,0.6182,0.359,0.656123459,0.083980128,0.259896368
"We addressed the infectivity of the central nervous system. First news from Wuhan
suggested that 36% of patients with COVID-19 show neurological symptoms, later European studies
showed up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,44.24,0,11.7,14.1,14.1,13.94,16,12.25,13.89,13th and 14th grade,243,37,5.648648649,6,0.029,0.7125,0.2585,0.650633276,0.086302161,0.263064533
"We looked at the infectivity of the central nervous system. Initial reports from Wuhan
claimed that 36% of COVID-19 patients had neurological symptoms, later European studies showed
that it was as high as 60%; cases of viral encephalitis were reported.",1041,Translated,TRUE,51.18,0,11.1,12.59,13.7,14.1,16,12.5,13,12th and 13th grade,252,40,5.375,6,0.0203,0.6952,0.2845,0.662343442,0.086522467,0.251134098
"We addressed central nervous system infectivity. The first news from Wuhan
suggested that 36% of patients with COVID-19 experience neurological symptoms, subsequent European studies
Appeared up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,28.33,0,13.7,16.88,16.2,14.88,18,12.75,16.14,16th and 17th grade,249,35,6.2,6,0.0274,0.6806,0.292,0.646162152,0.084232502,0.269605428
"We covered central nervous system infection. First news from Wuhan
Subsequent European studies suggested that 36% of COVID-19 patients had neurological symptoms
Up to 60% showed. Cases of viral encephalitis have been reported.",1041,Translated,TRUE,43.39,11.9,9.9,14.6,11.8,14.71,16,6.833333333333333,12.88,11th and 12th grade,226,33,5.939393939,6,0.0204,0.6622,0.3174,0.62678355,0.084768675,0.288447827
"We addressed central nervous system infectivity. The first reports from Wuhan
suggested that 36% of patients with COVID-19 experience neurological symptoms, subsequent European studies
showed up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,28.33,0,13.7,17.05,16.4,15.33,18,12.75,16.14,12th and 13th grade,250,35,6.228571429,6,0.0225,0.6078,0.3698,0.660504282,0.079919457,0.259576261
"We turned to central nervous system infection. First reports from Wuhan
suggested that 36% of patients with COVID-19 show neurological symptoms, later European studies
showed as much as 60%; reported cases of viral encephalitis.",1041,Translated,TRUE,45.76,0,11.1,14.5,14.1,15.16,16,11.5,13.86,14th and 15th grade,228,34,5.794117647,6,0.0177,0.4829,0.4994,0.644185185,0.084457934,0.271356821
"We have dealt with the infectivity of the central nervous system. First reports from Wuhan
A later European study suggested that 36% of COVID-19 patients had neurological symptoms.
A whopping 60% showed up; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,49.52,11.2,9.7,11.99,10.6,13.38,16,7.666666666666666,11.32,10th and 11th grade,254,40,5.425,6,0.0189,0.4373,0.5438,0.639119148,0.080391705,0.280489206
"We turned to central nervous system infection. The first reports from Wuhan
suggested that 36% of patients with COVID-19 experience neurological symptoms, subsequent European studies
showed up to 60%; cases of viral encephalitis have been reported.",1041,Translated,TRUE,36.28,0,12.7,15.6,15.5,15.06,17,13,16.09,15th and 16th grade,248,36,5.972222222,6,0.0154,0.4615,0.5231,0.644209504,0.079226956,0.276563555
"We address the infectivity of the central nervous system. First news from Wuhan
suggested that 36% of COVID-19 patients show neurological symptoms, subsequent European studies
showed up to 60%; Cases of viral encephalitis have been reported.",1041,Translated,TRUE,36.28,0,12.7,14.5,14.5,13.74,15,12.5,14.98,14th and 15th grade,241,36,5.777777778,6,0.0263,0.6351,0.3386,0.650005996,0.086913727,0.263080299
"Recent improvements in mRNA vaccines increase protein translation and modification
Innate and adaptive immunity, improving the birth process. mRNA vaccines are a new type of vaccine
A vaccine to protect against infectious diseases and was the first authorized coronavirus (COVID-19) vaccine
all over the world.",1042,Translated,TRUE,40.18,0,13.2,16.54,17.7,12.12,17,15.25,16.11,16th and 17th grade,310,45,5.977777778,2,0.7593,0.2356,0.0051,0.633800507,0.069416769,0.296782702
"Recent improvements in mRNA vaccines act to increase protein translation, mod
innate and adaptive immunogenicity and delivery improvement. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved COVID-19 vaccines
Worldwide.",1042,Translated,TRUE,35.27,0,13.1,17.81,17.1,13.3,17,12.5,13.92,12th and 13th grade,271,38,6.236842105,2,0.7679,0.2262,0.0058,0.6243397,0.07409656,0.301563799
"Recent improvements in mRNA vaccines act to increase protein translation and modulate
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type of
vaccine to protect against infectious diseases and were the first authorized COVID-19 vaccines
global.",1042,Translated,TRUE,34.26,0,13.5,16.82,16.6,12.52,17,13.5,15,13th and 14th grade,277,40,6.025,2,0.6329,0.3582,0.0089,0.634747922,0.067357965,0.29789412
"Recent improvements in mRNA vaccines increase protein translation and modification
Innate and adaptive immunity and improve the birth process. mRNA vaccines are a new type of vaccine
A vaccine to protect against infectious diseases and was the first approved vaccine against coronavirus (COVID-19)
around the world.",1042,Translated,TRUE,39.67,0,13.4,16.42,17.7,11.64,16,14.5,14.42,11th and 12th grade,315,46,5.934782609,2,0.8033,0.1918,0.005,0.626648486,0.067995518,0.305355966
"Recent improvements in mRNA vaccines enhance protein translation, modulate
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type
a vaccine that protects against infectious diseases and were the first COVID-19 vaccines to be approved
in the whole world.",1042,Translated,TRUE,41.7,0,12.7,15.72,16.3,12.2,17,13.5,14.11,12th and 13th grade,284,42,5.857142857,2,0.8273,0.1671,0.0056,0.622356415,0.066383161,0.311260372
"Recent improvements in mRNA vaccines increase protein translation and modification
Innate and adaptive immunity and improve the birth process. mRNA vaccines are a new type of vaccine
A vaccine to protect against infectious diseases and was the first approved vaccine against the coronavirus (COVID-19)
around the world.",1042,Translated,TRUE,39.16,0,13.6,16.08,17.7,11.52,16,14.75,14.51,14th and 15th grade,319,47,5.872340426,2,0.7959,0.1989,0.0052,0.624716878,0.06622123,0.309061944
"Recent improvements in mRNA vaccines increase protein translation,
Has innate and adaptive immunogenicity and improves delivery. mRNA vaccines are a new type of
It is the first COVID-19 vaccine approved to protect against infectious diseases.
Worldwide.",1042,Translated,TRUE,36.28,0,12.7,16.76,16.1,13.3,17,11.5,12.76,12th and 13th grade,253,36,6.138888889,2,0.7681,0.224,0.0079,0.616668046,0.081651233,0.301680803
"Recent improvements in mRNA vaccines increase protein translation,
It has innate and adaptive immunogenicity and improves delivery. mRNA vaccines are a new type
It is the first COVID-19 vaccine approved to protect against infectious diseases.
Worldwide.",1042,Translated,TRUE,36.28,0,12.7,16.76,16.1,13.3,17,11.5,12.76,12th and 13th grade,253,36,6.138888889,2,0.8836,0.1122,0.0042,0.615336299,0.077323571,0.307340175
"Recent improvements in mRNA vaccines act to increase protein translation, mod
innate and adaptive immunogenicity and delivery enhancement. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved covid-19 vaccines
Worldwide.",1042,Translated,TRUE,35.27,0,13.1,17.81,17.1,13.3,17,12.5,13.92,12th and 13th grade,271,38,6.236842105,2,0.7554,0.2385,0.0061,0.623996675,0.072047532,0.303955883
"Recent improvements in mRNA vaccines act to increase protein translation, modulation
innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved vaccines against COVID-19
all over the world.",1042,Translated,TRUE,41.7,0,12.7,16.71,17.2,11.82,16,13.5,14.11,16th and 17th grade,292,42,6.047619048,2,0.7873,0.2068,0.0059,0.625443816,0.063676096,0.310880095
"Recent improvements in mRNA vaccines act to increase protein translation, modulate
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved COVID-19 vaccines
worldwide.",1042,Translated,TRUE,35.27,0,13.1,17.98,17.2,12.89,17,12.5,13.92,12th and 13th grade,272,38,6.263157895,2,0.7158,0.2771,0.0071,0.628843248,0.068714939,0.302441835
"Recent improvements in mRNA vaccines increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first approved COVID-19 vaccines worldwide.",1042,Translated,TRUE,35.78,0,12.9,18.45,17.5,13.09,17,12.25,13.89,12th and 13th grade,269,37,6.297297297,2,0.8288,0.1664,0.0047,0.623206019,0.072501183,0.304292768
"Recent improvements in mRNA vaccines increase protein translation, modulate innate and adaptive immunogenicity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines approved worldwide.",1042,Translated,TRUE,35.78,0,12.9,18.45,17.5,13.09,17,12.25,13.89,12th and 13th grade,269,37,6.297297297,2,0.843,0.1526,0.0044,0.619556665,0.071045965,0.30939737
"Recent improvements in mRNA vaccines increase protein translation, modulate innate and adaptive immunity, and improve delivery. mRNA vaccines are a new type of vaccine to protect against infectious diseases and were the first COVID-19 vaccines approved worldwide.",1042,Translated,TRUE,35.78,0,12.9,17.52,16.7,13.09,17,12.25,13.89,12th and 13th grade,263,37,6.135135135,2,0.8512,0.1445,0.0043,0.619657815,0.071225129,0.309117138
"Recent improvements in mRNA vaccines act to increase protein translation, modulate
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type of
vaccine to protect against infectious diseases and were the first covid-19 vaccines to be approved
Worldwide.",1042,Translated,TRUE,42.21,0,12.5,16.24,16.5,12.36,17,13.25,14.05,12th and 13th grade,281,41,5.951219512,2,0.6828,0.3095,0.0077,0.623160481,0.064299077,0.312540472
"Recent improvements in mRNA vaccines work by increasing protein translation, modulating
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first approved vaccines against COVID-19
worldwide.",1042,Translated,TRUE,34.76,0,13.3,18.85,18.1,12.7,17,13.25,14.98,12th and 13th grade,285,39,6.41025641,2,0.8171,0.1772,0.0056,0.628422916,0.072883695,0.298693329
"Recent improvements in mRNA vaccines increase protein translation and modification
Innate and adaptive immunity, improving the birth process. mRNA vaccines are a new type of vaccine
A vaccine to protect against infectious diseases and was the first approved vaccine for the coronavirus (COVID-19)
all over the world.",1042,Translated,TRUE,39.16,0,13.6,15.61,17.4,11.86,17,15.25,15.36,15th and 16th grade,316,47,5.808510638,2,0.7838,0.2109,0.0053,0.630791545,0.069766283,0.299442142
"Recent improvements in mRNA vaccines act to increase protein translation and modulation.
innate and adaptive immunogenicity and improve delivery. mRNA vaccines are a new type
vaccine to protect against infectious diseases and were the first vaccines approved against COVID-19
all over the world.",1042,Translated,TRUE,48.5,11.2,10,15.71,13.4,11.32,16,8.166666666666666,11.3,10th and 11th grade,295,43,5.953488372,2,0.7549,0.2387,0.0065,0.627993226,0.067920968,0.304085791
"Recent improvements in mRNA vaccines increase protein translation and modification
Improving the birth process with innate and adaptive immunity. mRNA vaccines are a new type of vaccine.
This is the first approved coronavirus (COVID-19) vaccine to protect against infectious diseases.
Worldwide.",1042,Translated,TRUE,40.65,11.9,11,17.22,14.7,12.79,18,8.166666666666666,12.31,10th and 11th grade,295,41,6.292682927,2,0.8068,0.1888,0.0044,0.623754621,0.072008342,0.304237008
"We observed a slight effect of age on ICU admission. This is probably due to the first wave
Due to the new Corona virus (Covid-19) in Spain, a large number of elderly people have died in nursing homes before
He may even be hospitalized or admitted to the intensive care unit.",1043,Translated,TRUE,62.51,0,10.9,7.9,12.1,10.47,10,15.75,14.91,10th and 11th grade,275,51,4.450980392,2,0.0192,0.4868,0.494,0.636385441,0.089118488,0.274496138
"We noted a minor influence of age on ICU admissions. This is probably because in the first wave
of COVID-19 in Spain, a considerable number of elderly people died in nursing homes before
You could even be hospitalized or admitted to the ICU.",1043,Translated,TRUE,58.11,0,10.5,8.99,11.1,10.21,10,14.25,15.11,10th and 11th grade,241,43,4.674418605,2,0.0231,0.6436,0.3333,0.674972296,0.143167391,0.181860372
"We noticed a small effect of age on intensive care admissions. This is probably because in the first wave
of covid-19 in Spain, a large number of elderly people died in nursing homes before they
may even be hospitalized or admitted to the intensive care unit.",1043,Translated,TRUE,56.59,0,11.1,9.52,12,9.58,9,15,14.42,9th and 10th grade,259,46,4.695652174,2,0.0197,0.4523,0.528,0.67132777,0.105189785,0.223482385
"We found a small effect of age on ICU admission. This is probably because in the first wave of Covid-19 in Spain, many elderly people died in nursing homes before they were even admitted to hospital or ICU.",1043,Translated,TRUE,69.11,0,8.3,7.89,9,9.15,6,12,11.81,8th and 9th grade,206,38,4.447368421,2,0.025,0.5006,0.4743,0.675610185,0.153251931,0.171137929
"We found a minor effect of age on ICU admission. Probably because of the first wave.
In Spain, a significant number of elderly people have died in nursing homes due to COVID-19.
You may be hospitalized or admitted to the ICU.",1043,Translated,TRUE,69.48,10.1,6.1,6.59,4.9,9.54,9,5.625,9.97,9th and 10th grade,225,41,4.56097561,2,0.013,0.3094,0.6776,0.674987316,0.126855388,0.198157236
"We observed a small effect of age on ICU admission. This is probably because in the first wave
In Spain, a significant number of elderly people died prematurely in nursing homes due to COVID-19
even to a hospital or intensive care unit.",1043,Translated,TRUE,58.62,0,10.3,9.11,10.9,10.32,9,14,14.11,9th and 10th grade,236,42,4.69047619,2,0.0212,0.503,0.4758,0.690929234,0.112671927,0.196398795
"We observed a small effect of age on admissions to intensive care. This is probably because in the first wave of Covid-19 in Spain, a large number of elderly people died in nursing homes before they could be admitted to hospital or ICU.",1043,Translated,TRUE,66.57,0,9.3,8.36,10.6,9.48,8,13.75,13.25,8th and 9th grade,236,43,4.511627907,2,0.0228,0.5529,0.4243,0.696842849,0.106763594,0.196393639
"We found a small effect of age on ICU admission. Probably because of the first wave.
In Spain, a significant number of elderly people have died in nursing homes due to COVID-19.
You may be hospitalized or admitted to the ICU.",1043,Translated,TRUE,69.48,10.1,6.1,6.59,4.9,9.15,8,5.625,9.97,9th and 10th grade,225,41,4.56097561,2,0.0154,0.354,0.6306,0.672969699,0.125792503,0.201237768
"We noticed a minor influence of age on intensive care admissions. This is probably because during the first wave
of COVID-19 in Spain, a considerable number of elderly people died in nursing homes before they could
could even be hospitalized or admitted to intensive care.",1043,Translated,TRUE,48.64,0,12.1,11.9,13.7,10.02,11,15.75,16.11,11th and 12th grade,272,45,5.111111111,2,0.0172,0.4525,0.5303,0.665166736,0.112599447,0.222233832
"We found a minor effect of age on ICU admission. Probably because during the first wave.
In Spain, a significant number of elderly people have died from COVID-19 before entering nursing homes.
You may be hospitalized or admitted to an intensive care unit.",1043,Translated,TRUE,60.51,11.2,7.5,9.43,7.3,10.41,11,6.375,11.76,7th and 8th grade,255,43,5,2,0.0125,0.3488,0.6388,0.667036355,0.115616858,0.217346802
"We noticed a smaller influence of age on admissions to intensive care. This is probably because during the first wave
of COVID-19 in Spain, a considerable number of elderly people died in nursing homes before they could
even be hospitalized or admitted to intensive care.",1043,Translated,TRUE,48.64,0,12.1,11.78,13.6,10.02,11,15.75,16.11,11th and 12th grade,271,45,5.088888889,2,0.0241,0.5537,0.4222,0.662833631,0.109658346,0.227508008
"We observed a small effect of age on ICU admission. This is probably because in the first wave
of COVID-19 in Spain, a significant number of elderly people died in nursing homes before they
may even be hospitalized or admitted to intensive care.",1043,Translated,TRUE,58.11,0,10.5,9.57,11.6,10.21,10,14.25,15.11,9th and 10th grade,245,43,4.76744186,2,0.0205,0.5218,0.4577,0.698211551,0.114592656,0.187195867
"A minor effect of age on ICU admission was found. Probably due to the first wave.
In Spain, a significant number of elderly people have died in nursing homes due to COVID-19.
You may be hospitalized or admitted to the ICU.",1043,Translated,TRUE,69.48,10.1,6.1,6.12,4.6,9.54,9,5.625,9.97,9th and 10th grade,222,41,4.487804878,2,0.0105,0.2686,0.7209,0.691000521,0.115175426,0.193824083
"We observed a small effect of age on ICU admissions. This is probably due to the first wave
of COVID-19 in Spain, a significant number of elderly people died in nursing homes before
he could even be hospitalized or admitted to the ICU.",1043,Translated,TRUE,58.11,0,10.5,8.24,10.5,9.84,9,13.75,14.18,10th and 11th grade,235,43,4.534883721,2,0.0183,0.5198,0.4618,0.70373565,0.118117765,0.178146601
"We found a smaller effect of age on intensive care unit admission. Probably because of the first wave.
In Spain, a significant number of elderly people have died in nursing homes due to COVID-19.
You may be hospitalized or admitted to the intensive care unit.",1043,Translated,TRUE,68.47,11.2,6.5,8.45,6.7,9.46,10,6.625,10.74,6th and 7th grade,259,45,4.822222222,2,0.0189,0.3937,0.5874,0.642131805,0.108576186,0.249291971
"We noted a small effect of age on ICU admission. This is probably because in the first wave
a significant number of elderly people in nursing homes died of COVID-19 in Spain before
he could even be hospitalized or admitted to the ICU.",1043,Translated,TRUE,58.11,0,10.5,8.24,10.4,9.84,9,13.75,14.18,9th and 10th grade,234,43,4.511627907,2,0.0273,0.6965,0.2762,0.676755607,0.1428103,0.180434123
"We noted a smaller influence of age on intensive care admissions. This is probably because in the first wave
of covid-19 in Spain, a large number of elderly people died in nursing homes earlier
You may even be hospitalized or admitted to the intensive care unit.",1043,Translated,TRUE,56.59,0,11.1,9.87,12.3,10.27,11,16,16.16,9th and 10th grade,262,46,4.760869565,2,0.0261,0.5857,0.3882,0.668799341,0.109200388,0.22200036
"We found little effect of age on ICU admission. Perhaps due to the first wave.

In Spain, a large number of elderly people in nursing homes have died from COVID-19.

You may be hospitalized or admitted to ICU.",1043,Translated,TRUE,78.75,8.8,4.6,6,4.4,8.68,6,4.75,8.01,4th and 5th grade,209,38,4.578947368,2,0.0151,0.4474,0.5376,0.661833048,0.146615371,0.191551566
"We observed a small effect of age at ICU admission. This is probably due to the first wave
In Spain, a significant number of elderly people have died prematurely in nursing homes due to COVID-19
even in a hospital or intensive care unit.",1043,Translated,TRUE,58.11,0,10.5,8.47,10.7,10.21,9,14.25,14.18,10th and 11th grade,237,43,4.581395349,2,0.0183,0.4492,0.5325,0.69306612,0.116367675,0.190566227
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised people and
older people, were similar to those seen after previous vaccinations and mostly resolved on their own. Fatigue,
myalgia and fever were the most common systemic side effects reported (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,38.62,12.5,11.8,14.27,13.7,12.14,17,10.5,12.24,11th and 12th grade,318,47,5.85106383,7,0.0199,0.4548,0.5253,0.638981402,0.065003313,0.296015233
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised and
seniors, were similar to those observed after previous vaccines and mostly self-resolved. Fatigue,
myalgia and fever were the most frequently reported systemic adverse reactions (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,31.89,13.6,12.3,16.81,15.4,13.35,18,10.333333333333334,12.27,11th and 12th grade,307,42,6.404761905,7,0.022,0.5156,0.4625,0.65781039,0.068789549,0.273400068
"Local and systemic reactions after a third Pfizer vaccine, reported by the immunocompromised and
elderly, were similar to those seen after previous vaccines and mostly resolved. Fatigue,
myalgia and fever were the most frequently reported systemic adverse events (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,40.04,13,11.2,14.9,13.9,13.16,17,10.166666666666666,13.16,12th and 13th grade,299,43,6.046511628,7,0.0252,0.4859,0.4889,0.651252151,0.067564428,0.281183422
"Local and systemic reactions have been reported following the third Pfizer vaccine dose.
In older adults, events were similar to those observed after previous vaccination and were mostly self-resolving. fatigue,
Myalgia and fever were the most frequently reported systemic side effects (19.6%, 9.2%, 8.1%).
each).",1061,Translated,TRUE,47.79,13,10.3,14.49,14.2,13.15,16,10.5,12.22,10th and 11th grade,313,45,6.044444444,7,0.0211,0.5663,0.4126,0.653480947,0.070065774,0.276453316
"Local and systemic reactions after the third Pfizer vaccine, reported by immunocompromised and
In older people, they were similar to those observed after previous vaccinations and most were self-resolving. exhaustion,
Myalgia and fever were the most common systemic side effects (19.6%, 9.2%, and 8.1%).
respectively).",1061,Translated,TRUE,39.33,13,11.5,15.13,14.8,12.8,18,10.5,14,12th and 13th grade,318,45,6.155555556,7,0.0302,0.634,0.3358,0.650196493,0.072135307,0.277668178
"Local and systemic reactions after a third Pfizer vaccination, reported by immunocompromised individuals and
elderly individuals, were similar to those seen after previous vaccinations and mostly resolved on their own. Fatigue,
myalgia, and fever were the most common systemic side effects reported (19.6%, 9.2%, and 8.1%
respectively).",1061,Translated,TRUE,21.7,14.6,14.1,16.24,15.5,12.48,18,11.833333333333334,14.79,14th and 15th grade,336,47,6.234042553,7,0.019,0.4664,0.5146,0.643719018,0.061603773,0.294677258
"Local and systemic reactions after the third Pfizer vaccine reported in immunocompromised individuals and
in the elderly, were similar to those observed after previous vaccines and were mostly self-limited. fatigue,
myalgia and fever were the most common systemic adverse events (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,39.33,13,11.5,15.25,14.4,13.5,19,10.5,14,13th and 14th grade,315,45,6.088888889,7,0.0197,0.461,0.5193,0.656874955,0.069118463,0.274006546
"Local and systemic reactions after the third Pfizer vaccine, reported by immunocompromised a
In the elderly, they were similar to those seen after previous vaccinations, and most resolved on their own. exhaustion,
Myalgia and fever were the most common systemic adverse events (19.6%, 9.2% and 8.1%, respectively).
respectively).",1061,Translated,TRUE,38.32,13.6,11.9,14.32,14.3,12.33,17,11.333333333333334,13.9,13th and 14th grade,329,48,5.9375,7,0.0433,0.6974,0.2593,0.641201496,0.070381179,0.288417339
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised and
seniors, were similar to those observed after previous vaccines and usually self-resolved. Fatigue,
myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%
respective).",1061,Translated,TRUE,31.89,14.1,12.3,16.35,15.1,13.73,19,10.666666666666666,13.22,13th and 14th grade,304,42,6.333333333,7,0.0234,0.5229,0.4537,0.643405497,0.063888095,0.29270637
"Local and systemic reactions after the third Pfizer vaccine, reported by immunocompromised a
elderly, were similar to those seen after previous vaccines and mostly resolved on their own. Fatigue,
myalgia and fever were the most commonly reported systemic adverse events (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,39.33,13,11.5,14.09,13.5,12.8,17,10.5,13.11,12th and 13th grade,306,45,5.888888889,7,0.0201,0.4196,0.5603,0.644241989,0.06405925,0.291698784
"Local and systemic reactions following a third Pfizer vaccination reported by immunocompromised individuals and the elderly were similar to those following previous vaccinations and mostly resolved on their own. Fatigue, myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%, respectively).",1061,Translated,TRUE,22.11,15.9,14,17.04,15.9,12.63,18,12.666666666666666,15.69,15th and 16th grade,335,46,6.304347826,7,0.0259,0.4982,0.4759,0.63838917,0.058923628,0.302687168
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised people and
in older people, were similar to those seen following previous vaccines and mostly resolved on their own. Fatigue,
myalgia and fever were the most commonly reported systemic side effects (19.6%, 9.2%, and 8.1%
respectively).",1061,Translated,TRUE,38.32,13,11.9,14.09,13.7,12,17,11,12.23,11th and 12th grade,324,48,5.833333333,7,0.0185,0.4167,0.5649,0.640704334,0.064214215,0.295081466
"Local and systemic reactions after the third Pfizer vaccine, reported by immunocompromised a
older, were similar to those seen after previous vaccines and mostly disappeared. Fatigue,
myalgia and fever were the most commonly reported systemic adverse events (19.6%, 9.2% and 8.1%
respectively).",1061,Translated,TRUE,40.35,13,11.1,15.13,13.9,13.35,17,9,13.22,12th and 13th grade,294,42,6.095238095,7,0.0216,0.3936,0.5848,0.642226636,0.06513276,0.292640597
"Local and systemic reactions after the third Pfizer vaccine reported in immunocompromised individuals and
in the elderly were similar to those observed after previous vaccinations and were mostly self-limited. Fatigue,
myalgia and fever were the most common systemic adverse events (19.6%, 9.2% and 8.1%,
respectively).",1061,Translated,TRUE,30.87,13.6,12.7,15.77,14.8,13.5,19,10.833333333333334,14.89,13th and 14th grade,319,45,6.177777778,7,0.0191,0.4562,0.5248,0.648978293,0.068926394,0.282095224
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised and
seniors, were similar to those observed after previous vaccines and mostly self-resolved. Fatigue,
myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%
respective).",1061,Translated,TRUE,31.89,13.6,12.3,16.23,15,13.35,18,10.333333333333334,12.27,11th and 12th grade,303,42,6.30952381,7,0.022,0.4955,0.4825,0.648097336,0.064197384,0.287705183
"Local and systemic reactions after a third Pfizer vaccine, reported by immunocompromised people and
in older people, were similar to those seen after previous vaccines and usually resolved on their own. Fatigue,
myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2%, and 8.1%
respective).",1061,Translated,TRUE,38.32,13.6,11.9,14.09,13.7,12.33,18,11.333333333333334,13.07,13th and 14th grade,324,48,5.833333333,7,0.0254,0.5012,0.4734,0.622768462,0.059293889,0.317937613
"Local and systemic reactions following a third Pfizer vaccination reported by immunocompromised and elderly people were similar to those following previous vaccinations and generally resolved on their own. Fatigue, myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%, respectively).",1061,Translated,TRUE,22.41,15.9,13.9,17.16,15.9,12.8,18,12.5,15.78,15th and 16th grade,329,45,6.333333333,7,0.0288,0.4956,0.4757,0.634604752,0.062589429,0.302805781
"Local and systemic reactions after the third Pfizer vaccine reported in immunocompromised and
in the elderly, were similar to those observed after previous vaccines and mostly resolved on their own. Tiredness,
myalgia and fever were the most common systemic adverse reactions (19.6%, 9.2% and 8.1%).
respectively).",1061,Translated,TRUE,47.49,12.5,10.4,14.14,13.8,12.63,18,10.333333333333334,12.21,12th and 13th grade,314,46,5.913043478,7,0.0312,0.5651,0.4036,0.654541552,0.073437035,0.272021413
"Local and systemic reactions after a third Pfizer vaccine reported in immunocompromised a
in the elderly, were similar to those seen with previous vaccines and were mostly self-limiting. Tiredness,
myalgia and fever were the most commonly reported systemic adverse reactions (19.6%, 9.2% and 8.1%)
respectively).",1061,Translated,TRUE,39.33,14.1,11.5,14.72,14.1,12.45,17,11.166666666666666,14,11th and 12th grade,312,45,6.022222222,7,0.0174,0.3827,0.5999,0.66138953,0.066936448,0.271673977
"Grouping samples into pools of five for PCR testing led to increased testing for the coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,17.68,0,17.8,15.32,19,12.36,11,19,18.34,18th and 19th grade,184,28,5.642857143,0,0.1696,0.7948,0.0356,0.645964146,0.049526889,0.304508954
"Grouping samples into groups of five for PCR testing has led to an increase in testing for coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,24.11,0,17.4,14.23,18.9,11.97,11,20,18.67,18th and 19th grade,190,30,5.4,0,0.1157,0.8145,0.0698,0.630380988,0.055012442,0.314606518
"Grouping samples into groups of five for PCR testing has led to an increase in testing for the coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,23.09,0,17.7,13.82,19,11.8,11,20.5,18.85,18th and 19th grade,194,31,5.322580645,0,0.1475,0.802,0.0505,0.644136786,0.053656965,0.302206248
"Grouping samples into groups of five for PCR testing led to increased testing for the coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,17.68,0,17.8,15.55,19.1,12.36,11,19,18.34,18th and 19th grade,185,28,5.678571429,0,0.1598,0.8015,0.0387,0.650973022,0.050830659,0.298196346
"Grouping samples for PCR testing into pools of five increased the number of coronavirus tests
with minimal loss of sensitivity compared to testing each sample separately.",1066,Translated,TRUE,28.17,0,15.8,15.15,17.9,12.82,10,17,16.55,16th and 17th grade,170,26,5.615384615,0,0.111,0.8293,0.0596,0.63805002,0.060480841,0.301469207
"Grouping samples into groups of five for PCR testing has led to an increase in coronavirus testing
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,16.66,0,18.1,14.69,18.7,12.15,11,19.5,18.5,18th and 19th grade,186,29,5.482758621,0,0.0567,0.7488,0.1946,0.624464691,0.059305787,0.316229552
"Pooling samples into groups of five for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss in sensitivity compared to testing each sample individually.",1066,Translated,TRUE,9.22,0,18.9,15.73,19.3,12.92,12,20,19.77,19th and 20th grade,186,28,5.714285714,0,0.0488,0.8055,0.1458,0.647547007,0.051440436,0.301012576
"Pooling samples into groups of five for PCR testing has led to an increase in coronavirus testing
Ability with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,25.12,0,17,14.28,18.4,12.15,11,19.5,18.5,18th and 19th grade,184,29,5.413793103,0,0.0591,0.8167,0.1242,0.632123888,0.054761104,0.313114971
"Grouping samples into pools of five for PCR testing resulted in an increase in coronavirus testing
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,9.22,0,18.9,15.73,19.3,12.92,12,20,19.77,19th and 20th grade,186,28,5.714285714,0,0.0518,0.766,0.1822,0.652280331,0.049795344,0.29792431
"By grouping samples for PCR testing into pools of five, the number of coronavirus tests could be increased
with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,25.12,0,17,14.28,18.6,12.15,10,18.5,17.12,18th and 19th grade,185,29,5.448275862,0,0.0946,0.8404,0.0651,0.637054563,0.056380555,0.306564838
"By grouping the samples into pools of five for PCR testing, the testing capacity for the coronavirus could be increased with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,23.09,0,17.7,14.34,19.6,11.8,11,20.5,18.85,17th and 18th grade,198,31,5.419354839,0,0.1632,0.8031,0.0337,0.654058754,0.053311188,0.292629987
"Grouping samples into groups of five for PCR testing increased testing for the coronavirus
with minimal loss of sensitivity compared to testing each sample separately.",1066,Translated,TRUE,29.18,0,15.4,15.96,18,12.46,10,16.5,16.4,15th and 16th grade,167,25,5.76,0,0.1143,0.8254,0.0603,0.647354186,0.0571681,0.295477688
"Pooling samples into groups of five for PCR testing has led to an increase in coronavirus testing
A possibility with minimal loss of sensitivity compared to testing each sample separately.",1066,Translated,TRUE,24.11,0,17.4,13.88,18.5,11.97,11,20,18.67,18th and 19th grade,188,30,5.333333333,0,0.0386,0.7427,0.2186,0.64544642,0.05279135,0.301762253
"Grouping samples into five pools for PCR testing increased coronavirus testing.
There is minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,25.96,0,12.5,16.34,13,12.45,10,6.75,11.56,12th and 13th grade,162,23,6.130434783,0,0.1499,0.7752,0.0749,0.653535843,0.051925328,0.294538945
"Grouping of samples into groups of five for PCR testing led to increased testing for coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,17.68,0,17.8,15.32,19,12.36,11,19,18.34,18th and 19th grade,184,28,5.642857143,0,0.1198,0.8212,0.059,0.654079795,0.053118076,0.292802155
"Pooling samples into groups of five for PCR testing led to an increase in testing for the coronavirus
capacity with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,24.11,0,17.4,14.05,18.7,11.97,11,20,18.67,18th and 19th grade,189,30,5.366666667,0,0.1336,0.8319,0.0345,0.647035301,0.050883159,0.302081585
"By grouping samples into groups of five for PCR testing, the number of tests for coronavirus could be increased
with minimal loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,32.57,0,16.2,14.05,18.9,11.97,10,19,17.33,18th and 19th grade,190,30,5.4,0,0.0945,0.8359,0.0696,0.633274555,0.067294151,0.299431324
"Grouping samples into five pools for PCR testing increased coronavirus testing.
Minimizes loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,26.98,0,12.1,17.95,14.1,13.18,10,6.25,11.82,11th and 12th grade,155,21,6.476190476,0,0.0195,0.4744,0.5061,0.655824661,0.05247201,0.291703343
"Grouping samples into five groups for PCR testing increased coronavirus testing.
Minimizes loss of sensitivity compared to testing each sample individually.",1066,Translated,TRUE,26.98,0,12.1,18.24,14.3,13.18,10,6.25,11.82,11th and 12th grade,156,21,6.523809524,0,0.0173,0.4312,0.5514,0.642035544,0.063704185,0.294260234
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs 10.5%). Pre-existing comorbidities associated with severe disease were diabetes,
hypertension, renal disease, and cardiovascular disease.",1081,Translated,TRUE,34.63,11.9,11.2,15.81,13.9,15.34,13,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0131,0.2766,0.7103,0.659300625,0.178318232,0.162381157
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs. 10.5%). Previous comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,28.84,0,13.5,16.35,16.3,15.16,13,12,15.04,15th and 16th grade,244,34,6.264705882,8,0.0135,0.2903,0.6962,0.649707079,0.18577005,0.164522812
"Female COVID-19 patients had a higher risk of developing severe dengue compared to male patients in the main analysis
(16.2% vs. 10.5%). Previous comorbidities associated with severe disease were diabetes,
High blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,35.27,0,13.1,16.3,16.8,14.97,15,13,14.97,14th and 15th grade,269,38,6.157894737,8,0.0139,0.3176,0.6684,0.665140688,0.172319368,0.162539899
"Female covid-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% versus 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
high blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,42.38,11.2,10.3,15.82,13.6,14.32,14,7,11.47,10th and 11th grade,257,36,6.222222222,8,0.0125,0.2463,0.7412,0.652131259,0.183444276,0.164424539
"Female COVID-19 patients had a higher risk of severe dengue fever than male patients in the main analysis
(16.2% versus 10.5%). Pre-existing comorbidities associated with severe disease included diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,25.76,12.5,12.6,17.15,15,15.5,15,7.5,13.82,12th and 13th grade,261,35,6.542857143,8,0.0148,0.3083,0.6769,0.682424605,0.154680222,0.162895173
"Patients with COVID-19 had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs. 10.5%). Prior comorbidities associated with severe disease were diabetes,
hypertension, diseases of the kidneys and cardiovascular system.",1081,Translated,TRUE,36.28,0,12.7,14.67,15.3,15.06,14,12,13.87,14th and 15th grade,247,36,5.944444444,8,0.012,0.2632,0.7248,0.674243331,0.154380843,0.171375826
"Patients with COVID-19 had a higher risk of severe dengue than male patients in the main analysis
(16.2% vs. 10.5%). Comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,37.81,0,12.1,15.66,15.5,14.5,11,11.25,13.87,15th and 16th grade,233,33,6.151515152,8,0.0114,0.2273,0.7613,0.668921947,0.165500566,0.165577531
"In the main analysis, women with covid-19 had a higher risk of severe dengue fever than men
(16.2% versus 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
high blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,42.38,11.2,10.3,14.37,12.5,13.44,12,7,11.47,10th and 11th grade,249,36,6,8,0.015,0.2846,0.7004,0.668118775,0.16414088,0.167740375
"Female patients with COVID-19 had a higher risk of severe dengue than males in the main analysis
(16.2% vs 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,34.63,11.9,11.2,15.47,13.3,15.34,13,7,12.76,11th and 12th grade,243,34,6.235294118,8,0.0136,0.2796,0.7067,0.660267115,0.176696584,0.163036257
"Female COVID-19 patients had a higher risk of developing severe dengue compared to male patients in the main analysis
(16.2% vs. 10.5%). The pre-existing comorbidities associated with severe disease were diabetes,
High blood pressure, kidney disease, and cardiovascular disease.",1081,Translated,TRUE,34.76,0,13.3,16.3,17.3,15.13,15,13.25,14.98,14th and 15th grade,278,39,6.205128205,8,0.0137,0.3062,0.6801,0.675432384,0.160445437,0.164122239
"In the main analysis, female COVID-19 patients had a higher risk of developing severe dengue than male patients
(16.2% vs. 10.5%). Pre-existing comorbidities associated with severe illness were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,19.87,0,14.8,17.57,17.7,16.23,15,12.75,16.14,17th and 18th grade,260,35,6.514285714,8,0.0178,0.3725,0.6096,0.66412282,0.171749964,0.16412726
"Female patients with COVID-19 had a higher risk of developing severe dengue compared to male patients in the main analysis
(16.2% vs. 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
High blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,34.76,0,13.3,16.48,17.2,14.73,15,13.25,14.98,14th and 15th grade,277,39,6.179487179,8,0.013,0.2812,0.7057,0.677398741,0.158251241,0.164350018
"In the main analysis, female COVID-19 patients had a higher risk of developing severe dengue than male patients.
(16.2% versus 10.5%). Pre-existing comorbidities associated with serious illness were diabetes,
High blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,33.61,12.5,11.6,16.63,14.8,15.77,17,7.833333333333334,13.57,11th and 12th grade,272,37,6.432432432,8,0.0202,0.3847,0.595,0.653084934,0.182357132,0.164558008
"In the main analysis, women with covid-19 had a higher risk of severe dengue than men
(16.2% vs. 10.5%). Preexisting comorbidities associated with severe disease were diabetes,
high blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,36.79,0,12.5,14.38,15.1,13.98,11,11.75,13.86,13th and 14th grade,240,35,5.942857143,8,0.0143,0.2878,0.6979,0.648586154,0.187418357,0.163995415
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% versus 10.5%). Existing comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,34.63,11.9,11.2,16.16,13.9,14.88,14,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0129,0.2637,0.7233,0.652314126,0.182721794,0.164964139
"In the main analysis, female COVID-19 patients had a higher risk of severe dengue fever than male patients.
(16.2% vs. 10.5%). Existing complications associated with severe disease include diabetes,
These were high blood pressure, kidney disease, and cardiovascular disease.",1081,Translated,TRUE,43.22,0,12.1,15.61,16.8,14.32,14,12.75,13.95,12th and 13th grade,274,39,6.102564103,8,0.0205,0.3881,0.5914,0.685313582,0.129187182,0.185499251
"Female covid-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% versus 10.5%). Existing comorbidities associated with severe disease were diabetes,
high blood pressure, kidney disease and cardiovascular disease.",1081,Translated,TRUE,42.38,11.2,10.3,15.36,13.2,14.32,14,7,11.47,10th and 11th grade,254,36,6.138888889,8,0.0122,0.2507,0.737,0.646442235,0.189488649,0.164069161
"Female COVID-19 patients had a higher risk of severe dengue than male patients in the main analysis
(16.2% versus 10.5%). Previous comorbidities associated with severe disease were diabetes,
hypertension, kidney disease and cardiovascular disease.",1081,Translated,TRUE,34.63,11.9,11.2,16.16,13.9,14.88,14,7,12.76,11th and 12th grade,247,34,6.352941176,8,0.0134,0.2828,0.7038,0.653143823,0.183020577,0.163835675
"Female patients with COVID-19 were at higher risk of severe dengue than male patients in the main analysis
(16.2% vs. 10.5%). Previous comorbidities associated with severe illness were diabetes,
hypertension, kidney diseases and cardiovascular diseases.",1081,Translated,TRUE,28.33,0,13.7,16.7,16.8,15.33,14,12.25,15,16th and 17th grade,253,35,6.314285714,8,0.0127,0.2888,0.6985,0.645048976,0.189722598,0.165228337
"We estimate that out of 100,000 airline passengers, without testing or screening, there would be 649 actively infectious passengers. A PCR test before travel would reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Translated,TRUE,54.22,13,9.9,11.19,11,10.05,11,11.5,10.72,10th and 11th grade,309,51,5.078431373,15,0.0154,0.5933,0.3912,0.62902987,0.051911253,0.319058865
"We estimate that there would be among 100,000 air travelers, without testing or screening
649 actively contagious passengers. A PCR test before travel would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number
infected passengers to 560.",1082,Translated,TRUE,54.93,13,9.6,11.54,10.9,10.25,11,11.166666666666666,11.42,10th and 11th grade,299,49,5.183673469,15,0.0151,0.5989,0.386,0.633793592,0.047582898,0.318623543
"We estimate that among 100,000 airline travelers, without testing or controls, there would be
649 actively infectious passengers. A PCR test prior to travel would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.22,13,9.9,11.08,10.9,10.67,13,11.5,11.51,10th and 11th grade,308,51,5.117647059,15,0.0207,0.7085,0.2708,0.634081721,0.04851516,0.317403108
"We estimate that there would be 100,000 air travelers without testing or screening
649 actively infected passengers. A pre-travel PCR test would reduce the number of infected people
569 passengers. A rapid antigen test on the day of travel would reduce the number
infected passengers to 560.",1082,Translated,TRUE,55.54,13.6,9.4,12.06,10.9,10.46,10,11.166666666666666,10.54,10th and 11th grade,291,47,5.276595745,15,0.0141,0.5438,0.4421,0.627308249,0.048935603,0.323756129
"We estimate that among 100,000 air travelers without testing or screening, there would be 649 actively infectious passengers. A PCR test before travel would reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Translated,TRUE,54.52,13,9.8,11.19,10.7,10.15,11,11.333333333333334,11.48,10th and 11th grade,302,50,5.06,15,0.0149,0.6296,0.3555,0.612663746,0.056498501,0.330837786
"We estimate that of the 100,000 air passengers who are not screened or tested, 649 will be actively infected. Conducting a polymerase chain reaction test before traveling would reduce the number of infected travelers to 569. Conducting a rapid antigen test on the day of travel would reduce the number of infected travelers to 560.",1082,Translated,TRUE,52.9,14.6,10.4,11.43,11.5,10.29,13,13.166666666666666,13.14,9th and 10th grade,331,55,5.036363636,15,0.0112,0.4102,0.5786,0.622536063,0.051027846,0.326436102
"We estimate that out of 100,000 airline passengers, without testing or controls, there will be
649 passengers are actively infectious. A PCR test before traveling would reduce the number of infected people
Passengers to 569. Rapid antigen testing on the day of travel would reduce the number of passengers
Infected passengers to 560.",1082,Translated,TRUE,45.05,14.1,11.4,12.53,12.4,10.17,12,12.5,11.61,12th and 13th grade,333,53,5.358490566,15,0.0167,0.5908,0.3925,0.638755441,0.046862867,0.314381689
"We estimate that there would be among 100,000 air travelers without testing or screening
649 actively contagious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.93,13.6,9.6,11.42,10.8,10.57,11,11.5,11.42,10th and 11th grade,298,49,5.163265306,15,0.0161,0.6127,0.3712,0.620732546,0.051580299,0.327687263
"We estimate that among 100,000 airline travelers, with or without screening, there would be
649 actively infected passengers. A PCR test before travel would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers in 560.",1082,Translated,TRUE,54.52,13,9.8,11.08,10.7,9.83,10,11.333333333333334,10.68,10th and 11th grade,302,50,5.12,15,0.0191,0.7296,0.2514,0.631054342,0.05195361,0.316991955
"We estimate that there are 100,000 air travelers who have not been tested or screened.
There are 649 highly contagious passengers. Pre-travel PCR testing can help reduce the number of infections.
There are 569 passengers. Implementing rapid antigen testing on the day of travel could reduce passenger numbers.
560 passengers infected.",1082,Translated,TRUE,62.85,10.9,6.6,12.03,9.1,11.18,14,5.083333333333333,8.89,8th and 9th grade,334,51,5.62745098,15,0.0103,0.247,0.7427,0.623927653,0.045829918,0.330242425
"We estimate that among 100,000 air travelers, without testing or monitoring, there would be
649 actively infectious passengers. A PCR test before travel would reduce the number of infected people
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
passengers infected at 560.",1082,Translated,TRUE,54.22,13.6,9.9,11.42,11.2,10.05,11,11.833333333333334,12.29,11th and 12th grade,311,51,5.176470588,15,0.0187,0.667,0.3143,0.619539678,0.052321315,0.328139067
"We estimate that there would be among 100,000 air travelers without testing or control
649 actively contagious passengers. A PCR test before travel would reduce the number of infected people
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.22,13,9.9,11.08,10.7,10.05,11,11.5,11.51,11th and 12th grade,306,51,5.078431373,15,0.0147,0.5541,0.4313,0.630582273,0.049505521,0.319912225
"We estimate that among 100,000 air travelers who are not tested or screened, there will be:
649 highly contagious passengers. Pre-travel PCR testing can help reduce the number of infections.
There are 569 passengers. Implementing rapid antigen testing on the day of travel could reduce passenger numbers.
560 passengers infected.",1082,Translated,TRUE,52.87,11.6,8.4,12.68,9.9,11.4,14,6.2,9.6,9th and 10th grade,329,50,5.66,15,0.0162,0.3915,0.5923,0.629976571,0.047871333,0.322152108
"We estimate there will be 100,000 air passengers without testing or screening
649 passengers are actively infected. A PCR test before traveling would reduce the number of infected people
569 passengers. Rapid antigen testing on the day of travel would reduce the number
Infected passengers to 560.",1082,Translated,TRUE,47.08,13.6,10.6,12.93,11.6,10.13,10,11.166666666666666,10.54,10th and 11th grade,297,47,5.404255319,15,0.0134,0.4403,0.5462,0.627497852,0.049458608,0.323043555
"We estimate that for every 100,000 air travelers who are not screened or screened, there are 649 actively infected passengers. Implementing pre-travel PCR testing could reduce the number of infected passengers to 569. Implementing rapid antigen testing on the day of travel could reduce the number of infected passengers to 560.",1082,Translated,TRUE,45.76,14.6,11.1,13.34,12.7,10.36,10,12.5,11.51,12th and 13th grade,328,51,5.450980392,15,0.018,0.5698,0.4122,0.615012944,0.05823807,0.326749027
"We estimate that among 100,000 airline travelers, without testing or screening, there would be
649 actively infectious passengers. A pre-travel PCR test would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.93,13.6,9.6,11.89,11.3,10.89,12,11.5,11.42,11th and 12th grade,304,49,5.285714286,15,0.0201,0.7151,0.2648,0.616575181,0.054938301,0.328486413
"We estimate that among 100,000 air travelers without testing or monitoring, there would be 649 actively infectious passengers. A PCR test before travel would reduce the number of infected passengers to 569. A rapid antigen test on the day of travel would reduce the number of infected passengers to 560.",1082,Translated,TRUE,54.52,13.6,9.8,11.31,10.8,10.15,11,11.666666666666666,12.28,9th and 10th grade,303,50,5.08,15,0.0144,0.5923,0.3933,0.613518953,0.052736796,0.333744258
"We estimate that among 100,000 air travelers, without testing or screening, there would be
649 actively infectious passengers. A PCR test before travel would reduce the number of infected
passengers to 569. A rapid antigen test on the day of travel would reduce the number of
infected passengers to 560.",1082,Translated,TRUE,54.52,13,9.8,11.19,10.8,10.15,11,11.333333333333334,11.48,10th and 11th grade,303,50,5.14,15,0.0193,0.7206,0.2601,0.620181084,0.050801024,0.329017818
"We estimate that there would be 100,000 air travelers without testing or screening.
649 actively infected passengers. A pre-travel PCR test would reduce the number of infected
569 passengers. A rapid antigen test on the day of travel would reduce the number
infected passengers to 560.",1082,Translated,TRUE,59.8,12.2,7.8,11.06,8.9,10.39,10,7.25,8.95,8th and 9th grade,285,46,5.282608696,15,0.0125,0.4569,0.5306,0.624459684,0.048459943,0.327080429
"In the phase 1 trial, the potential vaccine formulation caused a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.68,14.6,11.89,11,13.75,13.95,13th and 14th grade,256,39,5.641025641,3,0.4277,0.5398,0.0326,0.641842961,0.067862928,0.290294021
"In a phase 1 trial, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In a phase 2 trial
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.39,14.4,11.89,12,13.75,13.95,13th and 14th grade,254,39,5.58974359,3,0.6498,0.3392,0.011,0.639054358,0.062002476,0.298943251
"In the phase 1 study, the potential vaccine formula caused a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formula showed better safety results.",1083,Translated,TRUE,43.22,0,12.1,13.52,13.8,11.89,11,13.75,13.95,13th and 14th grade,249,39,5.461538462,3,0.3228,0.6342,0.043,0.65504837,0.069628797,0.275322795
"In the phase 1 trial, the potential vaccine formulation caused a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.68,14.8,11.89,11,13.75,13.95,13th and 14th grade,257,39,5.666666667,3,0.3559,0.6095,0.0346,0.641662419,0.066213183,0.292124391
"In phase 1 trials, the potential vaccine formulation generated strong antibody responses.
It remained elevated in all participants for 3 months after the second vaccination. In phase 2 clinical trials,
Potential vaccine formulations have shown better safety outcomes.",1083,Translated,TRUE,24.74,14.1,13,16.17,13.4,12.58,14,9,15.61,12th and 13th grade,267,38,6.105263158,3,0.6568,0.3339,0.0093,0.651940346,0.065951072,0.282108516
"In the first phase of testing, the potential vaccine formula elicited a strong antibody response
remained elevated in all participants 3 months after the second vaccination. In phase 2 trials,
a potential vaccine formulation has shown better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.68,14.8,12.3,14,13.75,14.98,14th and 15th grade,257,39,5.666666667,2,0.6104,0.3799,0.0098,0.666684389,0.061810002,0.271505624
"In the phase 1 trial, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.97,15,11.89,12,13.75,13.95,13th and 14th grade,259,39,5.717948718,3,0.6367,0.3541,0.0091,0.647187114,0.064308092,0.288504869
"In the Phase 1 trial, the potential vaccine formulation elicited a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In the Phase 2 trial, the potential vaccine formulation showed better safety outcomes.",1083,Translated,TRUE,34.76,0,13.3,15.14,15.1,11.89,12,13.75,13.95,13th and 14th grade,260,39,5.692307692,3,0.7305,0.2624,0.0071,0.650911689,0.063603483,0.28548488
"In a phase 1 study, the potential vaccine elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In phase 2 of the trial,
potential vaccine formulation showed better safety results.",1083,Translated,TRUE,35.27,0,13.1,13.69,13.7,12.06,12,13,13.92,13th and 14th grade,244,38,5.5,3,0.677,0.3141,0.0089,0.641981959,0.060905177,0.297112852
"In the first phase of testing, the potential vaccine formula elicited a strong antibody response
remained elevated in all participants 3 months after the second vaccination. In phase 2 trials,
a potential vaccine formulation has demonstrated better safety outcomes.",1083,Translated,TRUE,26.3,0,14.4,15.9,15.7,12.3,15,14.25,16.01,15th and 16th grade,265,39,5.871794872,2,0.6326,0.3586,0.0087,0.668667734,0.059330828,0.272001475
"In the phase 1 trial, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the possible vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.85,14.9,11.89,12,13.75,13.95,13th and 14th grade,258,39,5.692307692,3,0.5791,0.4113,0.0096,0.643864989,0.063834526,0.292300463
"In a phase 1 trial, the potential vaccine formulation elicited a robust antibody response that remained high in all participants three months after the second vaccination. In phase 2 trials, potential vaccine formulations showed better safety outcomes.",1083,Translated,TRUE,35.78,0,12.9,15.95,15.3,12.66,14,12.75,13.89,12th and 13th grade,252,37,5.837837838,2,0.7193,0.273,0.0077,0.637039781,0.059471194,0.303489
"In phase 1 trials, the potential vaccine formulation generated strong antibody responses.
It remained elevated in all participants for 3 months after the second vaccination. In phase 2 clinical trials,
Potential vaccine formulations have shown better safety results.",1083,Translated,TRUE,24.74,14.1,13,15.99,13.3,12.58,14,9,15.61,12th and 13th grade,266,38,6.078947368,3,0.643,0.3471,0.0099,0.650381446,0.066164799,0.283453763
"In a phase 1 study, the potential vaccine formulation elicited a strong antibody response that remained elevated in all participants 3 months after the second vaccination. In a phase 2 study, the potential vaccine showed better safety results.",1083,Translated,TRUE,43.73,0,11.9,13.58,13.6,11.64,11,13,13.92,13th and 14th grade,243,38,5.421052632,3,0.7141,0.2776,0.0083,0.633431196,0.060336281,0.306232482
"In the Phase 1 trial, the candidate vaccine formulation elicited a strong antibody response that
remained high in all participants 3 months after the second vaccination. In the Phase 2 trial,
the candidate vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.39,14.5,11.49,11,13.25,12.93,12th and 13th grade,255,39,5.615384615,3,0.6424,0.3489,0.0087,0.636080801,0.061440744,0.302478433
"In a phase 1 trial, the potential vaccine combination caused a strong antibody response
It remained elevated in all participants 3 months after the second vaccination. In the second phase of the experiment,
The potential vaccine formulation showed better safety results.",1083,Translated,TRUE,25.29,0,14.8,14.68,15.2,11.97,13,14.75,16,14th and 15th grade,270,41,5.658536585,2,0.3702,0.6095,0.0202,0.617997229,0.052976001,0.329026788
"In the first phase of testing, the potential composition of the vaccine caused a strong antibody response
remained elevated in all participants 3 months after the second vaccination. In phase 2 trials,
the potential composition of the vaccine showed the best results in terms of safety.",1083,Translated,TRUE,39.67,0,13.4,12.89,14.8,11.3,12,15.5,14.42,12th and 13th grade,286,46,5.282608696,2,0.5674,0.421,0.0117,0.636589289,0.059638496,0.303772241
"In the Phase 1 trial, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In the phase 2 trial,
the possible vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.85,14.9,11.89,12,13.75,13.95,13th and 14th grade,258,39,5.692307692,3,0.5908,0.4001,0.0092,0.643864989,0.063834526,0.292300463
"In a phase 1 study, the potential vaccine formulation elicited a strong antibody response that
remained elevated in all participants 3 months after the second vaccination. In a phase 2 trial
the potential vaccine formulation showed better safety results.",1083,Translated,TRUE,34.76,0,13.3,14.39,14.4,11.89,12,13.75,13.95,13th and 14th grade,254,39,5.58974359,3,0.6565,0.3334,0.0101,0.638708711,0.061043601,0.300247729
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barracks style buildings. The corresponding doubling time for apartment-style buildings was
2.65 days.",1084,Translated,TRUE,70.5,7.8,5.7,12.61,10.1,12.56,7,4.333333333333333,6.58,12th and 13th grade,187,28,5.785714286,7,0.0271,0.6803,0.2926,0.641104937,0.062354457,0.296540618
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days
barrack style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,70.8,7.8,5.6,12.09,9.4,12.86,7,4.166666666666667,6.56,6th and 7th grade,177,27,5.666666667,7,0.0239,0.6121,0.364,0.638300598,0.055584002,0.306115419
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days
barracks style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,71.1,7.8,5.5,12.78,10.1,13.18,7,4,6.56,6th and 7th grade,175,26,5.846153846,7,0.0232,0.5904,0.3864,0.646383464,0.055197388,0.298419148
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
Barracks style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,70.5,7.8,5.7,11.63,9.1,12.56,7,4.333333333333333,6.58,6th and 7th grade,181,28,5.571428571,7,0.0256,0.6184,0.3559,0.636694074,0.061924979,0.301380903
"We found that the number of SARS-CoV-2 infections doubles every 1.56 days
Barracks style buildings. The corresponding doubling time for residential-style buildings was
2.65 days.",1084,Translated,TRUE,63.05,8.8,6.5,14.75,11.7,13.52,7,4.166666666666667,8.12,8th and 9th grade,178,25,6.24,7,0.02,0.6333,0.3466,0.64018476,0.053543128,0.306272119
"We found that the number of cases of SARS-CoV-2 infection doubles every 1.56 days
barrack style buildings. The corresponding doubling time for multi-apartment buildings was
2.65 days.",1084,Translated,TRUE,62.34,8.8,6.8,13.19,10.4,13.44,8,4.5,6.56,6th and 7th grade,183,27,5.888888889,7,0.0248,0.6883,0.2869,0.633182228,0.058303338,0.308514506
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days
barracks style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,70.8,7.8,5.6,12.32,9.6,12.86,7,4.166666666666667,6.56,6th and 7th grade,178,27,5.703703704,7,0.0224,0.5852,0.3924,0.638498425,0.05820214,0.303299367
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days.
Barracks style building. The corresponding doubling times for apartment-style buildings are:
2.65 days.",1084,Translated,TRUE,71.1,7.8,5.5,13.88,11.5,13.78,7,4,6.56,13th and 14th grade,183,26,6.153846154,7,0.0221,0.5411,0.4368,0.636064231,0.06755174,0.296383977
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days
Barrack style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,71.1,7.8,5.5,12.55,9.9,13.18,7,4,6.56,6th and 7th grade,174,26,5.807692308,7,0.0243,0.5901,0.3855,0.640338719,0.056527682,0.303133577
"We found that the number of SARS-CoV-2 cases doubles every 1.56 days.
Based on the barracks model. The corresponding doubling times for apartment-style buildings are:
2.65 days.",1084,Translated,TRUE,79.26,6.4,4.4,11.45,9.4,14.02,7,3.833333333333333,5.08,3rd and 4th grade,177,27,5.666666667,7,0.0256,0.8084,0.1661,0.644965053,0.05252783,0.302507102
"We found that the number of SARS-CoV-2 cases doubled every 1.56 days.
Barracks-style buildings. The corresponding doubling times for apartment-style buildings were:
2.65 days.",1084,Translated,TRUE,67.76,0,6.8,16.17,14.4,14.1,6,5.5,6.47,6th and 7th grade,175,24,6.416666667,7,0.0271,0.6845,0.2884,0.633942902,0.05534571,0.310711354
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days
barracks style buildings. The corresponding doubling time for condominiums was
2.65 days.",1084,Translated,TRUE,63.05,8.8,6.5,12.66,9.9,14.15,8,4.166666666666667,8.12,8th and 9th grade,168,25,5.84,7,0.0234,0.6191,0.3575,0.641472518,0.06207256,0.296454906
"We found that the number of SARS-CoV-2 infections doubles every 1.56 days
Barracks style buildings. The corresponding doubling time for residential buildings was
2.65 days.",1084,Translated,TRUE,63.05,8.8,6.5,13.59,10.6,13.52,7,4.166666666666667,8.12,8th and 9th grade,172,25,6,7,0.0186,0.5621,0.4193,0.644099236,0.051122651,0.304778099
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barrack-type buildings. The corresponding doubling time for residential buildings was
2.65 days.",1084,Translated,TRUE,62.34,9.7,6.8,12.73,10.1,13.44,8,4.833333333333333,8.04,9th and 10th grade,181,27,5.814814815,7,0.0261,0.7174,0.2565,0.639949739,0.05968339,0.300366849
"We found that the number of SARS-CoV-2 infections doubled every 1.56 days.
Barracks style building. The corresponding doubling times for residential buildings are:
2.65 days.",1084,Translated,TRUE,63.05,8.8,6.5,13.59,11,14.15,7,4.166666666666667,8.12,8th and 9th grade,174,25,6.08,7,0.0178,0.45,0.5322,0.639284015,0.060450494,0.300265491
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days.
Barracks style building. The corresponding doubling times for apartment buildings are:
2.65 days.",1084,Translated,TRUE,70.8,7.8,5.6,12.32,9.9,13.44,7,4.166666666666667,6.56,6th and 7th grade,180,27,5.777777778,7,0.0206,0.4805,0.4989,0.638051152,0.065801665,0.296147108
"We found that the number of cases of SARS-CoV-2 infection doubled every 1.56 days in
barracks style buildings. The corresponding doubling time for apartment style buildings was
2.65 days.",1084,Translated,TRUE,70.09,7.8,5.9,11.86,9.2,12.28,7,4.5,6.64,6th and 7th grade,187,29,5.551724138,7,0.0261,0.6542,0.3197,0.641039312,0.063702457,0.295258194
"We found that the number of SARS-CoV-2 infection cases in

shanty buildings doubled every 1.56 days. The corresponding doubling time for residential buildings was

2.65 days.",1084,Translated,TRUE,58.28,0,8.4,13.27,11.7,13.39,8,7,9.82,9th and 10th grade,174,26,5.807692308,7,0.0267,0.7479,0.2254,0.626801908,0.07331758,0.299880475
"We found that the number of SARS-CoV-2 infection cases doubled every 1.56 days
barrack style buildings. The corresponding doubling time for apartment buildings was
2.65 days.",1084,Translated,TRUE,71.1,7.8,5.5,12.55,9.9,13.18,7,4,6.56,6th and 7th grade,174,26,5.807692308,7,0.0245,0.6093,0.3662,0.640338719,0.056527682,0.303133577
"Without the initial lockdown, vaccinations and increased physical distancing, we estimated the number at 148.
Over 10 years, there will be one million cases of COVID-19 and 3.1 million deaths in the UK. best case
In this scenario, vaccination would minimize community transmission without increasing future body infections.
Keep your distance.",1095,Translated,TRUE,52.66,11.2,8.4,13.43,10.8,12.19,17,6.1,11.92,11th and 12th grade,343,51,5.803921569,9,0.031,0.5223,0.4467,0.623958051,0.048299428,0.327742517
"Without the initial lockdown, vaccinations and increased physical distancing, we estimated 148
There would be one million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. At the best case
Vaccination minimizes transmission in the community without future periods of increased physical stress
distancing.",1095,Translated,TRUE,38.32,14.1,11.9,14.67,13.4,12.33,14,11.666666666666666,13.9,11th and 12th grade,320,48,5.75,9,0.0251,0.4406,0.5343,0.643114626,0.048001219,0.308884174
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. At best
scenario, vaccination minimizes transmission in the community without subsequent periods of increased physical
distancing.",1095,Translated,TRUE,31.89,14.6,12.3,16.64,14.4,12.98,14,11,14.17,14th and 15th grade,298,42,6.19047619,9,0.0301,0.561,0.4088,0.648006141,0.048138767,0.303855091
"Without the initial lockdown, vaccination, and increased physical distancing, we estimated 148
One million coronavirus cases and 3.1 million deaths will occur in the UK over 10 years. At best
In the scenario, vaccination reduces community transmission without future periods of increased physical infection
Spacing.",1095,Translated,TRUE,30.87,14.1,12.7,16.17,14.4,13.15,18,11.166666666666666,14,13th and 14th grade,315,45,6.088888889,7,0.0203,0.4513,0.5284,0.641955733,0.043525167,0.314519167
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
million COVID-19 cases and 3.1 million deaths would occur in the UK over 10 years. At best
scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,Translated,TRUE,32.19,14.1,12.2,17.33,14.8,13.56,15,10.5,13.28,13th and 14th grade,296,41,6.317073171,9,0.0239,0.4984,0.4777,0.650086999,0.048074014,0.301838964
"Without the initial confinement, vaccination and increased physical distancing, we estimate 148
million COVID-19 cases and 3.1 million deaths would occur in the UK within 10 years. In the best case
In this scenario, vaccination minimizes community transmission without future periods of increased physical activity.
distancing.",1095,Translated,TRUE,30.57,15,12.8,16.7,15.1,13.32,17,12,14.82,14th and 15th grade,327,46,6.195652174,9,0.0296,0.5121,0.4582,0.650730133,0.045210239,0.304059654
"Without the initial lockdown, vaccination and increased physical distancing, we calculated 148
million cases of COVID-19 and 3.1 million deaths would occur in the UK over 10 years. In the best case
scenario, vaccination minimizes transmission in the community without future periods of increased fitness
distancing.",1095,Translated,TRUE,39.03,13.6,11.6,15.3,13.9,12.98,16,11,13.08,13th and 14th grade,315,46,5.934782609,9,0.0347,0.5859,0.3794,0.648070931,0.04606957,0.305859536
"Without the initial lockdown, vaccinations and increased physical distancing, an estimated 148
In the UK, there will be one million cases of coronavirus and 3.1 million deaths within ten years. In best case
According to the scenario, vaccination reduces community spread without increasing physical infection in the future
Spacing.",1095,Translated,TRUE,38.01,14.1,12,15.08,14,12.5,19,11.833333333333334,14.68,11th and 12th grade,331,49,5.836734694,5,0.0326,0.4631,0.5043,0.639195323,0.044274308,0.316530347
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
million COVID-19 cases and 3.1 million deaths would occur in the UK over 10 years. In the best case
In the scenario, vaccination minimizes community transmission without future periods of increased physical
distancing.",1095,Translated,TRUE,39.33,14.1,11.5,15.77,14.1,12.8,15,11.166666666666666,13.11,11th and 12th grade,312,45,6.022222222,9,0.0317,0.5508,0.4176,0.647466838,0.045405883,0.307127267
"Without the initial lockdown, vaccination and increased physical distancing, we estimated that there were 148 million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. At best, vaccination minimises community transmission without subsequent periods of increased physical distancing.",1095,Translated,TRUE,31.89,14.6,12.3,16.64,14.4,12.6,13,11,14.17,14th and 15th grade,298,42,6.119047619,9,0.0314,0.5515,0.4171,0.650750458,0.044162948,0.305086613
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
One million coronavirus cases and 3.1 million deaths are expected in the UK over 10 years. perfect
In the scenario, vaccination reduces community transmission without future periods of increased physical infection
Spacing.",1095,Translated,TRUE,22.71,14.6,13.7,17.33,15.1,13.7,19,11.333333333333334,14.97,14th and 15th grade,316,44,6.272727273,7,0.0257,0.5626,0.4117,0.642854452,0.044437859,0.312707722
"Without the initial lockdown, vaccination and increased physical distancing, we counted 148
There are expected to be 1 million Covid-19 cases and 3.1 million deaths in the UK over 10 years. At best
scenario, that vaccination reduces community transmission without future periods of increased fitness
Spacing.",1095,Translated,TRUE,47.49,12.5,10.4,14.43,13.2,13.32,17,10.333333333333334,12.21,12th and 13th grade,308,46,5.782608696,10,0.0249,0.4682,0.5069,0.641721785,0.045846403,0.312431753
"Without the initial lockdown, vaccination and increased physical distancing, we estimate 148
million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. At best
In this scenario, vaccination minimises community transmission without subsequent periods of increased physical activity.
distancing.",1095,Translated,TRUE,31.58,15,12.4,16.93,14.9,13.16,15,11.5,15.02,14th and 15th grade,308,43,6.255813953,9,0.0352,0.5636,0.4012,0.649824739,0.048596814,0.301578403
"Without the initial lockdown, vaccination and increased physical distancing, we estimate there would have been 148 million cases of COVID-19 and 3.1 million deaths in the UK over a decade. At best, vaccination minimizes community spread without subsequent periods of increased physical distancing.",1095,Translated,TRUE,40.04,14.1,11.2,15.59,13.7,11.69,12,10.833333333333334,13.16,10th and 11th grade,297,43,5.930232558,7,0.0246,0.4287,0.5467,0.642455459,0.045557693,0.311986893
"Without the initial lockdown, vaccination and increased physical distancing, we estimated 148
million cases of COVID-19 and 3.1 million deaths would occur in the UK over 10 years. In the best case
In this scenario, vaccination minimizes community transmission without future periods of increased physical risks.
distancing.",1095,Translated,TRUE,38.62,14.1,11.8,15.6,14.1,12.81,15,11.5,13.09,11th and 12th grade,323,47,5.957446809,9,0.0387,0.5428,0.4184,0.650598407,0.045072939,0.304328591
"Without the initial lockdown, vaccination and increased physical distancing, the UK would see 148 million cases of COVID-19 and 3.1 million deaths within 10 years. In the best case scenario, vaccination minimises community transmission without requiring periods of increased physical distancing in the future.",1095,Translated,TRUE,39.63,14.1,11.4,16.29,14.4,12.98,15,11,13.15,10th and 11th grade,309,44,6.045454545,9,0.031,0.5072,0.4617,0.646836281,0.045900114,0.307263613
"Without the initial lockdown, vaccinations and increased physical distancing, we had an estimated 148
million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. In best case
in the scenario, vaccination minimizes community spread without subsequent increased physical periods
distancing.",1095,Translated,TRUE,39.63,14.1,11.4,15.36,13.6,12.62,14,11,14.06,13th and 14th grade,302,44,5.954545455,9,0.04,0.5793,0.3807,0.64591074,0.045302913,0.308786392
"Without the initial lockdown, vaccinations and increased physical distancing, an estimated 148
million cases of COVID-19 and 3.1 million deaths in the UK over 10 years. In best case
in the scenario, vaccination minimizes community spread without further increased physical periods
distancing.",1095,Translated,TRUE,40.35,13.6,11.1,15.83,13.7,12.6,13,10.333333333333334,13.22,13th and 14th grade,292,42,6.047619048,9,0.043,0.6019,0.3551,0.646387935,0.046014547,0.307597488
"Without the initial lockdown, vaccination and increased physical distancing, we would see an estimated 148 million COVID-19 cases and 3.1 million deaths in the UK within 10 years. In the best case scenario, vaccination minimises community transmission without any future periods of increased physical distancing.",1095,Translated,TRUE,39.33,14.1,11.5,15.77,14.1,12.8,15,11.166666666666666,13.11,11th and 12th grade,312,45,5.955555556,9,0.0312,0.5154,0.4534,0.650365353,0.044865537,0.304769129
"When controlling for age, disease severity, and comorbidities, there was no association with tocilizumab
Fewer deaths in this study.",1097,Translated,TRUE,43.73,0,11.9,16.3,16.3,11.23,7,13.5,16.02,11th and 12th grade,132,19,6.052631579,0,0.0425,0.6623,0.2952,0.717145681,0.09190236,0.190951958
"After adjusting for age, disease severity, and comorbidities, tocilizumab was not associated with fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,15.95,15.8,11.55,7,13,16.09,15th and 16th grade,125,18,6,0,0.0195,0.4667,0.5138,0.709840178,0.087923646,0.202236116
"When controlling for age, disease severity, and comorbidities, tacilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.111111111,0,0.0276,0.633,0.3394,0.718102753,0.089103431,0.192793772
"After controlling for age, disease severity and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.59,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.111111111,0,0.0252,0.647,0.3277,0.694048405,0.082939312,0.223012254
"When controlling for age, disease severity and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,15.8,11.55,7,13,16.09,12th and 13th grade,125,18,6.055555556,0,0.0265,0.6317,0.3418,0.714439213,0.086627699,0.198933095
"After controlling for age, disease severity, and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.59,16.3,11.55,7,13,16.09,12th and 13th grade,127,18,6.166666667,0,0.0244,0.6339,0.3416,0.696151912,0.085174188,0.218673944
"After adjusting for age, disease severity, and comorbidities, tocilizumab was not associated with reduced mortality in our study.",1097,Translated,TRUE,19.37,0,15,17.22,16.9,11.55,8,14,18.31,16th and 17th grade,129,18,6.222222222,0,0.0217,0.5248,0.4535,0.747834444,0.087390684,0.164774805
"When controlling for age, disease severity, and comorbidities, tocilizumab was not associated with:
There were fewer deaths in this study.",1097,Translated,TRUE,42.72,0,12.3,15.78,16.6,10.94,7,14,16,15th and 16th grade,138,20,6,0,0.0512,0.6218,0.327,0.691839993,0.088632181,0.219527856
"When controlling for age, disease severity, and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.111111111,0,0.0257,0.6155,0.3588,0.714749396,0.090416998,0.194833592
"After adjustment for age, disease severity, and comorbidities, tocilizumab was not associated with fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.055555556,0,0.0229,0.5052,0.4718,0.697858155,0.086466961,0.215674832
"When controlled for age, disease severity, and comorbidities, tacilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,44.75,0,11.5,15.95,15.8,11.55,7,12,13.87,11th and 12th grade,125,18,6.055555556,0,0.0335,0.6861,0.2803,0.690719426,0.077604622,0.231675893
"After adjusting for age, disease severity, and comorbidities, there was no association with tocilizumab.
Fewer deaths in this study.",1097,Translated,TRUE,44.91,0,9.4,14.24,11.6,10.76,7,5.75,12.22,10th and 11th grade,132,19,6.052631579,0,0.053,0.7202,0.2268,0.712709904,0.090946294,0.196343735
"After controlling for age, disease severity, and comorbidities, tocilizumab was not associated with disease
Fewer deaths in this study.",1097,Translated,TRUE,35.27,0,13.1,17.23,17.1,11.23,7,13.5,16.02,13th and 14th grade,135,19,6.210526316,0,0.0933,0.7279,0.1788,0.715030372,0.088075802,0.196893826
"After adjustment for age, disease severity, and comorbidities, tacilizumab was not associated with fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.24,16.1,11.55,7,13,16.09,12th and 13th grade,126,18,6.055555556,0,0.0225,0.4984,0.4791,0.700377285,0.085100099,0.21452263
"Controlling for age, disease severity, and comorbidities, tocilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,37.3,0,12.3,16.88,16.2,11.91,7,12.5,16.21,11th and 12th grade,121,17,6.235294118,0,0.0239,0.6341,0.342,0.697915435,0.087893404,0.214191183
"When controlling for age, disease severity, and comorbidities, tocilizumab was not associated
fewer deaths in this study.",1097,Translated,TRUE,37.3,0,12.3,16.88,16.2,11.91,7,12.5,16.21,11th and 12th grade,121,17,6.235294118,0,0.0216,0.5082,0.4703,0.71269381,0.092889257,0.194416881
"After controlling for age, disease severity, and comorbidities, tacilizumab was not associated with
fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.59,16.3,11.55,7,13,16.09,12th and 13th grade,127,18,6.166666667,0,0.0258,0.646,0.3282,0.699026108,0.083705425,0.217268527
"After controlling for age, disease severity, and comorbidities, tocilizumab was not associated with fewer deaths in this study.",1097,Translated,TRUE,36.28,0,12.7,16.59,16.3,11.55,7,13,16.09,12th and 13th grade,127,18,6.111111111,0,0.0196,0.4538,0.5266,0.696151912,0.085174188,0.218673944
"After adjustment for age, disease severity, and comorbidities, tocilizumab was not associated with a reduction in mortality in our study.",1097,Translated,TRUE,17.34,0,15.8,15.78,16.4,10.94,8,16,20,15th and 16th grade,137,20,5.9,0,0.0219,0.5137,0.4644,0.751641154,0.076314837,0.172043964
"In Hawaii, white Caucasians make up 25%, Asians, including Japanese, Chinese, and other Asians
30%, Hawaiians 20%, and Pacific Islanders, primarily from Micronesia and Samoa,
4%. We found that the COVID-19 rate in the latter group was up to 10 times higher than in all other
groups combined, and they accounted for nearly 30% of cases.",1099,Translated,TRUE,59.98,0,11.8,10.16,16.1,12.36,14,17,15.49,11th and 12th grade,335,56,5.053571429,13,0.038,0.7912,0.1708,0.608247459,0.091527306,0.300225198
"n Hawaii, whites are 25%, Asians including Japanese, Chinese and other Asians
make up 30%, Hawaiians 20% and Pacific Islanders mostly from Micronesia and Samoa
4%. We found that the incidence of COVID-19 in the second group was up to 10 times higher than in all others
groups together and accounted for almost 30% of cases.",1099,Translated,TRUE,59.98,0,11.8,9.52,15.1,12.36,12,17.5,15.49,11th and 12th grade,323,56,4.839285714,13,0.0537,0.8412,0.1051,0.601771474,0.077145174,0.321083277
"In Hawaii, whites are 25%, Asians include Japanese, Chinese and other Asians.
They represent 30%, Hawaiians 20% and Pacific Islanders mostly from Micronesia and Samoa.
4%. We found that the incidence of COVID-19 in the second group was up to 10 times higher than in everyone else.
They are grouped together and represented almost 30% of the cases.",1099,Translated,TRUE,65.22,11.2,7.8,9.62,9.4,11.16,12,8.25,9.94,9th and 10th grade,347,58,5.051724138,13,0.0554,0.8718,0.0729,0.622727275,0.066863075,0.310409665
"In Hawaii, white Caucasians are 25%, Asians including Japanese, Chinese, and other Asians
make up 30%, Hawaiians make up 20%, and Pacific Islanders, mostly from Micronesia and Samoa, make up
4%. We found that the rate of COVID-19 in the latter group was 10 times higher than in all others
groups together, and they accounted for almost 30% of cases.",1099,Translated,TRUE,57.95,0,12.6,9.7,16.3,11.7,13,18,15.33,9th and 10th grade,349,60,4.883333333,13,0.044,0.8205,0.1355,0.608347952,0.081987165,0.309664875
"In Hawaii, whites are 25%, Asians, including Japanese, Chinese, and other Asians
make up 30%, Hawaiians 20% and Pacific Islanders mainly from Micronesia and Samoa
4%. We found that the incidence of COVID-19 in the second group was up to 10 times higher than in all others
groups together and accounted for nearly 30% of cases.",1099,Translated,TRUE,59.98,0,11.8,9.64,15.4,12.36,13,17.5,15.49,11th and 12th grade,326,56,4.892857143,13,0.0485,0.8531,0.0984,0.610427678,0.078152828,0.311419487
"In Hawaii, white Caucasians make up 25%, Asians, including Japanese, Chinese and other Asians
represent 30%, Hawaiians 20% and Pacific Islanders mainly from Micronesia and Samoa make up
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than that in all others
groups together and accounted for nearly 30% of cases.",1099,Translated,TRUE,57.95,0,12.6,10.11,16.3,12.23,15,18.5,16,12th and 13th grade,349,60,4.883333333,13,0.0383,0.8152,0.1465,0.608453035,0.082292251,0.309254706
"In Hawaii, Caucasian people make up 25%, with Asians including Japanese, Chinese, and other Asians.
make up 30%, Hawaiians 20% and Pacific Islanders, mainly from Micronesia and Samoa.
4%. We found that the rate of COVID-19 in this latter group was up to 10 times higher than everyone else.
groups combined and they represented almost 30% of cases.",1099,Translated,TRUE,73.68,10.1,6.6,9.45,9.4,11.43,14,7.75,9.25,9th and 10th grade,347,58,5.051724138,13,0.0527,0.8278,0.1195,0.620330453,0.088390268,0.291279286
"In Hawaii, Caucasians make up 25%, Asians including Japanese, Chinese and other Asians
30%, Hawaiians 20% and Pacific Islanders, mainly from Micronesia and Samoa,
4%. We found that the rate of COVID-19 in the second group was up to 10 times higher than in all others
groups together and accounted for almost 30% of cases.",1099,Translated,TRUE,60.48,0,11.7,9.7,15.2,12.18,13,16.75,14.64,11th and 12th grade,321,55,4.909090909,13,0.0443,0.8111,0.1446,0.606509805,0.096130565,0.297359675
"In Hawaii, 25% are Caucasians, including Asians, including Japanese, Chinese, and other Asians.
30%, Hawaiian 20%, and Pacific Islanders, mostly from Micronesia and Samoa,
4%. We found that the Covid-19 infection rate in the second group was up to 10 times higher than in all other groups
The clusters together account for approximately 30% of cases.",1099,Translated,TRUE,60.95,12.5,9.4,11.43,12.7,11.61,13,12,11.77,11th and 12th grade,350,56,5.321428571,13,0.0407,0.8245,0.1348,0.616102338,0.066179588,0.317718059
"In Hawaii, white Caucasians are 25%, Asians including Japanese, Chinese, and other Asians
make up 30%, Hawaiians make up 20%, and Pacific Islanders mostly from Micronesia and Samoa make up
4%. We found that the rate of COVID-19 in the latter group was 10 times higher than in all others
groups together accounted for almost 30% of cases.",1099,Translated,TRUE,58.96,0,12.2,9.93,15.8,11.88,13,17.5,15.05,11th and 12th grade,337,58,4.879310345,13,0.0382,0.8342,0.1275,0.60501194,0.08880607,0.306182057
"In Hawaii, white Caucasians make up 25% of Asians, including Japanese, Chinese, and other Asians.
They represent 30%, Hawaiians 20%, and Pacific Islanders mainly from Micronesia and Samoa.
4%. We found that the Covid-19 infection rate in the latter group was up to 10 times higher than in all other groups
The clusters together account for approximately 30% of cases.",1099,Translated,TRUE,59.64,12.5,9.9,10.97,12.7,12,16,12.666666666666666,12.67,12th and 13th grade,367,60,5.183333333,13,0.0385,0.8169,0.1447,0.617693782,0.066281274,0.31602484
"n Hawaii, white Caucasians make up 25%, Asians including Japanese, Chinese and other Asians
accounts for 30%, Hawaiians for 20%, and Pacific Islanders, mainly from Micronesia and Samoa, are made up of
4%. We found that the covid-19 rate in the latter group was up to 10 times higher than in all others
the groups combined and they accounted for almost 30% of the cases.",1099,Translated,TRUE,55.41,0,13.6,9.18,16.9,12.29,16,18.75,16.08,16th and 17th grade,369,65,4.738461538,13,0.0434,0.8266,0.13,0.614422619,0.070369497,0.315207899
"In Hawaii, white Caucasians make up 25%, Asians include Japanese, Chinese, and other Asians.
represent 30%, Hawaiians 20% and Pacific Islanders, mostly from Micronesia and Samoa, comprise
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than in everyone else.
These groups combined and accounted for almost 30% of the cases.",1099,Translated,TRUE,73.17,10.1,6.8,9.56,9.7,11.49,15,8,9.33,9th and 10th grade,360,60,5.066666667,13,0.0408,0.827,0.1321,0.616903961,0.08412604,0.298969954
"n Hawaii, 25% white, including Asians such as Japanese and Chinese
They make up 30%, Hawaiians make up 20%, and Pacific Islanders are mostly from Micronesia and Samoa.
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than the rate of COVID-19 in the other groups.
Together, the groups accounted for nearly 30% of cases.",1099,Translated,TRUE,75.24,11.2,8.1,7.72,10.7,10.61,11,12.666666666666666,11.65,10th and 11th grade,355,64,4.609375,15,0.0765,0.862,0.0615,0.613407016,0.086170167,0.300422817
"n Hawaii, 25% white, including Asians such as Japanese and Chinese
They make up 30%, Hawaiians 20%, and Pacific Islanders mostly from Micronesia and Samoa.
4%. We found that the latter group had up to a 10-fold higher incidence of COVID-19 than the other groups.
Together, the groups accounted for nearly 30% of the cases.",1099,Translated,TRUE,69.82,11.9,8.1,9.28,10.7,11.43,12,11.5,11.68,11th and 12th grade,322,55,4.927272727,13,0.0691,0.8547,0.0762,0.60871917,0.072363369,0.318917453
"n Hawaii, 25% white, including Asians such as Japanese and Chinese
They represent 30%, Hawaiians 20% and Pacific Islanders are mainly from Micronesia and Samoa.
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than the rate of COVID-19 in the other groups.
Together, the groups accounted for almost 30% of cases.",1099,Translated,TRUE,67.79,11.9,8.8,8.7,11,11.37,13,12.5,12.05,8th and 9th grade,348,61,4.770491803,15,0.0585,0.8674,0.0741,0.613100708,0.106705859,0.280193478
"n Hawaii, 25% white, including Asians such as Japanese and Chinese
They make up 30%, Hawaiians make up 20%, and Pacific Islanders mostly from Micronesia and Samoa.
4%. We found that the rate of COVID-19 in the latter group was up to 10 times higher than the rate of COVID-19 in the other groups.
Together, these groups accounted for almost 30% of cases.",1099,Translated,TRUE,75.54,11.2,7.9,8.07,10.8,10.69,11,12.5,11.57,10th and 11th grade,353,63,4.666666667,15,0.0743,0.8582,0.0674,0.612085044,0.097839758,0.290075153
"n Hawaii White Caucasians make up 25%, Asians including Japanese, Chinese and other Asians
accounting for 30%, Hawaiians for 20%, and Pacific Islanders mostly from Micronesia and Samoa include
4%. We discovered that the rate of COVID-19 in the latter group was up to 10 times higher than in all the others
groups combined, and they accounted for nearly 30% of cases.",1099,Translated,TRUE,56.93,0,13,10.63,17.2,12.81,17,19,16.92,12th and 13th grade,366,62,4.967741935,13,0.0411,0.8556,0.1032,0.61436522,0.067554235,0.318080455
"In Hawaii, white Caucasians make up 25%, Asians are Japanese, Chinese, and other Asians.

make up 30%, Hawaiians make up 20%, and Pacific Islanders, mostly from Micronesia and Samoa, make up

4%. We found that the COVID-19 rate in the latter group was up to 10 times higher than in all others.

These groups together accounted for nearly 30% of cases.",1099,Translated,TRUE,81.33,9.5,5.7,7.82,8.4,10.61,12,7.875,8.74,7th and 8th grade,351,61,4.819672131,13,0.0433,0.831,0.1256,0.611423612,0.067187525,0.32138887
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown that
if the level of testing and containment measures is maintained, the number of positive cases
New York State remains the same in March 2021, while in the UK it will decrease.",1166,Translated,TRUE,47.12,0,18.9,9.65,24.6,11.22,10,26.5,21.23,18th and 19th grade,272,49,4.612244898,6,0.0355,0.8681,0.0964,0.622228205,0.095668405,0.28210333
"The simulated results of the spread of COVID-19 in New York State and the United Kingdom demonstrated this
while maintaining the level of testing and containment measures, the number of positive cases in
New York State will remain at the same level in March 2021, while it will decrease in the UK.",1166,Translated,TRUE,35.62,0,21.2,10.58,26.8,10.77,10,31,24.65,10th and 11th grade,297,52,4.769230769,6,0.0462,0.9084,0.0454,0.627244473,0.05900456,0.313750982
"Modeled outcomes of COVID-19 spread in New York State and the United Kingdom have shown that
if levels of testing and containment measures are maintained, the number of positive cases in New York State will remain the same in March 2021, while it will decline in the United Kingdom.",1166,Translated,TRUE,38.66,0,20,10.81,25.6,10.9,10,26.5,21.23,10th and 11th grade,282,49,4.795918367,6,0.0295,0.8505,0.1201,0.621579289,0.067310475,0.311110228
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown this
if the level of testing and isolation measures is maintained, the number of positive cases
New York State will remain flat in March 2021, while the UK will see a decrease.",1166,Translated,TRUE,47.12,0,18.9,9.42,24.4,10.9,9,26.5,21.23,10th and 11th grade,270,49,4.571428571,6,0.0365,0.8601,0.1034,0.619095385,0.090397872,0.290506691
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown that
If the level of testing and containment measures is maintained, the number of positive cases in
The state of New York will remain the same during March 2021, while in the United Kingdom it will be reduced.",1166,Translated,TRUE,41.03,0,21.2,9.53,27.5,10.38,9,29.5,23.45,9th and 10th grade,304,55,4.581818182,6,0.037,0.8975,0.0655,0.631398797,0.062353931,0.306247234
"Modeling results for the spread of COVID-19 in New York State and the United Kingdom include:
If testing levels and lockdown measures are maintained, the number of positive cases in the country will be
In New York State it will remain the same for March 2021, but in England it will be reduced.",1166,Translated,TRUE,34.6,0,21.6,9.53,26.6,11.03,12,28.5,22.71,21st and 22nd grade,294,53,4.603773585,6,0.0315,0.8621,0.1065,0.640030026,0.05624193,0.303728014
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom showed this
if the level of testing and containment measures are maintained, the number of positive cases
New York State remains the same in March 2021, while it will decrease in the UK.",1166,Translated,TRUE,48.14,0,18.5,9.94,24.4,11.28,10,26,20.87,18th and 19th grade,269,48,4.666666667,6,0.0398,0.8788,0.0814,0.612412393,0.081575207,0.306012452
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom showed this
if the level of testing and containment measures is maintained, the number of positive cases in
New York State will remain the same during March 2021, while it will decrease in the UK.",1166,Translated,TRUE,46.11,0,19.3,9.82,25.2,10.85,9,27,21.6,10th and 11th grade,279,50,4.64,6,0.0399,0.8705,0.0896,0.616112113,0.073561631,0.310326248
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom demonstrated that
if the level of testing and containment measures are preserved, the number of positive cases in
New York State remains the same in March 2021, while in the United Kingdom it will decrease.",1166,Translated,TRUE,37.65,0,20.4,10.98,26.2,10.85,11,28,22.4,10th and 11th grade,289,50,4.84,6,0.0417,0.8705,0.0878,0.614960074,0.077662982,0.307376921
"Modeling results from COVID-19 outbreaks in New York State and the United Kingdom demonstrate that:
If testing levels and quarantine measures are maintained, the number of positive cases will be
New York State will remain the same in March 2021, while England will see a decrease.",1166,Translated,TRUE,41.71,0,18.9,12.61,25.6,11.75,13,26,21.01,25th and 26th grade,280,46,5.152173913,6,0.0247,0.7888,0.1865,0.616418004,0.066929348,0.316652685
"This was demonstrated by simulated results of the spread of COVID-19 in New York State and the United Kingdom
while maintaining the level of testing and containment measures, the number of positive cases
New York State will remain flat in March 2021, while the UK will see a decrease.",1166,Translated,TRUE,38.66,0,20,11.04,25.8,10.9,10,29.5,23.68,10th and 11th grade,284,49,4.857142857,6,0.0438,0.9131,0.043,0.611660421,0.078530811,0.309808701
"Modeled results of the spread of COVID-19 in New York State and the UK have shown this.
If the level of testing and isolation measures is maintained, the number of positive cases
in New York State will remain stable in March 2021, while the UK will see a decline.",1166,Translated,TRUE,71.99,0,9.3,7.9,11.5,9.69,9,13.25,11.43,9th and 10th grade,263,49,4.428571429,6,0.0377,0.854,0.1083,0.653718352,0.091373026,0.254908651
"The modeled results of COVID-19 spread in New York State and the UK have shown that
if the level of testing and containment measures is maintained, the number of positive cases i
New York State will remain the same in March 2021, while in the UK it will reduce.",1166,Translated,TRUE,47.12,0,18.9,8.37,23.6,10.9,9,26.5,21.23,10th and 11th grade,261,49,4.387755102,6,0.0479,0.8817,0.0704,0.611502051,0.07724458,0.311253369
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom showed this
if the level of testing and containment measures is maintained, the number of positive cases in
New York State remains the same in March 2021, while it will decrease in the UK.",1166,Translated,TRUE,47.12,0,18.9,9.53,24.5,11.22,10,26.5,21.23,18th and 19th grade,271,49,4.591836735,6,0.0431,0.8812,0.0757,0.614613235,0.082355626,0.303031087
"Model results for the spread of COVID-19 in New York State and the United Kingdom have shown that if testing and isolation measures are maintained, the number of positive cases in New York State will remain stable in March 2021, while the United Kingdom will see a decline.",1166,Translated,TRUE,39.68,0,19.6,10.46,24.8,10.62,9,26,20.87,10th and 11th grade,273,48,4.708333333,6,0.0513,0.8812,0.0676,0.626209378,0.07622461,0.297565967
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom showed this
if the level of testing and containment measures is maintained, the number of positive cases i
New York State will remain the same in March 2021, while it will decrease in the UK.",1166,Translated,TRUE,46.11,0,19.3,9.24,24.8,10.85,9,27,21.6,10th and 11th grade,274,50,4.54,6,0.0418,0.8665,0.0917,0.616624177,0.072954886,0.31042099
"The modeled results of the spread of covid-19 in the state of New York and the United Kingdom have shown that
if the level of testing and containment measures is maintained, the number of positive cases i
New York State remains unchanged in March 2021, while in the UK it will decrease.",1166,Translated,TRUE,44.08,0,20,9.36,25.9,11.38,11,28,22.34,19th and 20th grade,286,52,4.557692308,6,0.0332,0.8577,0.1092,0.619344771,0.091551073,0.289104134
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown that
if the level of testing and containment measures are maintained, the number of positive cases in
New York State will remain the same in March 2021, while in the United Kingdom it will decrease.",1166,Translated,TRUE,44.08,0,20,10.06,26.4,10.47,9,28,22.34,10th and 11th grade,292,52,4.673076923,6,0.0357,0.8852,0.0791,0.617172897,0.081196144,0.301630914
"Modeled results of the spread of COVID-19 in New York State and the United Kingdom have shown that
If the level of testing and containment measures is maintained, the number of positive cases
New York state will remain the same in March 2021, while in the UK it will decrease.",1166,Translated,TRUE,46.11,0,19.3,9.48,25,10.85,9,27,21.6,10th and 11th grade,276,50,4.58,6,0.0376,0.8625,0.0999,0.622109473,0.091835581,0.286054999
"Different amounts of antibodies produced after the two vaccine doses were found.
Individuals with a previous natural infection developed a higher level of antibodies. Between
individuals without a history of past SARS-CoV-2 infection, 5% had an antibody level to the same
order of magnitude of infected people, suggesting that they acquired the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Translated,TRUE,27.52,15.9,14,14.04,13.7,10.38,21,14.125,14.44,13th and 14th grade,476,73,5.602739726,2,0.0545,0.8698,0.0757,0.633320093,0.062638983,0.304040968
"The amount of antibodies produced after the two vaccinations was found to be different.
Individuals with a previous natural infection had higher antibody levels. Between
Among individuals with no previous SARS-CoV-2 infection, 5% had the same antibody levels.
In order of magnitude of the number of people infected, they indicate that they were infected during the following periods:
Asymptomatic method. For such individuals, one dose of vaccine may be sufficient to get:
Protective immune response.",1170,Translated,TRUE,30.87,15.1,12.7,14.09,12.8,9.85,20,11.9,13.47,12th and 13th grade,500,75,5.746666667,2,0.0391,0.8933,0.0675,0.651595116,0.049307577,0.29909727
"Different amounts of antibodies produced after the two vaccine doses were found.
People who had a previous natural infection developed a higher level of antibodies. From
in people with no history of SARS-CoV-2 infection, 5% had identical antibody levels
order of magnitude of those infected, suggesting that they contracted the infection in a manner
asymptomatically. In these people, one dose of vaccine may be enough to achieve
protective immune response.",1170,Translated,TRUE,36.79,15.2,12.5,13.74,13.4,10.82,21,13.25,14.43,13th and 14th grade,457,70,5.614285714,2,0.0475,0.8545,0.098,0.636530817,0.055311389,0.308157772
"Different amounts of antibodies produced after two doses of the vaccine were found.
Individuals with previous natural infection developed higher levels of antibodies. Between
of individuals with no history of SARS-CoV-2 infection, 5% had the same level of antibodies
order of infected people, suggesting that they acquired the infection in an
in an asymptomatic way. In such individuals, a single dose of vaccine may be sufficient to acquire a
protective immune response.",1170,Translated,TRUE,27.83,15.6,13.9,13.86,13.8,10.23,20,13.75,13.31,13th and 14th grade,471,72,5.625,2,0.0462,0.8535,0.1003,0.638138235,0.067275956,0.294585764
"Different amounts of antibodies were found to be produced after two doses of the vaccine.
Individuals with previous natural infection developed higher levels of antibodies. Among
people with no history of SARS-CoV-2 infection, 5% had the same level of antibodies
as infected people, suggesting that they acquired the infection in an
asymptomatic manner. In these individuals, a single dose of vaccine may be sufficient to acquire a
protective immune response.",1170,Translated,TRUE,36.79,15.2,12.5,13.92,13.6,10.59,21,13.25,13.29,13th and 14th grade,459,70,5.642857143,2,0.0458,0.8565,0.0977,0.635827482,0.073965319,0.290207237
"Different amounts of antibodies produced after two doses of the vaccine were detected.
Individuals with previous natural infection developed higher levels of antibodies. Among
of individuals without a history of SARS-CoV-2 infection, 5% had the same level of antibodies
order of magnitude of infected people, which indicates that they became infected in an
asymptomatic. In such people, a single dose of the vaccine may be sufficient to produce a
protective immune response.",1170,Translated,TRUE,27.83,15.9,13.9,14.09,13.9,10.45,21,14,14.42,13th and 14th grade,474,72,5.666666667,2,0.0414,0.8303,0.1283,0.635614574,0.072641261,0.291744143
"Different amounts of antibodies produced after the two doses of vaccine were noted.
People who had already been infected naturally developed a higher level of antibodies.
Among people without a history of SARS-CoV-2 infection, 5% had identical antibody levels
to those of infected people, suggesting that they contracted the infection in a way
asymptomatic. In these people, one dose of vaccine may be enough to obtain
a protective immune response.",1170,Translated,TRUE,36.79,14.6,12.5,12.99,12.8,10.37,20,12.75,13.29,12th and 13th grade,448,70,5.485714286,2,0.038,0.848,0.1141,0.63053298,0.066242814,0.303224295
"The amount of antibodies produced after the two vaccines was found to be different.
Individuals with a previous natural infection had higher antibody levels. Among
Among people without previous SARS-CoV-2 infection, 5% had the same antibody levels.
In order of magnitude of the number of infected people, they indicate that they were infected during the following periods:
Asymptomatic method. For these people, one dose of vaccine may be sufficient to receive:
Protective immune response.",1170,Translated,TRUE,39.53,14.3,11.4,13.74,12.4,9.92,20,11.2,12.95,11th and 12th grade,489,74,5.689189189,2,0.0409,0.8889,0.0702,0.643407106,0.056555446,0.300037473
"Different amounts of antibodies produced after the two doses of vaccine were found.
People who had already had a natural infection developed a higher level of antibodies. Among
people with no history of SARS-CoV-2 infection, 5% had an antibody level identical
order of magnitude to those infected, suggesting that they acquired the infection
asymptomatically. In these people, one dose of vaccine may be sufficient to elicit a
protective immune response.",1170,Translated,TRUE,36.79,14.9,12.5,13.51,13.2,10.37,20,13,13.86,12th and 13th grade,454,70,5.571428571,2,0.0551,0.862,0.0828,0.629931509,0.072459824,0.297608614
"Different amounts of antibodies produced after the two vaccine doses were found.
Individuals with a previous natural infection developed a higher antibody level. Among
individuals with no previous SARS-CoV-2 infection had 5% an antibody level in the same way
order of magnitude of infected people, suggesting that they acquired the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Translated,TRUE,28.03,15.9,13.8,13.8,13.5,10.52,21,13.875,14.44,13th and 14th grade,463,71,5.605633803,2,0.0536,0.8766,0.0699,0.63715893,0.056580577,0.306260407
"Different amounts of antibodies produced after two doses of the vaccine were found.
Individuals with previous natural infection developed higher levels of antibodies. Between
of individuals with no history of SARS-CoV-2 infection, 5% had the same level of antibodies
order of infected persons, indicating that they acquired the infection in a
in an asymptomatic way. In such individuals, a single dose of vaccine may be sufficient to acquire one
protective immune response.",1170,Translated,TRUE,27.83,15.6,13.9,13.98,13.9,10.45,21,13.75,13.31,13th and 14th grade,473,72,5.652777778,2,0.0524,0.863,0.0846,0.64206171,0.057899468,0.300038844
"The amount of antibodies produced after two vaccinations was found to be different.
Individuals with a previous natural infection had higher antibody levels. between
Among individuals who had not previously been infected with SARS-CoV-2, 5% had the same antibody levels.
The scale of the number of infected people indicates that they were infected during the following periods:
Asymptomatic method. For such individuals, one dose of vaccine may be enough to get:
Protective immune response.",1170,Translated,TRUE,39.53,14.6,11.4,13.85,12.5,9.92,19,11.4,12.95,12th and 13th grade,490,74,5.702702703,2,0.0318,0.8759,0.0923,0.6626544,0.048450414,0.28889516
"It was found that different amounts of antibodies were produced after the two doses of vaccine.
People with a previous natural infection developed higher levels of antibodies. Of those without a previous SARS-CoV-2 infection, 5% had antibody levels in the same range as infected people, suggesting that they acquired the infection asymptomatically. In such people, one dose of vaccine may be enough to produce a protective immune response.",1170,Translated,TRUE,45.76,14.2,11.1,13.28,12.8,10.52,19,12.25,12.68,12th and 13th grade,439,68,5.485294118,2,0.0439,0.88,0.0761,0.63411653,0.055153165,0.310730278
"Different amounts of antibodies produced after the two vaccine doses were found.
People with a previous natural infection developed a higher antibody level. Among
individuals without prior SARS-CoV-2 infection had 5% antibody levels similarly
order of magnitude of infected people, suggesting that they got the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to achieve a
protective immune response.",1170,Translated,TRUE,29.35,15.6,13.3,14.85,13.8,11.39,22,13,15.08,12th and 13th grade,443,66,5.803030303,2,0.0411,0.853,0.1058,0.630817056,0.068235263,0.300947607
"Different amounts of antibodies were found to be produced after the two doses of the vaccine.
People with previous natural infection developed higher levels of antibodies. Between
subjects with no history of previous SARS-CoV-2 infection, 5% had a concurrent antibody level
order of magnitude of infected individuals, suggesting that they acquired the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Translated,TRUE,27.52,16.2,14,14.56,14.2,11.03,24,14.375,14.99,14th and 15th grade,483,73,5.698630137,2,0.0427,0.8544,0.1029,0.638243437,0.05633631,0.30542025
"The amount of antibodies produced after two doses of vaccine was different.
Previously naturally infected individuals had higher antibody levels.
Among individuals without a previous SARS-CoV-2 infection, 5% had antibody levels at the same level as those who were infected.
This suggests that they were infected in an asymptomatic manner. For these individuals, one dose of vaccine may be sufficient to obtain a protective immune response.",1170,Translated,TRUE,32.7,13.7,12,13.85,11.9,10.51,21,9,11.95,11th and 12th grade,439,66,5.712121212,2,0.0299,0.8344,0.1357,0.635976613,0.069502234,0.294521093
"Different amounts of antibodies were found to be produced after the two doses of the vaccine.
Individuals who had a previous natural infection developed a higher level of antibodies. between the
In individuals with no history of previous infection with SARS-CoV-2, 5% had an antibody level at the same level
In terms of the size of the infected people, which indicates that they were infected in
Asymptomatic method. In such individuals, a single dose of the vaccine may be sufficient to obtain...
Protective immune response.",1170,Translated,TRUE,45.76,14.6,11.1,11.66,11.5,9.5,19,12.5,12.45,11th and 12th grade,525,85,5.247058824,2,0.0746,0.8841,0.0413,0.633863986,0.066174634,0.299961418
"Different amounts of antibodies produced after the two vaccine doses were found.
People who had a previous natural infection developed a higher level of antibodies. Of
in people with no history of SARS-CoV-2 infection, 5% had identical antibody levels
order of magnitude of those infected, suggesting that they contracted the infection in a way
asymptomatically. In these people, one dose of vaccine may be enough to achieve
protective immune response.",1170,Translated,TRUE,36.79,15.2,12.5,13.34,13.1,10.59,20,13.25,14.43,12th and 13th grade,452,70,5.542857143,2,0.0512,0.8551,0.0936,0.633180261,0.057389151,0.309430599
"Different amounts of antibodies were found to be produced after the two doses of the vaccine.
People with a previous natural infection developed a higher level of antibodies. Between
people with no history of previous SARS-CoV-2 infection, 5% had a level of antibodies to it
order of magnitude of infected individuals, suggesting that they acquired the infection in a
asymptomatic way. In such individuals, one dose of vaccine may be sufficient to obtain a
protective immune response.",1170,Translated,TRUE,34.97,15.9,13.2,12.71,13.2,9.93,20,14.625,13.95,12th and 13th grade,484,77,5.363636364,2,0.0512,0.8632,0.0856,0.643780231,0.054350439,0.301869333
"The proposed technique has a high similarity with the PCR testing technique. The results
The results obtained highlight the potential application of this simple and inexpensive magneto test for saliva.
Point-of-care based COVID-19 diagnosis.",1171,Translated,TRUE,43.09,11.2,10.1,15.99,13.1,12.09,13,6.666666666666667,11.58,11th and 12th grade,241,34,6.176470588,2,0.7612,0.235,0.0038,0.616699576,0.096584074,0.286716402
"The proposed technique showed great similarity with the PCR test technique. Results
the application potential of this simple, low-cost salivary magnetoassay was pointed out
point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,31.89,0,12.3,18.38,16.2,12.23,10,8.5,12.74,12th and 13th grade,209,28,6.571428571,2,0.8663,0.1294,0.0043,0.610965669,0.088361241,0.300673097
"The proposed technique showed great similarity with the PCR test technique. Results
the applicability of this simple, low-cost saliva magnetoassay was highlighted
point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,24.44,0,13.1,19.07,16.6,12.18,9,8,12.89,12th and 13th grade,199,26,6.769230769,2,0.852,0.1427,0.0053,0.613017201,0.087745696,0.299237162
"The proposed technology showed great similarity to PCR testing technology. result
Points are earned for the application potential of this simple and inexpensive magnetic method for saliva.
On-site treatment-based COVID-19 diagnosis.",1171,Translated,TRUE,27.18,13,12,17.9,14.4,14.84,12,7.166666666666666,13.15,12th and 13th grade,232,31,6.580645161,2,0.8944,0.1021,0.0034,0.627184868,0.051571857,0.321243346
"The proposed technique showed great similarity with the PCR testing technique. The results
obtained show the application potential of this simple, inexpensive saliva magnetoassay.
point-of-care-based diagnostics for COVID-19.",1171,Translated,TRUE,28.2,11.9,11.6,20.33,16.5,13.68,12,6,12.29,11th and 12th grade,225,28,7.142857143,2,0.915,0.0813,0.0036,0.613021553,0.082509905,0.304468513
"The proposed method was very similar to the PCR testing technique. Results
the obtained result indicates the application potential of this simple and inexpensive saliva magnetic analysis.
When diagnosed with COVID-19.",1171,Translated,TRUE,44.1,12.5,9.7,15.46,12.1,13.83,15,6.833333333333333,14.44,12th and 13th grade,217,31,6.096774194,2,0.5518,0.44,0.0082,0.624348402,0.075523071,0.300128609
"The proposed technique showed great similarity with the PCR testing technique. The results
obtained point to the potential application of this simple and low-cost magnetoassay for saliva-
Point-of-care based COVID-19 diagnosis.",1171,Translated,TRUE,38.82,0,11.7,17.98,16.2,12.55,11,10.25,12.65,12th and 13th grade,227,31,6.419354839,2,0.8772,0.1186,0.0042,0.611725628,0.092233285,0.296041161
"The proposed technique showed great similarity to the PCR test technique. The results
obtained point to the application potential of this simple, inexpensive magnetoassay for salivary
based covid-19 diagnosis in healthcare.",1171,Translated,TRUE,38.82,0,11.7,17.8,15.7,13.06,12,10.75,13.94,11th and 12th grade,223,31,6.290322581,2,0.8998,0.0963,0.0039,0.597607911,0.0785276,0.32386452
The proposed technology was very similar to the PCR testing technology. The results obtained demonstrate the potential of this simple and inexpensive magnetic assay to be applied to saliva-based clinic COVID-19 diagnosis.,1171,Translated,TRUE,29.86,0,13.1,16.12,14.5,13.81,15,11.5,13.9,13th and 14th grade,221,32,5.9375,2,0.7931,0.2029,0.004,0.614585996,0.060498558,0.324915498
"The proposed technique showed great similarity to the PCR testing technique. result
The obtained results demonstrate the applicability of this simple and inexpensive saliva magnetic analysis method.
Point-of-care based diagnosis for COVID-19.",1171,Translated,TRUE,35.23,11.2,11,18.71,14.9,14.04,14,6.333333333333333,11.78,11th and 12th grade,242,32,6.65625,2,0.89,0.1064,0.0036,0.61532706,0.083800748,0.300872147
"The proposed method was very similar to the PCR test technique. Results
the obtained result indicates the application potential of this simple and inexpensive salivary magnetic analysis.
When diagnosed with COVID-19.",1171,Translated,TRUE,44.1,12.5,9.7,15.29,12,13.32,14,6.833333333333333,14.44,12th and 13th grade,216,31,6.064516129,2,0.5697,0.4222,0.0081,0.623609722,0.068384245,0.308006078
"The proposed technique showed great similarity with the PCR test technique. Results
The obtained points indicate the potential application of this simple and low-cost magnetic saliva test.
Point-of-care COVID-19 diagnosis.",1171,Translated,TRUE,44.41,11.2,9.6,17.2,13.9,12.55,11,6,12,11th and 12th grade,222,30,6.5,2,0.8375,0.1584,0.0041,0.61609,0.089743406,0.294166565
The proposed technique showed great similarity to the PCR testing technique. The results obtained indicate the potential application of this simple and inexpensive magnetoassay for saliva-based point-of-care diagnosis of COVID-19.,1171,Translated,TRUE,22.41,0,13.9,19.83,17.6,13.85,13,11,15.33,13th and 14th grade,230,30,6.7,2,0.8386,0.157,0.0045,0.613438249,0.086487211,0.300074548
"The proposed technique showed great similarity with the PCR test technique. Results
the application potential of this simple, inexpensive saliva magnetoassay was pointed out
point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,31.89,0,12.3,18.78,16.4,12.79,11,9,14.17,12th and 13th grade,210,28,6.607142857,2,0.8933,0.1027,0.0041,0.60663861,0.080121353,0.313240111
"The proposed technique showed great similarity to the PCR testing technique. Results
The points obtained indicate the applicability of this simple and low-cost magnetic test for saliva.
Point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,44.1,10.5,9.7,15.87,12.9,12.3,11,5.833333333333333,10.57,10th and 11th grade,222,31,6.258064516,2,0.8004,0.1945,0.0051,0.616841316,0.085672952,0.297485709
"The proposed technique showed great similarity to the PCR testing technique. The results obtained indicate the application potential of this simple, low-cost magnetoassay for saliva-based point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,31.38,0,12.5,19.71,17.7,13.61,12,10.25,14.08,13th and 14th grade,224,29,6.75862069,2,0.8548,0.1408,0.0044,0.613480449,0.084624372,0.301895112
The proposed technology showed great similarity to the PCR testing technology. The results obtained indicate the applicability of this simple and low-cost magnetic test for saliva-based point-of-care diagnosis of COVID-19.,1171,Translated,TRUE,22.41,0,13.9,18.09,16.4,12.8,11,11,14,13th and 14th grade,222,30,6.433333333,2,0.8604,0.1357,0.0039,0.606508553,0.068738051,0.324753284
"The proposed technique showed great similarity with the PCR test technique. The obtained results indicate the application potential of this simple, inexpensive magnetoassay for saliva-based point-of-care diagnosis of COVID-19.",1171,Translated,TRUE,22.92,0,13.7,20.35,18,13.61,12,10.75,15.46,13th and 14th grade,226,29,6.827586207,2,0.8706,0.1251,0.0043,0.607826293,0.084069997,0.30810374
The proposed technique showed great similarity to the PCR testing technique. The results obtained indicate the possibility of applying this simple and low-cost magnetic test for saliva-based point-of-care diagnosis of COVID-19.,1171,Translated,TRUE,30.36,0,12.9,17.98,16.2,13.06,12,10.75,13.94,12th and 13th grade,227,31,6.35483871,2,0.7702,0.225,0.0048,0.617548108,0.086841054,0.295610815
"In the early stages of the COVID-19 pandemic, stay-at-home orders and social distancing were implemented. 
The guidelines required the U.S. health system to postpone elective tests and procedures. 
In the early stages of the pandemic, brain MRI scan volumes decreased by 17%.",1172,Translated,TRUE,60.82,10.1,7.4,11.75,9.8,12.43,13,5.75,8.01,7th and 8th grade,275,42,5.571428571,4,0.0151,0.4215,0.5634,0.646374941,0.082466617,0.271158457
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing guidelines forced health care systems in the United States to postpone scheduled exams and procedures.
During the early pandemic, there was a 17% decline in the number of brain MRI scans.",1172,Translated,TRUE,58.11,0,10.5,12.53,14.2,11.31,11,12.75,11.39,10th and 11th grade,269,43,5.302325581,4,0.0083,0.2624,0.7293,0.623918593,0.071433991,0.304647386
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing forced medical facilities in the United States to postpone scheduled exams and procedures.
During the early pandemic, there was a 17% decrease in brain MRI scans.",1172,Translated,TRUE,52.19,0,10.7,13.4,13.7,12.06,11,12.5,12.86,12th and 13th grade,244,38,5.473684211,4,0.0081,0.2321,0.7598,0.617520809,0.069923304,0.31255585
"In the early stages of the COVID-19 pandemic, stay-at-home orders and social distancing are implemented.
The guidelines required the U.S. health system to postpone elective tests and procedures.
At the beginning of the pandemic, brain MRI scan volumes fell by 17%.",1172,Translated,TRUE,61.02,10.7,7.3,11.4,9.4,12.23,12,5.875,8.02,7th and 8th grade,264,41,5.512195122,4,0.0151,0.3918,0.5932,0.649210274,0.085473232,0.265316546
"Stay-at-home orders and social distancing during the early stages of the COVID-19 pandemic
the guidelines forced healthcare systems in the United States to delay elective tests and procedures.
During the early pandemic, the volume of brain MRI scans decreased by 17%.",1172,Translated,TRUE,50.67,0,11.3,13.87,14.9,12.36,12,12.75,11.13,11th and 12th grade,267,41,5.585365854,4,0.012,0.2943,0.6937,0.640699744,0.095142305,0.264157981
"During the first phase of the COVID-19 pandemic, stay-at-home and social distancing orders were issued
The guidelines have forced U.S. health systems to postpone elective tests and procedures.
There was a 17% decline in the volume of brain MRI scans during the early pandemic.",1172,Translated,TRUE,65.01,10.5,7.8,11.65,10.9,12.26,12,8,8.61,7th and 8th grade,276,44,5.340909091,4,0.0095,0.2699,0.7206,0.629063189,0.083601549,0.287335306
"During the initial phase of the COVID-19 pandemic, containment and social distancing measures
The guidelines forced U.S. health systems to postpone elective tests and procedures.
There was a 17% decrease in brain MRI volume at the start of the pandemic.",1172,Translated,TRUE,66.44,10.5,7.3,11.88,10.4,12.98,13,7.333333333333334,9.32,7th and 8th grade,253,40,5.4,4,0.0117,0.3392,0.6491,0.626944184,0.084541731,0.288514048
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing guidelines forced U.S. health care systems to postpone scheduled tests and procedures.
During the early pandemic, there was a 17% decline in the number of brain MRI scans.",1172,Translated,TRUE,66.44,9.7,7.3,11.7,10.4,12.19,10,7,8.32,6th and 7th grade,253,40,5.375,4,0.0082,0.2542,0.7376,0.632954955,0.078162335,0.288882792
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines have forced United States health systems to postpone elective tests and procedures.
There was a 17% reduction in brain MRI volume during the early pandemic.",1172,Translated,TRUE,51.68,0,10.9,14.68,15.1,12.3,12,12.75,11.9,14th and 15th grade,260,39,5.743589744,4,0.0114,0.3205,0.6681,0.630424142,0.079242863,0.290333033
"Stay-at-home orders and social distancing during the early stages of the COVID-19 pandemic
the guidelines forced health care systems in the United States to delay elective tests and procedures.
During the early pandemic, the volume of brain MRIs decreased by 17%.",1172,Translated,TRUE,50.67,0,11.3,13.29,14.4,11.59,11,12.75,11.13,11th and 12th grade,263,41,5.487804878,4,0.015,0.3325,0.6525,0.650579154,0.103725761,0.245695114
"During the initial phase of the covid-19 pandemic, stays at home and social distancing
guidelines have forced the US health system to postpone elective tests and procedures.
There was a 17% reduction in brain MRI volume during the early pandemic.",1172,Translated,TRUE,59.64,0,9.9,12.01,13,12.13,11,12.5,12,12th and 13th grade,246,40,5.225,4,0.0124,0.3113,0.6763,0.646948814,0.08892101,0.264130175
"During the early stages of the COVID-19 pandemic, health care systems in the United States were forced to postpone scheduled exams and procedures due to stay-at-home orders and social distancing guidelines.
During the early pandemic, there was a 17% decline in the number of brain MRI scans.",1172,Translated,TRUE,56.08,0,11.3,12.25,14.9,10.85,11,14.25,11.95,11th and 12th grade,291,47,5.234042553,4,0.0089,0.2563,0.7348,0.655610383,0.073186219,0.271203458
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines have forced US healthcare systems to postpone screening tests and procedures.
Brain MRI volume was reduced by 17% during the early pandemic.",1172,Translated,TRUE,53.21,0,10.3,14.96,14.9,13.3,13,11.5,10.53,14th and 15th grade,244,36,5.861111111,4,0.0108,0.2957,0.6935,0.632185757,0.088183075,0.279631197
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
guidelines have forced United States health systems to postpone screening tests and procedures.
During the early pandemic, there was a 17% decrease in the volume of brain MRI scans.",1172,Translated,TRUE,58.62,0,10.3,13.81,15.2,12.2,12,13,11.26,12th and 13th grade,274,42,5.595238095,4,0.0106,0.3234,0.666,0.628288388,0.079301953,0.292409658
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing guidelines forced healthcare systems in the United States to postpone scheduled tests and procedures.
During the early pandemic, there was a 17% reduction in the number of brain MRIs.",1172,Translated,TRUE,50.67,0,11.3,13.69,14.7,11.59,11,12.75,12.1,11th and 12th grade,265,41,5.512195122,4,0.0186,0.46,0.5214,0.617977679,0.05750801,0.3245143
"From the early stages of the COVID-19 pandemic, containment and social distancing measures were implemented.
The guidelines required the U.S. healthcare system to postpone elective tests and procedures.
At the start of the pandemic, brain MRI volumes fell by 17%.",1172,Translated,TRUE,61.33,10.1,7.2,12.44,9.9,12.82,14,5.5,9,8th and 9th grade,263,40,5.65,4,0.0142,0.3676,0.6182,0.639205158,0.081314296,0.279480457
"During the early stages of the COVID-19 pandemic, lockdowns and social distancing guidelines forced health care systems across the United States to postpone preventive screenings and procedures.
During the early pandemic, there was a 17% decline in the number of brain MRI scans.",1172,Translated,TRUE,58.11,0,10.5,13.87,15.3,11.31,11,13.25,12.32,10th and 11th grade,279,43,5.534883721,4,0.0089,0.2609,0.7302,0.625293076,0.077462569,0.29724431
"During the initial phase of the COVID-19 pandemic, stay-at-home orders and social distancing
the guidelines forced United States health systems to postpone testing and screening procedures.
During the early pandemic, there was a 17% reduction in brain MRI volume.",1172,Translated,TRUE,51.68,0,10.9,14.97,15.5,12.3,13,12.75,11.9,11th and 12th grade,263,39,5.820512821,4,0.0144,0.4273,0.5583,0.625911057,0.083821274,0.290267766
"In the initial phase of the COVID-19 pandemic, containment and social distancing measures
The guidelines forced US health systems to delay elective tests and procedures.
There was a 17% decrease in brain MRI volume at the onset of the pandemic.",1172,Translated,TRUE,59.64,0,9.9,11.72,12.7,12.92,14,12.5,12,12th and 13th grade,244,40,5.175,4,0.0091,0.2655,0.7254,0.627475739,0.086325124,0.286199182
"It seems that the virus traveled by car on highways and highways; and that â€œsoloâ€ driving, that is
traveling in passenger cars, which now seems to be perceived by the public as a solution, was
probably one of the media that favored the initial dissemination.",1182,Translated,TRUE,34.26,0,19.7,10.69,23.9,11.48,11,27.5,21.56,10th and 11th grade,262,45,4.888888889,0,0.027,0.5978,0.3752,0.630515873,0.048921019,0.320563048
"The virus appears to have traveled by car on highways and highways; and that ""solo"" driving, ie.
traveling by passenger cars, which the public now seems to perceive as the solution, was
probably one of the means that facilitated the initial spread.",1182,Translated,TRUE,58.62,0,10.3,10.21,12.3,10.32,11,13,12.21,9th and 10th grade,248,42,4.976190476,0,0.0196,0.506,0.4744,0.622877002,0.046697352,0.33042559
"It appears that the virus traveled by car on freeways and highways; and that ""solo"" driving, i.e.
travel with passenger cars, which now seem to be perceived by the public as a solution, where
probably one of the agents that favored the initial spread.",1182,Translated,TRUE,66.07,0,9.5,8.94,11.8,10.47,12,12.5,10.62,9th and 10th grade,251,44,4.772727273,0,0.0287,0.6227,0.3486,0.640060842,0.047891777,0.312047452
"The virus appears to have traveled by car on highways and highways; and that ""solo"" driving, ie.
to drive passenger cars, which the public currently perceives as a solution, where
probably one of the agents that favored the initial spread.",1182,Translated,TRUE,59.64,0,9.9,10.56,12.1,10.55,11,12,11,10th and 11th grade,239,40,5.05,0,0.0316,0.6735,0.2949,0.632266343,0.048529174,0.31920442
"It appears that the virus traveled by car on freeways and highways; and that ""solo"" driving, i.e.
travel by passenger car, which now seems to be perceived by the public as a solution, was
probably one of the agents that favored the initial spread.",1182,Translated,TRUE,66.07,0,9.5,8.41,11.4,10.47,12,12.5,10.62,10th and 11th grade,247,44,4.681818182,0,0.019,0.524,0.457,0.641880333,0.047569662,0.310550034
"It seems that the virus traveled by car on freeways and highways. and this ""solo"" driving, ie.
passenger car travel, which now seems to be perceived by the public as a solution, was
possibly one of the media that favored the initial spread.",1182,Translated,TRUE,73.88,8.8,6.5,7.76,7.4,9.85,12,7.166666666666666,7.58,7th and 8th grade,240,43,4.651162791,0,0.0191,0.5159,0.465,0.638165474,0.049088307,0.312746167
"The virus appears to have traveled by car via highways and highways. And that â€œsoloâ€ driving, that is.
Traveling by car now seems to be recognized by the public as a solution.
It is probably one of the preferred means of initial diffusion.",1182,Translated,TRUE,77.43,9.5,5.1,7.58,5.9,10.05,11,5.625,8.97,5th and 6th grade,243,43,4.720930233,0,0.1082,0.7969,0.0949,0.631202519,0.04809159,0.320705861
"The virus appears to have been transmitted by car on highways and highways; And that â€œsoloâ€ leadership, that is.
Passenger car travel, which the public now seemed to see as a solution, was the answer
It may have been one of the means that favored the initial spread.",1182,Translated,TRUE,64.04,0,10.3,8.88,12.5,8.77,8,14,12.1,8th and 9th grade,270,48,4.6875,0,0.0308,0.5115,0.4577,0.624076128,0.045259062,0.330664754
"It appears the virus traveled by car on highways and interstates; and this â€œsoloâ€ behavior, that is to say
car transport, which now seems to be perceived by the public as a solution, has been
probably one of the means which favored the initial diffusion.",1182,Translated,TRUE,42.72,0,18.5,10.17,23.5,11.48,12,27.5,22.44,10th and 11th grade,258,45,4.8,0,0.0319,0.6177,0.3504,0.620015979,0.04653509,0.333448887
"The virus appears to have traveled by car on freeways and highways; and that ""solo"" driving, i.e.
passenger car travel, which now seems to be seen by the public as a solution, was
probably one of the means that supported the initial spread.",1182,Translated,TRUE,66.57,0,9.3,8.24,11,9.84,11,12.75,11.39,8th and 9th grade,240,43,4.651162791,0,0.0225,0.5797,0.3977,0.634840727,0.046724431,0.318434775
"The virus appears to have traveled by car on freeways and highways. and that ""solo"" driving, ie.
Traveling by passenger cars, which the public now seems to perceive as a solution, was
possibly one of the means that facilitated the initial spread.",1182,Translated,TRUE,65.73,10.5,7.6,9.33,8.6,10.35,12,7.666666666666666,9.41,7th and 8th grade,246,42,4.928571429,0,0.0193,0.5056,0.475,0.625948191,0.046866842,0.327185035
"It seems that the virus spread by car on motorways and expressways. And this ""driving alone"", i.e.
travelling by car, which now seems to be perceived by the public as a solution,
may have been one of the media that favored the initial spread.",1182,Translated,TRUE,81.93,9.7,5.5,7.18,7.2,8.67,9,7.666666666666666,9.52,9th and 10th grade,242,44,4.568181818,0,0.0197,0.471,0.5092,0.638543963,0.048204951,0.313251108
"It seems that the virus traveled by car on highways and highways; and that driving â€œaloneâ€, that is
traveling in passenger cars, which now seems to be perceived by the public as a solution, was
Probably one of the media that favored the initial dissemination.",1182,Translated,TRUE,34.26,0,19.7,10.81,24,11.48,11,27.5,21.56,10th and 11th grade,263,45,4.911111111,0,0.0235,0.5787,0.3978,0.627603471,0.048193805,0.324202806
"It appears that the virus was spread by car on highways and motorways, and that ""driving alone"", i.e. travelling by private car, which is now perceived by the public as a solution, was probably one of the factors that favoured its initial spread.",1182,Translated,TRUE,66.57,0,9.3,8.99,11.6,9.84,11,12.75,12.32,8th and 9th grade,246,43,4.744186047,0,0.0176,0.4876,0.4948,0.64310956,0.04854751,0.308342963
"The virus appears to have traveled by car on highways and highways. And this is ""independent"" management.
Traveling by car now seems to be accepted by the public as a solution.
It is probably one of the preferred means of initial diffusion.",1182,Translated,TRUE,69.28,10.7,6.2,7.92,6.1,9.42,12,6,10.87,5th and 6th grade,240,42,4.785714286,0,0.0865,0.775,0.1385,0.637338161,0.049003858,0.313657999
"The virus appears to have traveled by car on freeways and highways; and that ""solo"" management, i.e.
travel by private car, which now seems to be perceived by the public as a solution, was
probably one of the agents who supported the initial spread.",1182,Translated,TRUE,66.07,0,9.5,8.7,11.6,10.83,13,13,12.44,8th and 9th grade,249,44,4.727272727,0,0.0201,0.5085,0.4714,0.634385228,0.047349259,0.318265468
"It seems that the virus was transmitted by car on motorways and expressways. And this ""solo behaviour"", i.e. car travel, which now seems to be perceived by the public as a solution, was probably one of the reasons for the initial spread.",1182,Translated,TRUE,74.19,11.2,6.4,7.94,7.6,9.59,11,8,11.31,7th and 8th grade,237,42,4.666666667,0,0.0097,0.2926,0.6977,0.640291989,0.046827901,0.312880099
"The virus appears to have traveled by car on highways and freeways; and that ""solo"" management, i.e.
to travel in passenger cars, which now seems to be accepted by the public as a solution
probably one of the vehicles that contributed to the initial spread.",1182,Translated,TRUE,57.1,0,10.9,9.46,12.1,10.72,13,14.75,14.33,10th and 11th grade,257,45,4.777777778,0,0.0189,0.5176,0.4634,0.626235545,0.047031906,0.326732516
"It seems that the virus travelled by car on motorways and dual carriageways; and that â€œsoloâ€ driving, i.e.
travelling in passenger cars, which now seems to be perceived by the public as a solution, was
probably one of the means that favoured the initial spread.",1182,Translated,TRUE,65.56,0,9.7,10.22,12.9,10.72,10,14.25,13.44,9th and 10th grade,265,45,4.955555556,0,0.0201,0.562,0.4179,0.631860077,0.047950771,0.320189148
"Pure silver and stainless steel surfaces containing silver were found to be non-reflective
inhibits the effect on SARS-CoV-2 and H1N1 viruses. For comparison, both pure copper and
copper-containing stainless steel with a high copper content has a significant antiviral effect
properties.",1186,Translated,TRUE,33.75,0,13.6,16.65,17.2,11.2,12,13.75,14.05,13th and 14th grade,287,41,6.097560976,3,0.0229,0.5479,0.4292,0.639469802,0.044905934,0.315624237
"It has been discovered that surfaces of pure silver and silver-containing stainless steels do not appear
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
copper-containing stainless steel with a high copper content exhibits significant antiviral effect
properties.",1186,Translated,TRUE,33.24,0,13.8,17.81,18.3,11.82,14,14.5,15.07,11th and 12th grade,302,42,6.285714286,3,0.0509,0.7557,0.1935,0.622220159,0.050405577,0.32737419
"Pure silver and stainless steel surfaces containing silver were found to be non-reflective
inhibits the effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
copper-containing stainless steel with a high copper content has a significant antiviral effect
properties.",1186,Translated,TRUE,33.75,0,13.6,16.53,17.1,11.2,12,13.75,14.05,13th and 14th grade,286,41,6.073170732,3,0.0259,0.6032,0.3709,0.639064789,0.045078352,0.315856814
"It is found that pure silver and silver-containing stainless steel surfaces do not show
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Stainless steel with a high copper content exhibits important antiviral properties.
properties.",1186,Translated,TRUE,43.22,0,12.1,16.19,16.3,10.68,11,13.25,12.93,12th and 13th grade,270,39,6.025641026,3,0.1124,0.7308,0.1568,0.637940049,0.045702264,0.316357672
"Pure silver and silver-containing stainless steel surfaces were found to have no inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and high-copper-containing stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,29.86,0,13.1,20.12,18.4,11.83,11,12,15.15,11th and 12th grade,247,32,6.75,3,0.1727,0.7502,0.0771,0.643082857,0.044786952,0.312130213
"It has been discovered that surfaces of pure silver and silver-containing stainless steel do not appear
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
the copper content stainless steel with a high copper content exhibits significant antiviral effect
characteristics.",1186,Translated,TRUE,32.22,0,14.2,16.71,17.8,11.19,14,14.5,15.16,14th and 15th grade,307,44,6.068181818,3,0.0421,0.7277,0.2302,0.623732865,0.050820936,0.325446218
"Pure silver and stainless steel surfaces containing silver have been found not to display
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Copper-containing stainless steel with a high copper content exhibits significant antiviral effects
Properties.",1186,Translated,TRUE,34.26,0,13.5,17.98,17.9,11.34,13,13.5,14,13th and 14th grade,288,40,6.3,3,0.0195,0.4817,0.4987,0.637647569,0.043077428,0.319274932
"Pure silver and silver-containing stainless steel surfaces were found to have no inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and high-copper stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,38.32,0,11.9,18.33,16.8,11.83,11,12,15.15,11th and 12th grade,236,32,6.40625,3,0.1705,0.752,0.0775,0.640124023,0.045519598,0.314356357
"It was found that pure silver and silver-containing stainless steel surfaces do not appear to have any inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and high-copper-containing stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,35.78,0,12.9,17.98,17.5,10.96,11,13.25,14.97,17th and 18th grade,269,37,6.297297297,3,0.1096,0.7926,0.0978,0.641965568,0.044580922,0.313453496
"It has been shown that surfaces of pure silver and silver-containing stainless steel are not visible
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Stainless steel with a high copper content exhibits important antiviral properties.
characteristics.",1186,Translated,TRUE,33.75,0,13.6,16.82,17.3,11.59,13,14.25,15.03,13th and 14th grade,288,41,6.12195122,3,0.0642,0.7083,0.2275,0.642267644,0.049485881,0.308246523
"It has been found that pure silver and silver-containing stainless steel surfaces do not display
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, pure copper and
high-copper stainless steel exhibits significant antiviral properties
properties.",1186,Translated,TRUE,36.79,0,12.5,18.73,17.7,11.72,12,12.75,13.86,12th and 13th grade,260,35,6.542857143,3,0.043,0.6762,0.2808,0.644491076,0.045169074,0.310339868
"It was found that surfaces made of pure silver and stainless steel containing silver do not have an inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and high-copper stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,43.73,0,11.9,15.08,15.1,10.81,11,13.5,14.97,14th and 15th grade,255,38,5.736842105,3,0.1789,0.7642,0.0569,0.643486023,0.046549227,0.309964716
"It has been shown that pure silver and stainless steel surfaces containing silver are not visible.
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Stainless steel with a high copper content has important antiviral properties.
characteristics.",1186,Translated,TRUE,49.11,12.5,9.8,15.25,13.1,10.86,12,8.5,12.31,12th and 13th grade,281,41,5.951219512,3,0.0492,0.6325,0.3183,0.623384118,0.047115423,0.329500496
"It turns out that sterling silver and stainless steel surfaces containing silver do not display.
Inhibitory effect against SARS-CoV-2 and H1N1 viruses. In contrast, pure copper and
Copper-containing stainless steel with a high copper content exhibits significant antiviral effects.
property.",1186,Translated,TRUE,41.06,11.2,10.8,17.21,14.9,12.19,15,7.666666666666666,10.32,10th and 11th grade,291,40,6.375,3,0.029,0.4915,0.4795,0.629278004,0.047259465,0.323462516
"It has been proven that pure silver and silver-containing stainless steel surfaces do not exhibit
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Stainless steel with a high copper content has important antiviral properties.
properties.",1186,Translated,TRUE,42.72,0,12.3,15.95,16.4,10.94,11,14,14,13th and 14th grade,275,40,5.975,3,0.1806,0.735,0.0844,0.630261064,0.045768071,0.323970854
"Surfaces of pure silver and silver-containing stainless steel have been found not to show
inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, pure copper and
high copper stainless steel exhibits significant antiviral properties
properties.",1186,Translated,TRUE,36.79,0,12.5,17.75,16.8,11.27,11,12.25,13.86,12th and 13th grade,253,35,6.342857143,3,0.0335,0.6315,0.335,0.647251427,0.046189412,0.306559175
"Surfaces of pure silver and stainless steel containing silver have been found to be indistinguishable
Inhibitory effects on SARS-CoV-2 and H1N1 viruses. In comparison, both pure copper and
Copper-containing stainless steel with a high copper content shows significant antiviral effects
Properties.",1186,Translated,TRUE,33.75,0,13.6,18.22,18.4,11.2,12,14.25,15.03,13th and 14th grade,297,41,6.341463415,3,0.0271,0.6139,0.3591,0.636751473,0.044542633,0.318705857
"Pure silver and silver-containing stainless steel surfaces have been found to have no inhibitory effect on SARS-CoV-2 and H1N1 viruses. In comparison, pure copper and high-copper stainless steel exhibit significant antiviral properties.",1186,Translated,TRUE,38.32,0,11.9,18.33,16.8,11.83,11,12,15.15,11th and 12th grade,236,32,6.40625,3,0.1169,0.7545,0.1286,0.635071814,0.045502272,0.319425881
"It turns out that sterling silver and stainless steel surfaces containing silver are not displayed.
Inhibitory effect against SARS-CoV-2 and H1N1 viruses. In contrast, pure copper and
Copper-containing stainless steel with a high copper content shows significant antiviral effects.
Property.",1186,Translated,TRUE,49.52,11.2,9.7,17.21,14.9,12.19,14,7.666666666666666,10.32,9th and 10th grade,291,40,6.375,3,0.0345,0.5681,0.3974,0.630163431,0.047592957,0.322243631
"Results from hospitalized patients show that shedding of the virus in stool occurs for ~3-7 days
after a positive PCR test, you can get a nasal swab and that the stool could be excreted
continue 6-10 days after receiving a negative nasal swab.",1194,Translated,TRUE,44.75,0,17.7,10.06,22.1,12.75,10,27.5,22.78,22nd and 23rd grade,243,43,4.720930233,5,0.0418,0.9202,0.0379,0.643708169,0.065174133,0.291117698
"Results from hospitalized patients indicate that shedding of virus in stool occurs for approximately 3 to 7 days
After a positive PCR test result can be obtained from a nasal swab, this can be eliminated in the stool
It lasts for 6-10 days after a negative nasal swab is taken.",1194,Translated,TRUE,29.19,0,21.6,9.71,25,13.06,12,31,24.8,24th and 25th grade,277,50,4.6,5,0.0338,0.8688,0.0975,0.654754579,0.045300141,0.299945205
"Results from hospitalized patients have shown that viral shedding in the stool occurs for approximately 3 to 7 days.
If a positive PCR test result is obtained from nasal discharge, it can be excreted in the stool.
It lasts for 6 to 10 days after a negative nasal swab.",1194,Translated,TRUE,71.85,10.5,7.3,8,7.9,11.86,13,8.833333333333334,10.6,7th and 8th grade,268,49,4.530612245,5,0.0242,0.8619,0.1138,0.647607327,0.052771326,0.299621344
"Results from hospitalized patients indicate that virus excretion in faeces occurs for approx. 3 to 7 days
After a positive PCR test result can be obtained from a nasal swab, this can be eliminated in the stool
It lasts for 6-10 days after a negative nasal swab is taken.",1194,Translated,TRUE,55.07,0,11.7,8.83,12.2,12.26,13,15.25,14.7,11th and 12th grade,270,49,4.571428571,5,0.029,0.8304,0.1406,0.641760349,0.044748247,0.313491464
Results from hospitalized patients show that viral shedding in stool occurs approximately 3â€“7 days after a positive PCR test by nasal swab and that viral shedding in stool may continue for 6â€“10 days after a negative nasal swab.,1194,Translated,TRUE,32.91,0,18.1,12.14,21.6,13,10,24,20.46,12th and 13th grade,231,38,5.105263158,5,0.0172,0.7857,0.197,0.640419304,0.064080723,0.29549998
"Results from hospitalized patients suggest that viral shedding in fecal material occurs ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that emissions in feces could
continue for 6-10 days after a negative nasal wash.",1194,Translated,TRUE,29.86,0,19.3,11.91,22.6,14.53,15,25.5,21.28,-1th and 0th grade,245,41,5.048780488,5,0.0204,0.8252,0.1544,0.639970005,0.06064849,0.299381465
"Results from hospitalized patients suggest that shedding of the virus in the stool occurs ~3 to 7 days after a positive PCR test from a nasal swab.
Occurs later, and stool discharge may continue for 6 to 10 days after a negative nasal swab test.",1194,Translated,TRUE,65.56,0,9.7,8.42,10.9,11.77,11,13.25,12.56,12th and 13th grade,245,45,4.488888889,5,0.0205,0.8612,0.1183,0.651904583,0.070054717,0.278040737
"Results from hospitalized patients indicate that viral shedding in fecal matter occurs in approximately 3 to 7 days.
after a positive PCR test can be obtained from a nasal swab and that shedding in feces could
continue for 6 to 10 days after a negative nasal swab.",1194,Translated,TRUE,47.62,0,12.5,9.7,12.2,12.19,14,14.75,14.51,12th and 13th grade,264,47,4.680851064,5,0.0181,0.8407,0.1413,0.642549992,0.056197956,0.301252037
"Results from hospitalized patients indicate that viral shedding in faecal material occurs ~3-7 days
after a positive PCR test can be obtained from a nasal swab and that excretion in feces could
continue for 6-10 days after a negative nasal swab.",1194,Translated,TRUE,29.86,0,19.3,12.03,22.6,14.53,15,27.5,23.23,22nd and 23rd grade,245,41,5.048780488,5,0.0179,0.8254,0.1567,0.643519521,0.064439185,0.292041361
"Results from hospitalized patients show that virus shedding in stool occurs for about 3â€“7 days.
After a positive PCR test, a nasal swab can be taken and stool can be expelled.
After receiving a negative nasal swab, this takes 6â€“10 days.",1194,Translated,TRUE,74.49,9.7,6.3,9.16,8.4,11.63,9,7.166666666666666,9.38,9th and 10th grade,240,41,4.926829268,5,0.0219,0.8225,0.1555,0.631652951,0.055849437,0.312497556
"Results from hospitalized patients indicate that shedding of virus in stool occurs for approximately 3 to 7 days
After a positive PCR test result can be obtained from a nasal swab, this can be eliminated in the stool
It continues for 6-10 days after a negative nasal swab is taken.",1194,Translated,TRUE,29.19,0,21.6,10.17,25.4,13.06,13,32,25.6,25th and 26th grade,281,50,4.68,5,0.0273,0.8473,0.1254,0.643544495,0.054901771,0.301553696
"Results from hospitalized patients suggest that virus is shed in the stool for ~3â€“7 days
after a positive PCR test can be obtained from a nasal swab and that stool excretion could
continue 6-10 days after a negative nasal swab.",1194,Translated,TRUE,47.8,0,16.5,10.17,20.9,12.73,9,25,21,20th and 21st grade,229,40,4.8,5,0.0192,0.8365,0.1443,0.638351202,0.067494668,0.294154048
"Results from hospitalized patients have shown that viral shedding in the stool occurs for ~3 to 7 days.
After a positive PCR test, you can confirm that stool may be excreted by collecting nasal discharge.
Continue for 6-10 days after a negative nasal swab.",1194,Translated,TRUE,65.01,11.2,7.8,9.39,8.7,12.26,13,8.333333333333334,11.33,8th and 9th grade,256,44,4.886363636,5,0.0215,0.8629,0.1156,0.638834715,0.061064512,0.300100803
"Results from hospitalized patients have shown that viral shedding in the stool occurs in ~3 to 7 days.
It may be excreted in the stool after a positive PCR test using a nasal swab.
Continue for 6 to 10 days after a negative nasal swab.",1194,Translated,TRUE,73.17,10.5,6.8,6.26,6,11.4,11,8.166666666666666,10.44,6th and 7th grade,235,45,4.288888889,5,0.0162,0.7993,0.1845,0.649866939,0.068521917,0.281611145
"Results from hospitalized patients indicate that viral shedding in feces occurs in approximately 3 to 7 days.
after a positive PCR test can be obtained from a nasal swab and excretion in the stool could
continue for 6 to 10 days after a negative nasal swab.",1194,Translated,TRUE,48.13,0,12.3,9.52,11.8,12.33,14,15,15.29,11th and 12th grade,257,46,4.652173913,5,0.0181,0.8033,0.1786,0.643365145,0.063372873,0.293261975
"The results of hospitalized patients show that the virus is spread in feces for ~3-7 days
after a positive PCR test, you can get a nasal swab and that the excretion with feces could
continue 6-10 days after a negative nasal swab test.",1194,Translated,TRUE,44.75,0,17.7,8.84,21.1,12.01,8,26.5,21.85,21st and 22nd grade,234,43,4.511627907,5,0.0263,0.8321,0.1416,0.656460285,0.04370977,0.29982993
Results from hospitalized patients show that fecal viral shedding occurs approximately 3â€“7 days after a positive PCR test from a nasal swab and that fecal shedding may continue for 6â€“10 days after a negative nasal swab.,1194,Translated,TRUE,34.94,0,17.3,12.78,21.2,13.76,11,23,19.96,-1th and 0th grade,223,36,5.222222222,5,0.0166,0.7802,0.2032,0.632867515,0.058980271,0.308152199
"Results from hospitalized patients suggest that shedding of virus in fecal material occurs ~3-7 days
after a positive PCR test can be obtained from a nasal swab and that faecal emissions could
continue for 6-10 days after negative nasal wash.",1194,Translated,TRUE,30.88,0,18.9,12.14,22.5,14.7,14,25,21,18th and 19th grade,242,40,5.125,5,0.0233,0.8816,0.0951,0.646550238,0.069379583,0.284070164
"Results from hospitalized patients indicate that shedding of virus in feces occurs ~3-7 days
after a positive PCR test can be obtained from a nasal swab and that faecal excretion could
continue for 6-10 days after a negative nasal swab.",1194,Translated,TRUE,30.88,0,18.9,11.33,21.8,14.31,13,26,22,21st and 22nd grade,236,40,4.975,5,0.0206,0.8669,0.1125,0.647723317,0.066327557,0.2859492
"The risk of death among COVID-19 patients with asthma was significantly increased in Asia, but not elsewhere.
Europe, North America, South America.",1195,Translated,TRUE,60.31,0,7.6,13.15,11.1,10.64,5,6,6.22,7th and 8th grade,147,22,5.772727273,2,0.0235,0.5313,0.4452,0.638060927,0.178400174,0.183538899
"Asthma patients with COVID-19 had a significantly increased mortality risk in Asia, but not in the country
in Europe, North America and South America.",1195,Translated,TRUE,38.66,0,13.8,12.77,15.5,11.41,6,16,12.93,12th and 13th grade,150,24,5.333333333,2,0.0176,0.4568,0.5256,0.671445608,0.149788588,0.178765774
"Asthma patients with COVID-19 had a significantly increased risk of mortality in Asia, but not in the country
in Europe, North America and South America.",1195,Translated,TRUE,46.1,0,13,12.02,15.4,11.19,6,16.5,13.2,12th and 13th grade,153,25,5.2,2,0.0175,0.4648,0.5177,0.670976639,0.146551207,0.18247214
"COVID-19 patients with asthma had a significantly increased risk of mortality in Asia, but not in
Europe, North America and South America.",1195,Translated,TRUE,40.69,0,13.1,12.53,14.6,11.9,6,15,12.44,12th and 13th grade,138,22,5.363636364,2,0.0173,0.4619,0.5207,0.683203995,0.130304202,0.186491773
"Asthma patients with COVID-19 had a significantly increased mortality risk in Asia, but not in Asia.
Europe, North America and South America.",1195,Translated,TRUE,51.85,0,8.8,11.87,9.7,11.36,6,6.5,8.04,8th and 9th grade,141,22,5.5,2,0.0231,0.5552,0.4217,0.674910188,0.135161638,0.189928129
"Asthma patients with COVID-19 had a significantly increased risk of mortality in Asia, but not in
Europe, North America and South America.",1195,Translated,TRUE,40.69,0,13.1,12.53,14.6,11.9,6,15,12.44,12th and 13th grade,138,22,5.363636364,2,0.0165,0.4603,0.5232,0.677284956,0.135980576,0.186734468
"The risk of death among patients with asthma from COVID-19 increased significantly in Asia, but not elsewhere.
Europe, North America, South America.",1195,Translated,TRUE,60.31,0,7.6,13.44,11.2,10.64,5,6,6.22,7th and 8th grade,148,22,5.818181818,2,0.0185,0.4079,0.5736,0.639371634,0.172142088,0.188486293
"The risk of death in COVID-19 patients with asthma was significantly increased in Asia, but not elsewhere.
Europe, North America, South America.",1195,Translated,TRUE,60.31,0,7.6,12.39,10.4,10.64,5,6,6.22,7th and 8th grade,144,22,5.636363636,2,0.0243,0.537,0.4386,0.643414676,0.164655238,0.191929966
"COVID-19 patients with asthma had a significantly increased risk of death in Asia, but not in
Europe, North America and South America.",1195,Translated,TRUE,57.61,0,10.7,11.43,13.8,11.19,5,14,10.62,10th and 11th grade,134,22,5.181818182,2,0.0178,0.4332,0.549,0.672155678,0.138087049,0.189757198
"Asthma patients with COVID-19 had a significantly increased risk of mortality in Asia, but not in Europe, North America, and South America.",1195,Translated,TRUE,40.69,0,13.1,12.53,14.8,11.9,6,15,12.44,12th and 13th grade,139,22,5.363636364,2,0.0215,0.5423,0.4362,0.677651823,0.133206442,0.189141735
"The risk of death increased significantly in asthmatic patients infected with COVID-19, but not in Asia.
Europe, North America and South America.",1195,Translated,TRUE,51.85,0,8.8,12.91,10.6,11.36,6,7,9.85,9th and 10th grade,145,22,5.681818182,2,0.0175,0.398,0.5846,0.652071416,0.146468967,0.201459602
"Asthma patients with COVID-19 had a significantly increased risk of death in Asia, but not in Asia.
Europe, North America and South America.",1195,Translated,TRUE,68.26,0,6.6,10.01,8.5,10.39,5,6.25,6.34,6th and 7th grade,140,23,5.173913043,2,0.024,0.5385,0.4376,0.657634854,0.145126551,0.197238609
"The risk of death among COVID-19 patients with asthma was significantly increased in Asia, but not elsewhere.
Europe, North America and South America.",1195,Translated,TRUE,59.8,0,7.8,12.57,10.6,10.39,5,6.25,6.34,10th and 11th grade,150,23,5.608695652,2,0.0255,0.5632,0.4113,0.640227795,0.178564951,0.181207165
"Asthma patients with COVID-19 had a significantly increased risk of mortality in Asia but not in Asia.
Europe, North America and South America.",1195,Translated,TRUE,51.34,0,9,11.06,9.1,11.07,6,6.75,8.08,8th and 9th grade,143,23,5.304347826,2,0.0248,0.5942,0.381,0.672874033,0.138026819,0.189099178
"COVID-19 patients with asthma had a significantly increased risk of death in Asia, but not in Europe, North America, and South America.",1195,Translated,TRUE,57.61,0,10.7,11.43,14,11.19,5,14,10.62,10th and 11th grade,135,22,5.181818182,2,0.0226,0.5081,0.4692,0.671246886,0.135957927,0.192795157
"Asthmatic patients with COVID-19 had a significantly increased risk of mortality in Asia, but not in Europe, North America, and South America.",1195,Translated,TRUE,40.69,0,13.1,13.29,15.5,11.9,6,16,14.25,15th and 16th grade,142,22,5.5,2,0.0185,0.4785,0.503,0.668899238,0.141027793,0.190072864
"Asthma patients with COVID-19 had a significantly increased risk of death in Asia, but not in Asia.
in Europe, North America and South America.",1195,Translated,TRUE,67.76,0,6.8,9.61,8.1,10.15,5,6.5,6.47,6th and 7th grade,143,24,5.041666667,2,0.0192,0.4648,0.5159,0.659622669,0.151961148,0.188416213
"COVID-19 patients with asthma have a significantly increased risk of death in Asia;
This was not the case in Europe, North America, and South America.",1195,Translated,TRUE,54.56,0,11.9,11.09,14.8,10.56,5,15.5,11.6,11th and 12th grade,150,25,5.08,2,0.0166,0.3491,0.6343,0.68001622,0.124225788,0.195758045
"The risk of death among COVID-19 asthma patients increased significantly in Asia, but not in Korea.
In Europe, North America and South America.",1195,Translated,TRUE,59.8,0,7.8,10.77,9.1,11.07,6,6.25,6.34,10th and 11th grade,143,23,5.304347826,2,0.0171,0.4588,0.5241,0.611581266,0.212001801,0.176416889
"Evaluation results show a high diagnosis accuracy of 89% to 99%. The proposed method
X-ray images using image processing for early detection and classification of COVID-19
has proven to be useful as it provides end-to-end structure without the need for manual manipulation
feature extraction and manual selection methods.",1199,Translated,TRUE,21.74,0,16.2,15.15,17.5,13.38,19,17.5,17.93,17th and 18th grade,321,48,5.770833333,6,0.7889,0.204,0.007,0.629945457,0.094171815,0.275882781
"The evaluation results show high diagnostic accuracy, from 89% to 99%. The proposed method
for early detection and classification of covid-19 through X-ray imaging
has proven useful as it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,32.22,0,14.2,15.03,16.7,12.62,15,15.5,16.07,15th and 16th grade,297,44,5.840909091,6,0.8516,0.1423,0.006,0.637460172,0.095873579,0.266666234
"The evaluation results showed a high diagnostic accuracy ranging from 89% to 99%. Proposed method
For early detection and classification of coronavirus (COVID-19) through image processing using X-ray images
It is proven to be usable because it provides a comprehensive structure without requiring a manual
Feature extraction and manual selection methods.",1199,Translated,TRUE,20.21,0,16.8,16.66,19.4,14.5,23,19.25,19.61,16th and 17th grade,354,51,6.019607843,6,0.7579,0.234,0.0082,0.625469387,0.084520467,0.290010154
"The evaluation results show a high diagnostic accuracy, from 89% to 99%. The proposed method
for early detection and classification of COVID-19 using X-ray image processing
has proven to be useful as it provides an end-to-end structure without the need for manual methods of
feature extraction and selection.",1199,Translated,TRUE,38.66,0,13.8,13.47,16.2,12.72,17,16.5,17.1,16th and 17th grade,308,48,5.5,6,0.8339,0.1596,0.0065,0.644070029,0.090829857,0.265100151
"The evaluation results show high diagnostic accuracy, from 89% to 99%. The proposed method
for early detection and classification of covid-19 through X-ray images
has proven useful as it provides an end-to-end structure without the need for manual
features extraction and manual selection methods.",1199,Translated,TRUE,32.22,0,14.2,15.03,16.7,12.62,15,15.5,16.07,15th and 16th grade,297,44,5.840909091,6,0.8451,0.1485,0.0065,0.63874507,0.09472762,0.266527325
"The evaluation results show a high diagnostic accuracy of 89% to 99%. The proposed method
for early detection and classification of COVID-19 by image processing using X-ray images
has proven to be usable as it provides an end-to-end structure without the need for
Feature extraction and manual selection methods.",1199,Translated,TRUE,38.15,0,14,13.29,16.2,13.23,19,16.75,17.15,13th and 14th grade,312,49,5.448979592,6,0.8054,0.1865,0.0081,0.641792834,0.091256179,0.266950935
"The evaluation results show a high diagnostic accuracy ranging from 89% to 99%. The proposed method
for early detection and classification of Corona virus through X-ray imaging
has proven its usefulness because it provides a comprehensive structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,30.2,0,15,16.02,17.8,13.05,19,17.5,17.93,17th and 18th grade,325,48,5.854166667,4,0.8436,0.1508,0.0056,0.636678278,0.087196372,0.276125371
"The results of the assessment show high diagnostic accuracy - from 89% to 99%. The proposed method
for early detection and classification of COVID-19 by image processing using X-rays
it is proven to be usable as it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,37.13,0,14.4,13.06,16.5,12.95,18,18,17.26,12th and 13th grade,324,52,5.307692308,6,0.8265,0.1668,0.0067,0.629953861,0.093204685,0.276841402
"The evaluation results show a high diagnostic accuracy, from 89% to 99%. The proposed method
for early detection and classification of covid-19 using X-ray imaging
has proven useful as it provides a comprehensive structure without the need for a manual
feature extraction and manual selection methods.",1199,Translated,TRUE,31.21,0,14.6,14.39,16.3,13.02,17,16.5,17.03,16th and 17th grade,301,46,5.630434783,6,0.8471,0.1466,0.0064,0.645955324,0.090662293,0.263382405
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method
for the early detection and classification of COVID-19 through image processing using X-ray images
it is proven to be usable since it provides a comprehensive structure without the need for a manual
feature extraction and manual selection methods.",1199,Translated,TRUE,28.17,0,15.8,14.16,17.5,13.12,20,18.5,18.09,17th and 18th grade,337,52,5.557692308,6,0.8173,0.176,0.0066,0.630903065,0.090723589,0.27837342
"The results of the assessment show high diagnostic accuracy - from 89% to 99%. The proposed method
for early detection and classification of COVID-19 through X-ray imaging
it has proven useful as it provides a comprehensive structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,39.16,0,13.6,14.63,16.7,12.53,16,17,17.06,16th and 17th grade,310,48,5.541666667,6,0.8749,0.1193,0.0059,0.635636568,0.098837934,0.265525401
"The evaluation results show a high accuracy of diagnosis, from 89% to 99%. The proposed method
for early detection and classification of COVID-19 through X-ray image processing
proved to be useful as it provides a comprehensive structure without the need for a manual
feature extraction and manual selection methods.",1199,Translated,TRUE,29.69,0,15.2,13.93,16.6,12.59,17,17.75,17.96,17th and 18th grade,316,49,5.530612245,6,0.7764,0.216,0.0076,0.637199521,0.090568066,0.272232413
"The evaluation results show a high diagnostic accuracy ranging from 89% to 99%. The proposed method has been proven
For early detection and classification of COVID-19 through image processing using X-ray images
It is usable as it provides a comprehensive architecture without the need for manual feature extraction and manual selection methods.",1199,Translated,TRUE,28.17,0,15.8,15.03,18.1,13.43,21,19,18.86,18th and 19th grade,344,52,5.673076923,6,0.8325,0.1618,0.0057,0.637420833,0.089764565,0.272814572
"The evaluation results show high diagnosis accuracy, from 89% to 99%. The proposed method
for early detection and classification of COVID-19 through X-ray imaging
has proven to be useful as it provides an end-to-end structure without the need for manual
features extraction and manual selection methods.",1199,Translated,TRUE,39.67,0,13.4,14.39,16.5,12.33,15,16,16.16,16th and 17th grade,303,46,5.673913043,6,0.8515,0.1431,0.0054,0.637922108,0.096043952,0.266033888
"The evaluation results show a high diagnostic accuracy - from 89% to 99%. The proposed method
for early detection and classification of COVID-19 by X-ray image processing
it is proven to be usable as it provides a comprehensive structure without the need for a manual
feature extraction and manual selection methods.",1199,Translated,TRUE,29.18,0,15.4,13.06,16.1,12.77,18,18.25,18,12th and 13th grade,316,51,5.274509804,6,0.8278,0.1655,0.0067,0.634574831,0.093215466,0.272209704
"Evaluation results show a high diagnostic accuracy ranging from 89% to 99%. Proposed method
For early detection and classification of the Corona virus through X-ray imaging
It has proven useful because it provides a comprehensive structure without the need for a manual
Feature extraction and manual selection methods.",1199,Translated,TRUE,30.2,0,15,15.15,17.2,12.72,18,17,17.1,16th and 17th grade,318,48,5.708333333,4,0.7873,0.205,0.0077,0.625960469,0.09147726,0.282562196
"The evaluation results show a high diagnostic accuracy of 89% to 99%. The proposed method
for early detection and classification of COVID-19 through X-ray imaging
has proven useful as it provides an end-to-end structure without the need for
Feature extraction and manual selection methods.",1199,Translated,TRUE,40.69,0,13.1,14.1,15.9,12.62,15,15,16.07,12th and 13th grade,289,44,5.659090909,6,0.8344,0.1582,0.0074,0.64323169,0.094358146,0.262410164
"Evaluation results show a high diagnosis accuracy of 89% to 99%. The proposed method
X-ray images with image processing for early detection and classification of covid-19
has proven useful as it provides end-to-end structure without the need for manual manipulation
feature extraction and manual selection methods.",1199,Translated,TRUE,22.75,0,15.8,15.9,17.6,13.36,18,17,17.9,15th and 16th grade,314,46,5.913043478,6,0.7728,0.2194,0.0079,0.630495429,0.094783381,0.274721175
"The evaluation results show a high diagnostic accuracy of 89% to 99%. The proposed method
for early detection and classification of COVID-19 by image processing from X-ray images
is proven to be viable as it provides an end-to-end structure without the need for manual
feature extraction and manual selection methods.",1199,Translated,TRUE,37.64,0,14.2,13.18,16.3,12.77,18,17.5,17.2,12th and 13th grade,317,50,5.42,6,0.731,0.2602,0.0089,0.63730222,0.088887356,0.273810357
